Quality of Care and Outcomes Assessment  by unknown
A236  ABSTRACTS - Quality of Care and Outcomes Assessment JACC March 11, 2008 
Qu
ali
ty 
of 
Ca
re 
an
d O
utc
om
es 
A
ss
es
sm
en
t
ACC.POSTER CONTRIBUTIONS
1005 
Quality of Care; Biomedical Computing/
Info Tech
Sunday, March 30, 2008, 9:00 a.m.-12:30 p.m.
McCormick Place, South Hall 
11:00 a.m.
1005-127 Do Top Performing Cardiac Hospitals Based On 
Mortality Also Have Lower Risk-Adjusted Non-Fatal 
Complication Rates Than All Other Hospitals Among 
Medicare Beneficiaries Undergoing Revascularization 
Procedures?
Aaron D. Kugelmass, David J. Cohen, Matthew R. Reynolds, Phillip P. Brown, April W. 
Simon, Steven D. Culler, Emory University, Atlanta, GA, Cardiac Data Solutions, Inc., 
Atlanta, GA
Background: This study examines if Medicare beneficiaries (MB) undergoing 
revascularization procedures (PCI or CABG) in a top ranked heart hospital (based on 
lives saved) also experience lower risk-adjusted complication rates.
Methods: This retrospective analysis uses the MedPar Files for 2003 through 2005. The 
sample consists of 710 hospitals treating at least 52 MB for each of the following: AMI, 
PCI, and CABG during each fiscal year. Logistic regressions were estimated to predict 
each MB’s probability of experiencing four CABG related complications (Infection, New 
Onset Hemodialysis (HD), Stroke, or ARDS) and two PCI related complications (HD or 
Vascular Complication). Mean risk-adjusted complication rates and relative risk ratios 
were calculated for each complication for the top 46 performing hospitals (ranked in the 
top quartile of the number of lives saved across the three cardiac care services) and for 
the other 664 hospitals.
Results: The table reports the relative risk of a MB experiencing each complication in one 
of the 664 other study hospitals versus in one of the 46 best cardiac hospitals over three 
years. For only two complications (Infection following CABG and HD following PCI) in 
FY2003, were MB significantly more likely (p<0.01) to experience a complication among 
lower performing hospitals.
Conclusion: The 46 best heart hospitals across three cardiac services do not significantly 
reduce risk-adjusted complication rates of revascularization procedures among MB. 
Relative Risk of Experiencing Complications in All Other Hospitals versus the 46 Top 
Heart Hospitals
FY-2003 FY-2004 FY-2005
CABG Complications:
Post-Operative Infection 1.46 (p<0.01)
1.09 
(p=0.45)
1.15 
(p=0.19)
New Onset Hemodialysis 1.16 (p=0.29)
1.04 
(p=0.71)
1.01 
(p=0.94)
Post-Operative Stroke 0.94 (p=0.65)
1.03 
(p=0.85)
0.94 
(p=0.57)
ARDS 1.08 (p=0.65)
0.93 
(p=0.31)
1.19 
(p=0.26)
PCI Complications:
New Onset Hemodialysis 1.38 (p<0.01)
1.01 
(p=0.88)
0.92 
(p=0.54)
Vascular Complication 1.00 (p=1.00)
1.01 
(p=0.94)
0.96 
(p=0.59)
11:00 a.m.
1005-128 Lack of impact of randomized trials on percutaneous 
coronary intervention (PCI) practice: Data from 
the American College of Cardiology National 
Cardiovascular Data Registry (ACC-NCDR)
Sunil V. Rao, Dadi Dai, Sameer Mehta, Steven Marso, Eric D. Peterson, Tim Sanborn, 
Lloyd W. Klein, Duke Clinical Research Institute, Durham, NC
Background: The impact of clinical trial data on PCI practice remains unclear. We 
examined the impact of the SYNERGY and ACUITY trials on antithrombin use during PCI 
in patients with non ST-segment elevation acute coronary syndromes (NSTE ACS).
Methods: Data from NSTEACS patients undergoing PCI entered in the ACC-NCDR 
(N=353,356; 631 sites) from 1/2004-3/2007 were analyzed to assess patterns of 
antithrombin use during PCI. Temporal trends in the use of UFH, low molecular weight 
heparin (LMWH), BIV, combined UFH & LMWH, & combined LMWH & BIV were compared 
relative to the publication or presentation of SYNERGY& ACUITY.
Results: There was an increase in LMWH and decrease in UFH after SYNERGY. The use 
of combined UFH & LMWH increased after SYNERGY. Over time, the use of either UFH 
or LMWH as the sole antithrombin agent declined. The use of BIV and combined LMWH 
& BIV began to increase before the ACUITY presentation (Figure).
Conclusions: Results of major NSTEACS trials with important safety or efficacy data have 
had varying impact on PCI practice. Use of some antithrombins did not reflect important 
safety results (combined LWMH & UFH) while other antithrombins were adopted before 
supporting trials were completed (BIV; combined LMWH & BIV). These data suggest that 
the choice of antithrombin in NSTEACS patients undergoing PCI is often at the discretion 
of the operator rather than based on trial data. Efforts should focus on improving the 
adoption of trial results into PCI practice. 
11:00 a.m.
1005-129 Prevalence and In-hospital Outcomes of Multivessel 
PCI during Primary PCI for ST-segment elevation 
myocardial infarction: Results from the American 
College of Cardiology National Cardiovascular Data 
Registry (ACC-NCDR)
Matthew A. Cavender, Sarah Milford-Beland, William S. Weintraub, Matthew T. Roe, Eric 
D. Peterson, Sunil V. Rao, Duke Clinical Research Institute, Durham, NC
Background: Current guidelines give a class III recommendation (not useful, may 
be harmful) to PCI of a non-infarct related artery during primary PCI for ST-segment 
elevation myocardial infarction (STEMI) in patients without hemodynamic compromise. 
There are no large studies on the prevalence & outcomes of multivessel PCI (MVPCI) 
during primary PCI in clinical practice.
Methods: We analyzed data from the ACC-NCDR (N=708,481 admissions, 638 sites) to 
determine the prevalence of MVPCI during primary PCI between 2004-2007. Patients 
with STEMI undergoing MVPCI during the primary PCI were compared with STEMI 
patients undergoing single vessel PCI (SVPCI). Multivariable logistic regression was used 
to determine the association between MVPCI and in-hospital mortality after adjustment, 
using SVPCI as the reference.
Results: Of the 31,681 patients with STEMI & multivessel disease who underwent primary 
PCI, 9.9% (n=3134) underwent MVPCI and 81.4% (n=25,802) underwent SVPCI during 
the procedure. 8.7% underwent staged procedures during the admission & were excluded. 
Patients undergoing MVPCI were younger, heavier, & more likely to have shock & present 
later than those undergoing SVPCI; they were less likely to have had prior PCI or prior 
bypass surgery. The unadjusted rate of in-hospital mortality was significantly higher for 
MVPCI patients (7.9% vs. 5.1%, p<0.0001). After excluding patients in shock & adjusting 
for confounders, multivessel PCI during primary PCI was not significantly associated with 
increased in-hospital mortality [adjusted OR 1.23 (0.94-1.61)].
Conclusion: Up to 10% of patients undergoing primary PCI for STEMI will receive 
MVPCI during the procedure. The lack of a statistically significant association between 
this strategy and in-hospital mortality suggests that MVPCI in STEMI patients who are 
hemodynamically stable may be a reasonable strategy.
11:00 a.m.
1005-130 Continuous Quality Improvement Decreases Mortality 
in Cardiac Surgery
Sotiris C. Stamou, Sara L. Turner, Robert M. Stiegel, Mark K. Reames, Eric Skipper, 
Marcy Nussbaum, Francis Robicsek, Kevin W. Lobdell, Carolinas Heart Institute, 
Charlotte, NC
Background: This study investigates Continuous Quality Improvement and goal-oriented, 
multidisciplinary protocols on outcomes after cardiac surgery.
Methods: Patients were divided into two groups: those who had surgery (coronary artery 
bypass-CABG-, isolated valve or CABG + valve) after the establishment of the continuous 
quality improvement program (CQI, 2005-2006, n=922) and those prior to the institution 
of the quality improvement program (non-CQI, 2002-2003, n=1289). Patients from 2004, 
where the system and processes were re-engineered, were not included in the analysis. 
The protocols included standardized communication tools and goal sheets, sedation 
monitoring, respiratory protocols for early extubation and best pulmonary practices bundles, 
computerized euglycemia management, blood management and infection control programs, 
and multidisciplinary ICU rounds. Logistic regression and propensity score analysis were 
used to adjust for imbalances in the patients’ preoperative characteristics.
Results: Operative mortality was lower in the CQI group compared to the non-CQI group 
(2.6 vs. 5.0 %, respectively, p<0.01). The unadjusted odds ratios was 0.5 (95% CI 0.3-
0.8, p < 0.01) and the propensity score-adjusted odds ratio was 0.6 (95% CI 0.4-0.99, 
p = 0.04). In the multivariable analysis, diabetes (p<0.01), chronic renal insufficiency 
(p=0.05), previous cardiovascular operation (p=0.04), congestive heart failure (p<0.01), 
unstable angina (p<0.01), age over 75 years (p<0.01), prolonged pump time (p<0.01) 
and prolonged operation (p=0.05) emerged as independent predictors of higher mortality 
after cardiac surgery, while QIP (p<0.01) and male gender (p=0.03) were associated 
with lower mortality after cardiac surgery. Mortality in diabetics improved more than non-
diabetics (p=0.04).
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Conclusions: CQI coupled with the application of goal-directed, multi-disciplinary protocols 
is associated with lower mortality after cardiac surgery.
11:00 a.m.
1005-131 High Rates of Preventable Iatrogenic Adverse Events in 
Patients Admitted to the Coronary Care Unit
Sherali A. Rahim, Anita Mody, Jennifer Pickering, Salim Yusuf, Hamilton Health 
Sciences, McMaster University, Hamilton, Canada
BACKGROUND: In the coronary care unit (CCU), advances in evidence based medical 
and interventional therapy theoretically allow optimal patient care; however, sometimes 
these treatments have life threatening adverse effects that may be compounded when 
used together. We sought to determine the frequency and nature of iatrogenic adverse 
events (IAEs) in the CCU of a major tertiary care center.
METHODS: Retrospective review of all consecutive charts of patients admitted to the CCU 
at the Hamilton General Hospital (Ontario, Canada) from November 1, 2005 to January 1, 
2006. IAEs and causal health care management issues were identified. IAEs were defined 
as any unintended injury or complication that was caused by health care management 
rather than the underlying disease process. Preventability was also determined.
RESULTS: 194 consecutive admissions to the CCU were reviewed. 99 (51%) patients had 
at least 1 IAE. Of the patients who experienced IAEs, 75/99 (76%) patients experienced 
at least one major IAE and 45/99 (45%) patients experienced one or more that were 
preventable and deemed unacceptable. The most common health care management 
issues among those who had a preventable IAE were procedure (22/50, 44%), treatment 
(13/50, 26%) and diagnosis related (9/50, 18%). The most common preventable IAE was 
bleeding (14/45, 31%). 17/194 (8.8%) patients died in hospital and of these, 9/17 (53%) 
patients had an IAE, all of which were causally related to their death. Of those patients 
who died in hospital, 6/17 (35%) were related to IAEs that were preventable.
CONCLUSION: In patients admitted to the CCU at a major tertiary care center, there is 
an unexpectedly high rate of IAEs, particularly bleeding. Almost half of these IAEs are 
preventable and close to three quarters of these are due to treatments or procedures. 
About one third of deaths occurred after an IAE that was preventable. If our data are 
confirmed in larger studies involving several centers, it suggests that substantial morbidity 
and mortality may be potentially reduced by having quality assurance systems in place, to 
monitor and prevent serious IAEs.
11:00 a.m.
1005-132 Development of a Novel Diagnostic Error Taxonomy for 
Pediatric Echocardiography
Oscar J. Benavidez, Kimberlee Gauvreau, Tal Geva, Children’s Hospital Boston, 
Department of Cardiology, Boston, MA
Background: A taxonomy for diagnostic errors in pediatric echocardiography could assist 
in targeting quality improvement initiatives. Our objectives are to describe a new diagnostic 
error taxonomy for pediatric/congenital echocardiography, apply this method to elucidate 
categories and causes of diagnostic error and identify areas for quality improvement.
Methods: A diagnostic error taxonomy for pediatric echocardiography was developed to 
categorize errors by type, severity and preventability. Diagnostic errors were identified 
by quality improvement initiatives and voluntary reporting at a high-volume academic 
pediatric cardiac center. Each case was examined to identify and categorize contributing 
factors by reviewing medical records, diagnostic images and conducting interviews. The 
taxonomy was applied prospectively from December 2004 to August 2007.
Results: During the study period approximately 32,000 echocardiograms were performed. 
Among the 87 diagnostic error cases identified, 61% were false negative, 20% false positive 
and 20% discrepant diagnosis (wrong pathologic diagnosis). Regarding severity, 30% 
were minor and had no clinical impact; 63% moderate and impacted clinical management 
or the patient was at risk or experienced a transient adverse event; 6% major, experienced 
permanent adverse event; and 1% catastrophic, the error contributed to patient demise. 
One-third of errors were preventable (the correct diagnosis was apparent on the study); 
46% possibly preventable and 21% not preventable. Sixty-nine percent of preventable 
errors were moderate severity or greater. Top contributors to diagnostic errors were: 
poor imaging windows,17%; image misinterpretation, 13%; modality limitation, 11%; 
incomplete examination, 10%; and under appreciation of a finding 10%.
Conclusion: Diagnostic errors are an important factor affecting quality of care. Most errors 
have an impact on clinical management, 33% are preventable and 69% of preventable 
errors are at least of moderate severity. These findings illustrate the utility of a diagnostic 
error taxonomy to identify targets for quality improvement such as preventable diagnostic 
errors of moderate severity.
11:00 a.m.
1005-133 International Participation in Cardiovascular 
Randomized Controlled Trials Sponsored by the NHLBI 
: Is There a Problem?
Soo Hyun (Esther) Kim, Thomas P Carrigan, Venu Menon, Cleveland Clinic, Cleveland, OH
Background NIH sponsored cardiovascular (CV) randomized clinical trials (RCTs) are high 
impact and answer critical questions in cardiology practice. The perceived decline in US 
enrollment led us to explore rates of international participation (IP) in these “landmark trials.”
Methods We searched www.clinicaltrials.gov for phase 3/4 CV RCTs funded by the NHLBI 
with outcomes of stroke, MI, or death published between 1997-2006. We examined 
relationships between IP and acuity of the trial, type of CV disease, or level of risk of 
the intervention. In “acute” studies, the intervention was initiated during the acute phase 
of illness (MI, sudden death, surgery, or heart failure). Physically invasive interventions 
were “high risk.”
Results Of 982 CV studies, we found 203 RCTs, 144 phase 3/4 studies in adults, 58 with 
pertinent outcomes, and 18 published between 1997-2006. We had complete information 
for 17 studies: 7 acute, 7 high risk, 8 CAD, 3 CHF, and 6 EP. Thirteen had IP, and the 
average IP for all studies was 25%. IP in CAD trials was 47% (range 0-100%) (Fig). There 
was no association between IP and acuity or level of risk. All 17 trials were published in 
top tier journals, and 14 were cited in major guidelines.
Conclusion: A quarter of all patients enrolled in landmark NIH CV RCTs are international. 
This deserves scrutiny as it may reflect decreased patient recruitment in the US. This 
underperformance by US academic sites on peer reviewed trials of pivotal importance 
should not be ignored and mandates urgent attention.
11:00 a.m.
1005-134 Rates of Guideline-Recommended Venous 
Thromboembolism Prophylaxis in US Hospital Critical 
Care Patients
Alpesh N. Amin, Jay Lin, Guiping Yang, Stephen Stemkowski, University of California-
Irvine School of Medicine, Orange, CA
Background: Critical care patients are a heterogeneous group with varied diagnoses and 
comorbidities, including cardiovascular disease patients in the coronary care unit. As 
critical care patients are both immobile and exhibit a range of additional risk-factors, such 
as heart failure, it is important that they receive appropriate prophylaxis for the prevention 
of venous thromboembolism (VTE). We assessed the real-world rate of appropriate VTE 
prophylaxis, in accordance with the 7th American College of Chest Physicians (ACCP) 
guidelines, in at-risk critical-care patients in US hospitals.
Methods: A retrospective cohort study using the Premier’s Perspective™ inpatient 
database was performed. Discharges aged ≥ 40 years, with a length of stay ≥ 6 days, 
admitted to any critical care unit, and without contraindications for anticoagulation were 
included. Appropriate VTE prophylaxis was determined by identifying the daily use of 
anticoagulants and compression devices, dosage, and duration of prophylaxis for each 
discharge, and comparing with the 7th ACCP recommendations for the discharge’s 
primary diagnosis.
Results: A total of 259,682 critical care discharges met the inclusion criteria. Despite 
79.0% of discharges receiving an anticoagulant or mechanical prophylaxis, only 15.2% 
of all discharges were fully compliant with the 7th ACCP guidelines for prophylaxis 
choice, dosage and duration. The reasons for inappropriate prophylaxis were insufficient 
duration of therapy (51.0%), receiving mechanical prophylaxis alone (13.7%), receiving 
an incorrect dose of anticoagulant (12.7%), and receiving no form of prophylaxis (7.3%). 
Although still low, appropriate prophylaxis rates appeared higher in teaching compared 
with non-teaching hospitals (16.1% vs 14.3%) and urban compared with rural hospitals 
(15.3% vs 14.1%).
Conclusions: Despite physicians providing some form of VTE prophylaxis in the majority 
of critical care patients, over 80% of these patients are receiving prophylaxis that does not 
follow the recommendation of the ACCP. As critical care patients are at very high risk for 
VTE, efforts are required to improve the rate of guideline-recommended VTE prophylaxis 
in these patients.
11:00 a.m.
1005-135 Impact of Computerized Dosing on Eptifibatide 
Associated Bleeding and Mortality
David Putney, Neal Kleiman, John Buergler, The Methodist Hospital, Houston, TX
Introduction: Excessive doses of eptifibatide have been shown to increase bleeding 
rates and hospital mortality. Dosing adjustments based on renal function have been 
recommended, but their implementation and clinical impact have not been assessed in 
daily practice.
Methods: A computerized algorithm was implemented in January 2006 to calculate 
appropriate eptifibatide dose (1 mcg/kg/min for CrCl < 50 mL/min or 2 mcg/kg/min for CrCl 
≥ 50 mL/min) using the Cockroft-Gault formula. All patients had hemoglobin determined 
before and the day following the procedure. Mortality and bleeding were compared in 
consecutive patients before and after implementation of the algorithm.
Results: A total of 413 patients qualified for inclusion (pre-algorithm: n=116, post- 
algorithm: n=297). There was a significant increase in appropriateness of dosing for renal 
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function (75.9% pre-algorithm vs. 97.0% post-algorithm, p=<0.0001). Twenty-four hour 
bleeding complications were significantly reduced as summarized in the chart below. Pack 
red blood cell transfusion rates were similar between both groups (6.0% pre-algorithm vs. 
3.7% post-algorithm, p=0.30). In hospital mortality was significantly reduced (4.3% pre-
algorithm vs. 0% post-algorithm, p=0.002). 
pre-algorithm 
n=115
post-algorithm 
n=296
p 
value OR (95% CI)
TIMI Bleeding Score
Major 0 (0) 1 (0.3)
0.001 0.40 (0.23_0.68)Minor 8 (6.9) 6 (2.0)Minimal 22 (19.0) 31 (10.4)
GUSTO Bleeding Score
Severe 6 (5.2) 1 (0.3)
0.008 0.46 (0.26_0.82)Moderate 2 (1.7) 9 (3.0)Mild 17 (14.7) 24 (8.1)
REPLACE-2 Bleeding 
Score
Major 14 (12.1) 13 (4.4) 0.001 0.39 (0.23_0.67)Minor 16 (13.8) 23 (7.7)
Conclusions: In patients initiating eptifibatide in the cath lab and undergoing percutaneous 
coronary intervention implementation of a computerized algorithm was associated with 
appropriate dosing with reduced bleeding and mortality.
11:00 a.m.
1005-137 Continuation of Beta-Blockade in Patients Admitted for 
Acute Decompensated Heart Failure Does Not Alter 
Mortality, Hospital or Intesive Care Unit Lenght of Stay
David Romerill, David Putney, Robert Fromm, Craig Pratt, The Methodist Hospital, 
Houston, TX
Introduction: The safety and efficacy of continuing beta-blockade in patients admitted for 
acutely decompensated heart failure has not yet been established in clinical trials. The 
paucity of evidence regarding continuation of beta-blocker therapy has led to inconsistent 
medical management in acute heart failure. Concerns about sodium retention and blood 
pressure reduction that can lead to worsening heart failure and symptomatic hypotension 
mitigate benefits that have been well-established in chronic heart failure therapy.
Methods: Medical records of patients admitted with clinically decompensated heart 
failure in which outpatient beta-blockers were either continued or stopped from January 
2004 through October 2006 were reviewed. Hospital length of stay and mortality during 
hospitalization for the two groups were evaluated.
Results: A total of 650 patients with diagnosis-related group (DRG) code 127 were 
screened to identify 108 patients taking beta-blockers prior to admission for acutely 
decompensated heart failure: 50 patients who were continued on beta-blocker therapy 
during their hospitalization and 58 patients whose beta-blocker therapy was discontinued. 
Overall, there was no difference detected in hospital length of stay (median (interquartile 
range)) between the two groups (5 (3-7) days beta blocker continued vs. 3 (2-6) days 
beta-blocker discontinued, p=0.13). Patient’s requiring admission to the ICU was in 3.9% 
in beta-blocker continued vs. 8.1% in beta-blocker discontinued, p=0.45. Mortality during 
initial hospitalization was similar between the two groups (4% beta-blocker continued 
vs. 3.4% beta-blocker discontinued, p>0.99). Beta-blockade at hospital discharge was 
significantly higher in the continuation group (92% vs. 32.8%, p<0.0001).
Conclusions: There were no differences detected on the hospital length of stay between patients 
who continued and those who did not continue beta-blocker therapy for acute decompensated 
heart failure upon hospitalization. The results of our study add to the limited data on the use of 
beta-blockers in patients admitted for acutely decompensated heart failure.
11:00 a.m.
1005-138 Predictors of Warfarin Discontinuation in Older Patients 
With Atrial Fibrillation
Margaret C. Fang, Alan S. Go, Yuchiao Chang, Leila H. Borowsky, Niela K. Pomernacki, 
Natalia Udaltsova, Daniel E. Singer, University of California, San Francisco, San 
Francisco, CA
Background: Although warfarin is strongly recommended for most patients with atrial 
fibrillation, it can be difficult to manage and increases bleeding risk, particularly in 
older patients. Clinicians often perceive that older patients are less likely to remain 
on warfarin, but little is known about actual discontinuation rates. We analyzed data 
from the ATRIA cohort of 13,559 patients with atrial fibrillation to describe rates and 
predictors of warfarin discontinuation.
Methods: We identified from the cohort 4395 people newly started on warfarin and 
tracked longitudinal warfarin use over the first 12 months of therapy, using pharmacy 
and laboratory databases. Data on patient characteristics, serial international normalized 
ratio [INR] tests, and incident hemorrhage events were collected from clinical and 
laboratory databases. The primary outcome was warfarin discontinuation, with prolonged 
discontinuation defined as >= 6 months off warfarin.
Results: Thirty-five percent of patients newly started on warfarin discontinued warfarin 
at some point during the first year of therapy. Of these, 1242 (28%) had prolonged 
discontinuation of at least 6 months. Patients who had prolonged discontinuation were 
younger (mean age 70 vs. 72 yrs, p<0.01), more likely to be male (62.6% vs. 57.2%, 
p<0.01), and had fewer stroke risk factors (mean CHADS2 score 1.3 vs. 1.6, p<0.01). 
Patients aged 80 years or older were no more likely than younger patients to have 
prolonged warfarin discontinuation (28.1% vs. 28.3%, p=0.90). Patients with prolonged 
discontinuation had fewer INR tests performed in the first 12 weeks (5.9 vs. 8.2, p<0.01), 
fewer INR tests in a therapeutic range of 2.0-3.0 (32% vs. 37%, p<0.01), and higher rates 
of major hemorrhage (1.1% vs. 0.4%, p=0.03).
Conclusions: A substantial proportion of patients newly started on warfarin will discontinue 
therapy during the first year. Although poorer INR control, fewer INR tests, and higher 
bleeding rates were associated with higher rates of discontinuation, older age was not. 
Older patients had comparable rates of warfarin discontinuation to younger patients.
11:00 a.m.
1005-139 Treatment Of Dyslipidemia in Patients With 
Cerebrovascular Disease: The Canadian VP and GOALL 
Registries Experience
Andrew T. Yan, Raymond T. Yan, Gustavo Saposnik, David H. Fitchett, Lawrence A. 
Leiter, Anatoly Langer, Shaun G. Goodman, Canadian Heart Research Centre, Toronto, 
ON, Canada, Terrence Donnelly Heart Centre, St Michael’s Hospital, University of 
Toronto, Toronto, ON, Canada
Background: Patients with cerebrovascular disease (CVD) are at high risk for adverse 
cardiovascular events and evidence from recent clinical trials supports the use of statins in 
these patients. While current management guidelines recommend aggressive LDL-cholesterol 
(LDL-C) lowering to the same target as for patients with coronary artery disease (CAD), it is 
not known to what extent CVD patients achieve the optimal LDL-C level in the “real world”.
Methods: Between Dec 2001 and Dec 2004, the prospective Vascular Protection (VP) 
and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries recruited 5033 
ambulatory patients with known CAD and/or CVD. We examined and compared the lipid 
profile and treatment among patients with CAD versus CVD.
Results: Of the 5033 patients, 3891 (77.3%) patients had known CAD only; 659 (13.1%) 
patients had known CVD only; 483 (9.6%) patients had both documented CAD and CVD. 
Overall, 82.7% of patients were taking a statin; 50.5% and 24.7% had LDL-C levels of 
<2.5 mmol/L (97mg/dL) and <2.0 mmol/L (77mg/dL), respectively. 
Patients with 
known CAD only 
(n=3891)
Patients with 
CAD and 
CVD 
(n=483)
Patients with 
known CVD 
only 
(n=659)
P value 
(3-group 
comparison)
TC (mmol/L) 4.58±1.03 * 4.58±1.08 * 4.94±1.13 <0.001
Triglycerides 
(mmol/L) 1.76±0.81 1.82±0.78 1.74±0.77 0.20
LDL-C (mmol/L) 2.59±0.86 * 2.55±0.92 * 2.85±0.97 <0.001
HDL-C (mmol/L) 1.18±0.33 * 1.19±0.35 * 1.29±0.38 <0.001
TC: HDL-C ratio 4.08±1.23 4.07±1.23 4.05±1.24 0.80
Achieved LDL<2.5 
mmol/L (%) 51.8 * 54.4 * 40.6 <0.001
Achieved LDL<2.0 
mmol/L (%) 24.7 29.3 * 21.1 0.007
Statin use (%) 84.0 * 81.0 76.0 <0.001
Use of any lipid-
modifying agent 
(%)
85.4 * 82.2 78.3 <0.001
Data presented as mean±SD 
TC, total cholesterol 
* P<0.01 for post-hoc pairwise comparisons with the CVD group 
Recommended target in the Canadian Dyslipidemia guidelines was LDL-C <2.5 mmol/L 
(equivalent to LDL-C 97mg/dL, similar to ATP III - National Cholesterol Education 
Program (NCEP) Expert Panel LDL-C <100 mg/dL) until 2006; current Canadian 
guidelines recommend LDL-C < 2.0 mmol/L (77mg/dL)
Conclusions: The majority of patients with known CVD were neither at previous nor current 
guideline-recommend target LDL-C levels. Furthermore, despite the same guideline-
recommended target for all patients with established cardiovascular disease, CVD patients 
were less likely to be treated with a statin and to attain the target LDL-C level compared to those 
with known CAD. Quality improvement initiatives are needed to narrow this treatment gap.
11:00 a.m.
1005-140 Underuse of Left Ventricular Function Assessment in 
Patients With Newly Diagnosed Heart Failure
Lesley H. Curtis, Alisa M. Shea, Bradley G. Hammill, Kevin A. Schulman, Pamela S. 
Douglas, Duke University Medical Center, Durham, NC
Background: National performance measures mandate that patients with newly 
diagnosed heart failure (HF) undergo assessment of left ventricular ejection fraction (EF). 
Moderately high levels of adherence are recorded in inpatient quality improvement (QI) 
registries. However, little is known about adherence in real world and outpatient settings 
or changes in practice over time.
Methods: Using Medicare claims data, beneficiaries were identified with a new diagnosis 
of HF reported on 1 inpatient claim or 3 outpatient claims within 20 months in 1995, 1999, 
and 2003. CPT codes identified cardiac tests yielding an EF measure including nuclear 
imaging, echocardiography, cardiac MRI, and left heart catheterization. Claims were 
examined for evidence of EF assessment from 30 days prior through 60 days following 
diagnosis. Logistic regression models identified patient characteristics associated with 
performance of EF.
Results: There were 41,231 incident HF patients in the 1995 cohort, 35,085 in the 1999 
cohort, and 36,832 in the 2003 cohort. EF assessment in the 30 days prior through 60 
days following diagnosis increased from 49.1% in 1995 to 55.4% in 1999, and 60.6% in 
2003 (p <0.001). In multivariable analyses, patients diagnosed while hospitalized were 
3 times more likely than patients diagnosed as outpatients to undergo EF assessment 
(odds ratio [OR] 3.42; 95% CI, 3.33-3.52). Women were 16% less likely than men (OR 
0.84, 95% CI, 0.81-0.86) and patients with dementia were 53% less likely to undergo EF 
assessment (OR 0.47, 95% CI 0.44-0.49). Patients in the Northeast region were 38% 
more likely to undergo EF assessment than those in the West (OR 1.38, 95% CI 1.32-
1.45). Of patients alive 60 days after diagnosis, those receiving EF assessments had 
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a12% reduction in 1 year mortality compared with those who did not (hazard ratio 0.88, 
95% CI 0.86-0.91). 
Conclusions: Despite the existence of a broad national consensus on HF performance measures 
which include EF measurement, and increasing rates of testing from 1995-2003, many patients 
still do not receive appropriate care. Improving the availability of the diagnostic information 
required for optimal care will help QI and HF management programs improve outcomes.
11:00 a.m.
1005-141 Unexpected INR Outcomes and Lab Compliance in 
Pediatric Cardiac Patients Taking Coumadin
Jane Todd, Emory University, Atlanta, GA
Unexpected INR Outcomes and Lab Compliance in Pediatric Cardiac Patients Taking 
Warfarin
Background: Inadequate anticoagulation can cause the malfunction of prosthetic cardiac 
valves and allow clot formation on the walls of poorly contracting hearts. Consensus 
guidelines recommend monthly assessment of coagulation status and some previous 
series in children have reported that INR measurements are within the therapeutic range 
more than 60% of the time. In the present study we sought to determine the percentage 
of time INR values are in the therapeutic range and to identify factors associated with 
anticoagulant status.
Methods: We retrospectively reviewed the data from 86 pediatric cardiology patients. At 
our institution children on chronic Warfarin therapy are to have monthly INR measurements 
and adjustment made according to published guidelines. The relationship between 
county of residence, physician, gender and insurance status and INR measurements was 
determined using regression analysis.
Results: We found that 38% of patients had 2 to 6 month lapses between INR 
measurements. A further 28% waited six or more months between laboratory visits. Only 
two patients had INR values in the therapeutic range over 70% of the time. A majority of 
the patients, 71%, had INR values in the therapeutic range less than 50% of the time. 
There was not a significant association between insurance status, gender, or county of 
residence and therapeutic INR levels. An association was present between INR levels 
and the patient’s physician.
Conclusion: Among a cohort of children receiving Warfarin for cardiac conditions in a 
large metropolitan area, non-adherence to clinic-based assessment of anticoagulation 
was common. Very few children achieved the adequate anticoagulation (therapeutic 
INR measurements > 70% of time). It appears that the physician has a strong influence 
on adequate anticoagulation status. Alternative approaches to maintaining sufficient 
anticoagulation, such as home visits, home-based anticoagulation status, study of 
genetic polymorphism of Warfarin metabolism or a coumadin clinic are needed in these 
high-risk populations.
11:00 a.m.
1005-142 Patient Knowledge About Heart Failure and Self-Care 
Strategies Is Limited and Varies By Ethnic Group
Percy F. Morales, Ramaswami Nalini, Ranjita Misra, Gabriel Anzueto, Jesus Villanueva, 
Ashok Balasubramanyam, Allison M. Pritchett, Baylor College of Medicine, Houston, TX
Background: JCAHO requires that patients discharged from the hospital with heart failure 
(HF) be educated about salt restriction, daily weight measurements, and symptoms of 
worsening HF. We sought to assess the adequacy of this education in a multi-ethnic 
cohort recently discharged from an urban county hospital.
Methods: 43 patients with HF (modified Framingham criteria) and the metabolic syndrome 
(NCEP ATP III criteria) completed a questionnaire. This questionnaire assessed 
depression symptoms, social support, dietary habits, and included 15 questions to 
identify patient’s knowledge of heart failure and self-care strategies. Questionnaires were 
available in both English and Spanish.
Results: Although 67% of respondents reported feeling confident about managing their 
heart failure, knowledge scores were low with a mean score of 6.9 ± 3.1 out of 15 (46%). 
Responders claimed dietary indiscretion by eating processed foods (55%) and fried foods 
(51%). 53% of responders do not own a scale, and on average weigh themselves only 
2 ± 3.1 days a week. There were drastic differences in knowledge and education when 
comparisons were made by race and by primary language. 
Comparison by Race White (n = 7) African American (n= 18)
Hispanic 
(n= 17)
P 
Value
Baseline Knowledge - # 
Correct of 15 (%) 9.4 ± 1.3 (62%) 7.2 ± 2.8 (48%)
5.5 ± 3.3 
(37%) 0.038
Mean Education Level 13th Grade ± 3 12th Grade ± 2 7th Grade 
± 3 0.000
Comparison by Primary 
Language
English Speaking 
(n= 31)
Spanish Speaking 
(n = 11)
P 
Value
Baseline Knowledge - # 
Correct of 15 (%) 7.7 ± 2.7 (51%) 4.7 ± 3.0 (31%) 0.004
Mean Education Level 12th Grade ± 2 6th Grade ± 3 0.000
Conclusion: Despite education, patients have a poor understanding of heart failure 
symptoms and self-care strategies, particularly in ethnic minorities and non-English 
speaking patients. Educational materials need to be modified to be culturally-sensitive, in 
a patient’s native language, and at an appropriate education level.
11:00 a.m.
1005-143 Are Guideline Recommended Therapies Being Applied 
to Elderly Patients Hospitalized With Heart Failure?
Daniel E. Forman, Christopher P. Cannon, Nancy M. Albert, Gregg C. Fonarow, Clyde 
W. Yancy, Li Liang, Adrian F. Hernandez, Brigham and Women’s Hospital, Boston, MA, 
VAMC, Boston, MA
Background: Although heart failure (HF) is highly prevalent with aging, with high mortality/
morbidity, age-related therapeutic gaps are common. Iatrogenic risks are often cited as 
impediments to guidelines-based therapy, but age and gender bias may contribute.
Methods: Get With The Guidelines (GWTG) HF data were collected by 257 hospitals on 
57,937 patients from 01/01/05-04/08/07. Data on demographics and quality of care were 
collected and stratified by age groups.
Results: Mean age was 73 ± 14 yrs, mean LVEF was 39.6% ± 17, and 50.6% were female. 
Age-stratified univariate analysis shows progressive age-related declines in therapy. A 
related opportunity composite score shows that the total eligible measures received by 
patients decreases with age (Table). However, a defect free composite measure increases 
with age, suggesting that as the range of suitable therapeutic options contracts with age, 
e.g. less LV Systolic Dysfunction (LVSD ), older HF patients were more likely to receive 
the full extent of therapy for which they remained eligible. Multivariate regression analysis 
shows that performance and quality measures all decrease with age, independent of 
other factors.
Conclusions: Among GWTG-HF participating hospitals, the majority of elderly HF patients 
were treated with recommended HF therapies for which they were eligible, though at rates 
below that of younger patients for most measures. Further efforts should be made to 
ensure recommended HF care, irrespective of age
Evidence-Base Care Stratified by Patient Age Groups
GWTG 
PERFORMANCE 
MEASURES
<65 
(N=16,245)
66-75 
(N=12,488)
76-85 
(N=18,398)
>85 
(N=10,806)
Univariate 
P-value
Discharge 
instructions, % 77.5 77.8 76.6 75.9 0.0063
Documentation of 
LVEF, % 93.8 93.1 92.8 89.4 <.0001
LVSD and on ACEI/
ARB, % 88.6 84.3 81.8 79.0 <.0001
Smoking cessation 
counseling, % 88.7 86.3 84.0 74.4 <.0001
LVSD and on beta 
blockers, % 90.9 88.4 88.0 82.7 <.0001
Opportunity 
composite measure 
(interventions 
provided / total 
opportunities), %
85.7±24.5 85.0±25.7 84.8±27.0 82.7±30.6 0.2201
Defect-free 
composite measure 
(all or none), %
67.2 68.1 70.3 71.0 <.0001
GWTG QUALITY 
MEASURES 
• Anticoagulation for 
atrial fibrillation, % 
• LVSD and on 
aldosterone 
antagonist, % 
• LVSD and on 
evidence based beta-
blocker, % 
• ICD for EF≤30%, %
• 71.0 
• 28.5 
• 71.4 
• 31.2
• 68.3 
• 24.7 
• 69.7 
• 36.6
• 64.6 
• 20.5 
• 67.0 
• 30.0
• 53.9 
• 17.7 
• 61.6 
• 11.5
• <.0001 
• <.0001 
• <.0001 
• <.0001
• LENGTH OF STAY, 
days, mean 
• DEATH IN 
HOSPITAL, %
• 5.5±7.6 
• 1.6
• 5.9±9.7 
• 3.1
• 5.6±6.6 
• 3.8
• 5.4±65.8 
• 5.3
• <.0001 
• <.0001
11:00 a.m.
1005-144 In-Hospital Disease Management Program for Acute 
Decompensated Heart Failure Favorably Influences 
Quality of Care and Outcomes
Vimal Rabdiya, Richard J. Soucier, Saint Francis Hospital, Hartford, CT, University of 
Connecticut Health Center, Farmington, CT
Background: Acute decompensated heart failure (ADHF) is the leading cause of 
hospitalization for adults older than 65. We assessed the impact of an in-hospital disease 
management program (DMP) for ADHF on quality of care indicators & outcomes.
Methods: We analyzed the prospectively collected data of patients admitted to our 
hospital for ADHF over 1 year. Based on whether the admission was to the DMP (heart 
failure floor) & who was the primary physician responsible for patient care, patients were 
divided into 3 groups: A. DMP, B. Cardiology & C. Medicine. These groups were compared 
for the average length of hospital stay (LOS) & rates of conformity with the JCAHO core 
performance measures - discharge instructions (HF1), assessment of left ventricular 
function (HF2), use of ACE inhibitors or Angiotensin receptor blockers (HF3) & smoking 
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cessation counseling (HF4).
Results: A Total of 1707 patients were admitted to our hospital with ADHF over a period of 
1 year; 608, 761 & 338 patients respectively in groups A, B & C. There was no significant 
difference in baseline patient characteristics among the groups. Group A was associated 
with a shorter LOS & a higher rate of conformity with JCAHO measures (p<0.05). 
JCAHO Measures Percent AdherenceA (n=608) B (n=761) C (n=338)
HF1 71.71% 42.7% * 15% *†
HF2 98% 97.6% 85.7% *†
HF3 82.8% 72.5% * 61.57% *†
HF4 100% 100% 63.6% *†
LOS (Days) 5.4 6.4 * 6.3 *
* p<0.05 Vs. DMP; † p<0.05 Vs. Cardiology
Conclusions: A comprehensive in-hospital DMP improves quality of care & adherence 
to performance measures, while reducing length of stay for the patients hospitalized with 
ADHF.
11:00 a.m.
1005-145 Evidence of Disparity in the Application of Quality 
Improvement Efforts for the Treatment of Acute 
Myocardial Infarction The American College of 
Cardiology’s Guidelines Applied in Practice Initiative in 
Michigan
Adesuwa B. Olomu, Mary Grzybowski, Vijay S. Ramanath, Adam Rogers, Benrong Chen, 
Bonnie Motyka, Canopy MPRO Roychoudhury, Elizabeth A. Jackson, Kim A. Eagle, 
Michigan State University, East Lansing, MI, University of Michigan, Ann Arbor, MI
Background: Racial disparities exist in the treatment of patients with cardiovascular 
disease in the United States. The American College of Cardiology’s Guidelines Applied in 
Practice (ACC’s GAP) program has been shown to increase the rates of evidence-based 
medication use in patients with AMI. OBJECTIVE: To evaluate if a structured initiative 
for improving care of patients with AMI (GAP) led to equal care of white and nonwhite 
patients admitted to GAP hospitals in Michigan.
Methods: Medicare patients comprised two cohorts-those admitted prior to GAP 
implementation (n=1,368) and those admitted after GAP implementation (n=1,489). 
The main outcome measure was adherence to guideline medications/recommendations 
and use of the GAP discharge tool. To evaluate differences in prescibed medications, 
only patients without contraindications to the use of evidenced-based medications were 
included. Chi-square and Fisher’s exact tests were used to determine differences between 
whites (n=2367) and nonwhites (n=490).
Results: In-hospital GAP tool and aspirin use significantly improved for both races. Beta-
blocker (BB) use in-hospital improved significantly for nonwhites only (66% vs 83.3%, 
p=0.04). At discharge, nonwhites were 28% and 59% less likely to have had the GAP 
discharge tool used (p=.030) and receive smoking cessation counseling (p<.001), 
respectively, than whites. Among whites, GAP improved discharge prescription rates for 
aspirin by 10.8% (p<.001) and BBs by 7.0% (p=.047). However, among nonwhites, aspirin 
prescriptions increased by 1.0% and BB prescriptions decreased by 6.0% (both p-values 
nonsignificant).
Conclusions: ACC’s GAP program led to significant increase in rates of evidence-based 
care in both whites and nonwhite Medicare patients. However, our results show evidence 
of disparity in the application of quality improvement tools at discharge between whites 
and nonwhites.. Policies designed to reduce racial disparities in health care must address 
bias in the delivery of quality improvement programs.
11:00 a.m.
1005-146 Shared Decision Making Preferences of Patients
Gregory K. Mulvey, John A. Spertus, Carole Decker, Judith H. Lichtman, Phil Jones, 
Lan Xiao, Donna M. Buchanan, Harlan M. Krumholz, Saint Luke’s Mid-America Heart 
Institute, Kansas City, MO, Yale University School of Medicine, New Haven, CT
Background: Little is known about preferences for shared decision-making for patients 
with myocardial infarction (MI). We examined the prevalence of these preferences among 
MI patients.
Methods: The Prospective Registry Evaluating MI: Event and Recovery (PREMIER) 
enrolled 2,498 patients with an MI between 1/1/03 and 6/28/04 from 19 U.S. medical 
centers. Using a validated tool, patients were asked to characterize their preferred 
decision making style on a 5-point Likert scale (where: 1 = doctor alone; 2 = mostly the 
doctor; 3 = both equally; 4 = mostly me and 5 = me alone) for 3 problem solving and 1 
decision making tasks. Problem solving tasks were decisions requiring technical medical 
knowledge (who should determine the cause of symptoms?; who should determine 
treatment options?; who should determine the risks and benefits of each treatment 
option?). The decision making task asked patients “given all the information about risks 
and benefits of the possible treatments” who should decide which treatment should be 
selected. Preferences were examined by demographic, clinical, patient, and health status 
data distributions.
Results: Overall, 77% (1872/2427) of patients preferred to leave problem solving tasks to 
a physician, with little variation across demographic groups. In the decision making task 
there was a general preference for sharing (40.35% [987/2446]). The largest discrepancy 
in decision making preferences was between age cohorts (42.05% [656/1560] of patients 
>=65). Female patients (43.25% [346/800]) and those with at least a high school (HS) 
education (41.10% [780/1898]) also preferred sharing more than their demographic 
counterparts (Male, 38.98% [641/1646]; less than HS education, 36.82% [190/516]).
Conclusion: A majority of MI patients wanted to defer problem solving to their physician, 
but decision making preferences were more varied, suggesting a need to tailor decision 
making approaches to individual patients. The diversity of patient preferences in shared 
decision making suggests opportunities for further study in this area examining whether 
those preferences are correlated with outcomes, satisfaction and adherence.
11:00 a.m.
1005-147 Coordinated ST Elevation Myocardial Infarction Process 
of Care Eliminates Off-Hour Variations of Door-to-
Balloon Times
Joji J. Varghese, Syeda Rumman, Sushma Koneru, Gadiel Berrio, Karen Baur, Steve 
Markwell, David Griffen, Frank Mikell, Frank V. Aguirre, Southern Illinois University School 
of Medicine, Springfield, IL, Prairie Cardiovascular Consultants. Ltd, Springfield, IL
Background: ST Elevation Myocardial Infarction (STEMI) patients (pts) presenting “off-
hours” have longer Door - Balloon (D2B) times with fewer achieving D2B time ≤ 90 
minutes compared to “on-hour” presentation. We examined the impact of a coordinated 
quality assurance program which provided real-time feedback to all participating hospital 
departments on 3 individual components of D2B time during on-hours and off-hours over 
6 years among STEMI pts recieving primary percutaneous coronary intervention (PPCI).
Methods: Between 2001-2006, all STEMI pts presenting to the emergency department of 
our tertiary care center were assessed. Three individual components of STEMI process 
of care were evaluated: 1) Door - ECG time (i.e. STEMI Diagnosis), 2) ECG -cardiac cath 
lab (CCL) time (i.e. treatment and triage), and 3) CCL - balloon time (i.e. procedural time). 
The total D2B time were assessed for patients presenting during on-hours (7 AM - 5 PM 
weekdays) and off-hours (5PM - 7 AM on weekdays and weekends).
Results:
D2B times during On Hours and Off Hours
On-hours
2001 
(n=25)
2002 
(n=20)
2003 
(n=15)
2004 
(n=15)
2005 
(n=30)
2006 
(n=23)
Trend 
p-value
Door - ECG time (median) 12 9 6 2 3 4 0.0002
ECG - CCL time(median) 36 30 23 36 26 34 NS
CCL - balloon 
time(median) 24 29 26 30 29 26 NS
Total D2B time(median) 85 80 58 73 61 70 0.046
D2B ≤ 90 min (%) 52 75 87 80 80 91 0.0035
Off hours
2001 
(n=41)
2002 
(n=22)
2003 
(n=36)
2004 
(n=40)
2005 
(n=47)
2006 
(n=43) Trend p-value
Door-ECG time(median) 11 9 9 6 3 4 0.0001
ECG-CCL time(median) 62 44 41 48 43 41 0.0001
CCL - Balloon 
time(median) 24 29 28 32 29 24 NS
Total D2B time(median) 100 86 79 83 76 73 0.0001
D2B ≤ 90 min (%) 42 55 64 65 66 81 0.0002
Over 6 yrs, among pts presenting off-hours, there has been a 27% reduction in D2B time 
resulting in a 2-fold higher rate of the proportion of pts acheiving D2B ≤ 90 minutes
Conclusions: In this single center 6-yr experience, our institutional coordinated STEMI 
care resulted in significantly shorter Door- ECG times, total D2B times, and proportion of 
patients acheiving D2B ≤ 90 minutes, regardless of time of day, meeting current ACC D2B 
alliance quality benchmarks even among patients presenting off-hours.
11:00 a.m.
1005-148 Impact of Drug Eluting Stents on Clinical and Economic 
Outcomes in an Unselected Interventional Practice
Charanjit Rihal, James Ryan, Mandeep Singh, John Bresnahan, Ryan Lennon, David 
Holmes, Henry Ting, Kirsten Hall Long, Mayo Clinic/Mayo Foundation, Rochester, MN
Background: Controversy exists regarding the efficacy, safety, and cost-effectiveness of 
Drug-Eluting Stents (DES). We assessed the clinical and economic impact to a general 
interventional practice following introduction of DES.
Methods: Using Mayo Clinic PCI Registry linked to administrative data we compared all 
patients undergoing PCI in pre-DES era (2000-2002) with a cohort from the DES era (2004-
4/31/2006). Logistic and Cox proportional hazard modeling was used to estimate the risk of 
events and generalized linear modeling for length of stay (LOS) and hospital costs.
Results: 3422 patients from the DES era were compared to 4303 patients from the pre-
DES era (mean age 67, 70% male, mean 1.5 stents / case in both cohorts); 90% of 
patients in the pre-DES era had bare-metal stents (BMS) implanted; in DES-era 83% 
of patients had DES, 14% BMS, and 6% no stents. Glycoprotein IIb/IIIa inhibitor use 
decreased from 65% pre-DES to 56% (p<0.001) and mean length of stay from 2.55 to 
2.32 days (p=0.024). In follow-up the incidence of death or MI was not different between 
cohorts, but repeat procedures were significantly fewer in the DES era. Models suggest 
reduced LOS and total in-hospital cost savings for PCI in the DES era. 
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ADJUSTED OUTCOMES Odds Ratio for Events in DES Era
95% Confidence 
Interval
In-hospital Clinical Events
Death 1.07 0.74, 1.56
MI 0.79 0.62, 1.00
Death/Q-wave MI/CABG/
Stroke 1.09 0.81, 1.46
Hazard Ratio for Events in 
DES Era
95% Confidence 
Interval
Follow-up Clinical Events
Death 0.97 0.81, 1.15
Death/MI 0.93 0.82, 1.05
TVR* 0.58 0.50, 0.68
Death/MI/TVR* 0.80 0.72, 0.88
In-Hospital Economic 
Outcomes Adjusted Mean Difference
95% Confidence 
Interval
LOS (days) -0.42 -0.60,-0.24
Costs (2007 constant dollars) -1,990 -2965,-1014
*TVR, target vessel revascularization (CABG or repeat PCI)
Conclusions: In an unselected cohort, introduction of DES was associated with improved 
clinical outcomes at 24 months, and reduced in-hospital costs. These data suggest more 
expensive technologies can be introduced into a practice setting while improving patient 
outcomes with incremental cost savings.
11:00 a.m.
1005-149 Hospital Strategies for Reducing Door-to-Balloon Time
Elizabeth H. Bradley, Brahmajee K. Nallamothu, Amy F. Stern, Jason R. Byrd, Emily J. 
Cherlin, Yongfei Wang, Christina Yuan, Ingrid Nembhard, John E. Brush, Jr., Harlan M. 
Krumholz, Yale University School of Medicine, New Haven, CT, American College of 
Cardiology, Washington, DC
Background: Less than half of U.S. hospitals meet guidelines for prompt treatment of 
ST-segment elevation myocardial infarction (STEMI). The Door-to-Balloon (D2B) Alliance 
is a collaborative effort of more than 900 hospitals committed to implementing evidence-
based strategies for reducing door-to-balloon time. We present data on the prevalence 
of these evidence-based strategies in participating hospitals and identify key hospital 
characteristics associated with their use.
Methods: We conducted a cross-sectional study of U.S. hospitals that joined the D2B 
Alliance through a Web-based survey about their current practices in caring for patients 
who received primary percutaneous coronary intervention (PCI) for treatment of STEMI. 
Of the 915 U.S. hospitals enrolled in the D2B Alliance, 797 (87%) completed the survey.
Results: Only 6% of surveyed hospitals (n=797) reported employing all 5 of the key 
strategies recommended by the D2B Alliance. A total of 30% of hospitals reported at 
least 4 of the strategies, whereas 9% reported having none of the strategies. The most 
prevalent of the strategies (81.5% of hospitals) was the expectation that the catheterization 
team would be available in the catheterization laboratory within 20 - 30 minutes of being 
paged. Fewer hospitals reported that emergency physicians activate the catheterization 
laboratory (51.4%) or that the hospital provided prompt (< 1 week) data feedback about 
D2B times to emergency department and catheterization laboratory staff (53.1%). Less 
than one third of hospitals reported that the catheterization laboratory was activated with 
a single-call system (30.1%) or with pre-hospital electrocardiograms while the patient was 
still en route to the hospital (32.3%). There was no pattern of correlation between reported 
strategies and size, geographic location, teaching status, or ownership type.
Conclusions: Our findings indicate that as of the beginning of the D2B Alliance, many 
hospitals were not implementing the evidence-based strategies to reduce D2B time. 
Future work will evaluate the influence of the D2B Alliance on adoption of hospital-based 
strategies and D2B times.
11:00 a.m.
1005-150 Operator Dependence of Door to Balloon Times in ST 
Elevation Myocardial Infarction
William E. Lawson, Lisa Wilbert, Joseph Chernilas, Anil Mani, Allen Jeremias, Luis 
Gruberg, Mary Maliszewski, William Greene, SUNY Stony Brook, Stony Brook, NY
Background: Primary PCI for STEMI requires teamwork and optimization of each step to 
facilitate early reperfusion. The extent to which operator and assistant influence the door 
to balloon (D2B) time is critical in optimizing the reperfusion process. Examining direct 
transfers to the cath lab eliminates variables that obscure their effects on D2B times in 
STEMI patients (pts).
Methods: STEMI transfers for primary PCI over a 2 year period were examined. The 
operator (5 FT [A-E], aggregate private faculty) and assistant (interventional or non-
interventional fellow), D2B times were benchmarked against a 45 minute standard 
for transfers (from arrival to initial reperfusion device). Initial chi square analysis of 
success in meeting this goal was followed by unpaired t test comparison of operators. 
The performance of interventional fellows was compared and contrasted with non-
interventional fellows. Evidence of operator and assistant interaction was also examined.
Results: Of 404 primary PCI attempts, 228 were in transferred pts. Chi square 
demonstrated a highly significant (p=0.001) variability between FT operators in achieving 
D2B ≤45 min (A 18.8%, B 43.8%, C 42.9%, D 66.7%, E 85.7%; Privates 55.0%). Mean 
± SD and median (range) operator times were: A 59.3±20.7; 59.5 (29-85), B 59.3±24.7; 
52.5 (30-120), C 48.1±15.8; 49 (30-87), D 45.3±14.4; 40 (28-88), E 44.1±22.6; 40 (21-
141) and for interventional fellows: a 40.9±7.8; 40 (33-55), b 48.1±29.1; 33 (25-104). 
Significant differences (all p < 0.05) were present between operators A/B and C/D/E, 
between interventional fellows a and b and between the interventional and non-
interventional fellows as assistants. There was also evidence of significant operator and 
fellow interaction effecting D2B times differently depending on the combination.
Conclusions: Examination of D2B times in STEMI transfer pts allows direct evaluation 
of operator and fellow performance. Marked variability in achieving the target D2B time 
of ≤ 45 min was noted to be related most closely to the primary operator. Assistant 
performance was significantly variable and influenced times, but attending-assistant 
interaction was noted and affected the expected results.
11:00 a.m.
1005-151 Comparing Administrative Coding Algorithms in 
Identifying Patients with Heart Failure
Ashley A. Fitzgerald, Michael O’ Callaghan, David J. Magid, Christina Clarke, David 
Brand, Pamela N. Peterson, Frederick Masoudi, University of Colorado Health Sciences, 
Denver, CO
Background: Identifying patients with heart failure (HF) from administrative data remains 
an important challenge. Studies using administrative codes to identify HF often focus on 
inpatients with a principal discharge dx of HF because of the high PPV of this criterion. We 
assessed if other combinations of administrative codes could accurately classify patients 
with HF.
Methods: Among 15,323 patients in the Kaiser Permanente Colorado system with an 
ICD-9 HF code for any encounter between 1/1/01 and 12/31/06, 11,465 did not have a 
hospitalization with a principal discharge dx of HF. Combinations of administrative codes 
were constructed based upon diagnosis frequency and site of care (Table). From each 
of the algorithms, a random sample of charts was reviewed. The diagnosis of HF was 
validated by the presence of 1) Framingham criteria for HF; or 2) documented LVSD. 
PPVs were calculated for each of the algorithms.
Results: Of the six algorithms, only one, which included only 54 patients, had a PPV 
exceeding 95% (Table). Others, particularly those using outpatient codes, had poor 
PPVs.
Conclusions: Administrative algorithms among patients without a principal discharge dx 
of HF include many patients without evidence of HF. The use of administrative data alone 
to identify patients with HF is thus constrained to hospitalized patients, and primarily 
those with a principal discharge diagnosis of HF. 
Algorithm n PPV (95% CI)
1: >=2 inpatient stays with a secondary HF discharge code 
and a principal CAD discharge code 54 98% (90-99)
2: >=3 inpatient stays with a secondary HF discharge code 850 80% (67-88)
3: >=2 outpatient visits with a HF code 4878 63% (53-73)
4: >=3 outpatient visits with a HF code 3721 67% (56-76)
5: >=3 ED visits with a HF code 162 89% (72-96)
6: >=2 inpatient stays with a secondary HF discharge code 
and >=1 outpatient visit with a HF code 1660 76% (62-86)
11:00 a.m.
1005-152 Prediction of Outcome of Surgical Ventricular 
Restoration Procedure in Patients with Congestive 
Heart Failure Utilizing Computer Simulation
Salvatore Chiaramida, Rumei Dong, Michael Craig, Frederick Vetter, Ying Sun, Medical 
University of South Carolina, Charleston, SC, University of Rhode Island, Kingston, RI
Background: Surgical ventricular restoration (SVR) has been successfully utilized to 
improve left ventricular (LV) function in patients with severe congestive heart failure. 
The extent of SVR to effect the optimal amount of remodeling is not clear. In this study 
modeling and simulation were used to characterize the relationships between the extent 
of SVR and LV performance.
Methods: A finite element model of the LV was based on a truncated ellipsoidal geometry 
with an infarct zone of adjustable size. The LV model was dynamic by defining stress-
strain relations with time-varying Young’s moduli. The hemodynamic model was an analog 
circuit defined by 28 differential equations. The LV model and the hemodynamic model 
were coupled and solved at time steps of 5 ms.
Results: The figure shows an example of the model prediction. The control was an 
impaired LV with mass = 225 g, end-diastolic volume = 225 ml, and infarct size = 93 g 
(41%). In the simulation the infarction was progressively removed, from 5% to 40 % of the 
original total LV mass. The LV pressure-volume loops showed an optimal operating point 
at 30% removal. This was also demonstrated with the Starling curves by varying preload 
pressure in each case.
Conclusions: The findings indicate that an optimal point exists for the SVR procedure that is 
in the range of current practice and varies with pre-operative condition of the LV. Computer 
simulation may prove to be an important tool for designing useful templates for SVR. 
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88.7+1.2 kg) and waist circumference (42.1+0.4 vs. 39.6+0.4 cm) when compared to Rural, 
while Rural had greater walk distance (496+7.0 vs. 419+7.8 m). Rural showed greater 
improvements from Baseline to 1 yr for weight (-1.0+0.3 vs. +0.2+0.3 kg), waist circumference 
(-0.3 + 0.4 vs +1.1 + 0.5 cm), and walk distance (+17.2+4.7 vs. +0.7+5.1 m).
Conclusions: There were differences in the response to Telemedicine for rural versus urban 
locations. The increased exercise capacity of the Rural group may have contributed to 
the improved weight, BMI and Waist Circumference that the Urban group did not show. 
Increasing physical activity appears more difficult or less desirable in urban locations; 
therefore, risk reduction strategies may need to differ for rural versus urban environments. 
Future research needs to focus on: 1) Rural versus urban environments regarding behavioral 
change strategies. 2) If differences were environmental versus Race related since the Urban 
group was predominantly black (77%) and Rural group predominantly white (99%).
ACC.POSTER CONTRIBUTIONS
1012 
Outcomes Assessment I
Sunday, March 30, 2008, 1:00 p.m.-4:30 p.m.
McCormick Place, South Hall 
3:00 p.m.
1012-127 The Impact of Race and Insurance Status on Utilization 
Rates and Outcomes after Percutaneous Coronary 
Interventions in the Commonwealth of Massachusetts
Oz M. Shapira, Louis M. Stevens, Amit Korach, Emelia Benjamin, Ann Lovett, Treacy 
Silverstein, Arvind K. Agnihotri, David F. Torchiana, Richard J. Shemin, Alice K. Jacobs, 
Sharon-Lise T. Normand, Boston Medical Center, Boston, MA, Harvard Medical School, 
Boston, MA
Background: The association of race and insurance status with utilization rates and 
outcomes after percutaneous coronary interventions (PCI) in Massachusetts (MA) was 
evaluated.
Methods: The mandatory Adult PCI database linked to the Registry of Vital Records and 
Statistics and Inpatient Acute Hospital Case Mix Charge Database in MA, the National 
Health Interview Survey, and US Census data for 22,139 patients undergoing PCI 
between 4/2003-12/2004 were used. Outcomes modeled: 1) 30-day all-cause mortality; 
2) Major adverse cardiac and cerebral events (MACCE); 3) Other morbidity; 4) Hospital 
stay (LOS); 5) One-year mortality. Multivariable models were constructed by sequentially 
including: race, insurance type, patient clinical and procedural characteristics and 
socioeconomic profiles.
Results: PCI was performed less often in Hispanic (vs whites) and in Medicaid-insured 
patients but more often in Medicare (vs Commercial insurance) patients. Thirty-day 
mortality and MACCE after PCI were similar regardless of race or insurance, except for 
patients other than white, black or Hispanic. Morbidity was increased in Medicare patients 
while LOS was increased in Medicaid and uninsured patients. One-year mortality was 
higher in blacks and Medicare and Medicaid patients.
Conclusions: Significant racial and insurance-based disparities in PCI utilization and 
outcomes exist. The recently enacted healthcare reform in MA may reduce these 
disparities. 
Outcome
Utilization 
Rates 
(/1000 CAD 
Residents)
30-Day 
Mortality
Hospital 
Morbidity
MACCE
Hospital 
Stay
One-year 
Mortality
Unadjusted 
Rate 
N=22,139
46.8 2.09% 6.27% 4.43% 4.4 days 6%
RACE 
Relative Risk 
[95% CI]
White
44.9 
[41.0, 48.8] 1 1 1 1 1
Black
38.1 
[25.3, 50.9]
1.64 [0.80, 
3.35]
0.65 [0.40, 
1.03]
0.77 [0.32, 
1.87]
1.05 [0.96, 
1.15]
1.50 [1.05, 
2.12]*
Hispanic
31.5 
[22.6, 40.5]*
0.98 [0.42, 
2.27]
0.74 [0.55, 
1.01]
0.94 [0.59, 
1.52]
1.06 [0.99, 
1.14]
0.90 [0.62, 
1.31]
Other
91.8 
[0, 720.3]
1.65 [1.33, 
2.05]*
1.16 [0.94, 
1.44]
1.23 [0.96, 
1.58]
0.98 [0.89, 
1.09]
1.12 [0.87, 
1.46]
INSURANCE 
Relative Risk 
[95% CI]
Commercial
41.6 
[37.0, 46.1] 1 1 1 1 1
Medicare
120.0 
[100.2, 
139.9]*
1.18 [0.96, 
1.46]
1.16 [1.02, 
1.31]*
0.95 [0.84, 
1.06]
1.04 [0.99, 
1.08]
1.29 [1.13, 
1.48]*
Medicaid
10.6 
[8.2, 12.9]*
1.61 [0.68, 
3.82]
1.30 [0.88, 
1.94]
1.37 [0.88, 
2.14]
1.14 [1.03, 
1.25]*
1.58 [1.08, 
2.34]*
Uninsured
41.5 
[24.5, 58.5]
1.31 [0.91, 
1.88]
1.17 [0.98, 
1.38]
0.81 [0.55, 
1.18]
1.09 [1.04, 
1.14]*
0.90 [0.62, 
1.32]
11:00 a.m.
1005-153 Feasibility and Validation of Clinical Status With 
Internet-Based Remote Intrathoracic Impedance 
Monitoring in Patients With Heart Failure
Wilfried Mullens, Linda Kelly, Tanya Verga, Zuheir Abrahams, W H Wilson Tang, 
Cleveland Clinic, Cleveland, OH
Background: Serial monitoring of intra-thoracic impedance (Z) has been proposed as 
part of heart failure disease management and a derived fluid index (FI) threshold has 
been examined to predict heart failure (HF) hospitalizations. We aim to prospectively 
determine the frequency of FI crossing in a routine internet-based Z monitoring program, 
and prospectively identify potential contributors that led to changes in Z.
Methods: Patients previously implanted with a device capable of measuring Z were 
scheduled for remote transmission of device check every three months. A heart failure 
nurse analyzed all transmitted data daily and called the patient if the FI crossed the 
threshold at 60 Ω∙days to identify clinically relevant events.
Results: Mean data analysis time was 30 minutes daily. A total of 194 patients (130 
with CRT, 64 with ICD) were followed within a 4-month period, of which only 34 (18%, 
mean age 62±14 years, mean LVEF 29±12%) had a FI threshold crossing, averaging 
0.52(pt•yr)-1. Thirty-two (94%) with FI values above threshold had evidence of worsening 
dyspnea, edema, or weight during this period when interviewed by phone. Among them, 6 
(18%) had HF hospitalizations, and 19 (56%) had reported changes in HF therapy.
Conclusions: Remote internet-based intra-thoracic impedance monitoring is feasible as part 
of disease management program without significant time commitment. In our prospective 
series with phone interviews, threshold crossing can be attributed to changes in clinical status, 
suggesting the ability of impedance monitoring of underlying physiologic alterations.
11:00 a.m.
1005-154 Intelligent Wireless Monitoring of Acute Cardiac 
Patients in a Platform Using Computerized Guidelines 
Models: the SAPHIRE Project
Maria Dorobantu, Ana-Gabriela N. Fruntelata, Silviu Ghiorghe, Liviu Ghilencea, Gokce 
Banu Laleci Enturkmen, Asuman Dogac, Emergency Hospital of Bucharest, Bucharest, 
Romania, Middle East Technical University, Ankara, Turkey
Background: Improvement of in-hospital healthcare for patients with acute coronary 
syndromes (ACS) in order to reduce complications and costs, and also the clinical workload 
is a current target for many health policies. Standardization of care by implementing 
international guidelines via guidelines models and also use of wireless monitoring have 
not been tried to achieve these goals in this specific patient population.
Methods: Hospital Pilot Application for the The Intelligent Healthcare Monitoring Based 
on a Semantic Interoperability Platform Project (the SAPHIRE Project) uses a firstly 
developed prototype of intelligent wireless monitoring for patients with acute coronary 
syndromes. It includes 12 leads ECG, blood pressure and oxygen saturation monitoring 
for 24-48 hours, the information from the sensors being transmitted via semantically 
enriched web services to an interoperability platform, to be integrated with data from the 
Electronic Health Record (EHR). These data generate real-time alerts also transmitted 
via web services to the medical staff and are also integrated into computerized guidelines 
models that have been developed based on the current guidelines for ACS, using an 
extension of Guideline Interchange Format (GLIF) [3] Version 3.4.
Results: First SAPHIRE prototype is now tested on virtual patient data, to demonstrate 
that the SAPHIRE system can provide not only bedside intelligent monitoring in a wireless 
fashion, but also patient-specific computer-generated clinical decision in accordance to 
the latest guidelines. The physician receives alert messages from the sensors and from 
the guidelines model and also clinical recommendations that are afterwards medically 
validated. The study will be continued with second prototype to be used in monitoring of 
75 real patients with ACS during the hospital pilot application.
Conclusions: This is the first study to provide computer-assisted, monitoring-based real-
time decisions in accordance with current standards. In this pilot application, the guideline 
execution environment provides continuous feedback to the physicians that is aimed to be 
patient-specific and guideline-oriented, to provide optimized medical care.
11:00 a.m.
1005-155 Differential Impact of Telemedicine on Exercise Capacity 
and Body Composition in Urban and Rural Underserved 
Populations
Timothy R. McConnell, William Santamore, Francis J. Menapace, Alfred Bove, Carol 
Homko, Arun Kalyanasundaram, Geisinger Medical Center, Danville, PA, Temple 
University, Philadelphia, PA
Background: Although Telemedicine is effective for reducing factors related to 
cardiovascular risk, there may be differences in the response to Telemedicine when 
comparing urban versus rural populations. We wished to determine if rural (Northcentral 
PA) or urban (Philadelphia, PA) groups responded differently to telemedicine regarding 
exercise capacity, weight and waist circumference.
Methods: Rural (north central PA; n=197; 57% men; 99% white; age = 63.6+9.2 yrs) and 
Urban (Philadelphia; n=165; 53% men; 77% black; age = 58.1+10.2 yrs) adults with a 10%, 
10-yr CV Risk participated in a web-based telemedicine (electronic data reporting, discussion 
and feedback) study designed to reduce risk over a 1-yr follow up period. Weight (kg), waist 
circumference (cm), and 6-min walk distance (m) were measured at baseline and after 1-year 
of Telemedicine Treatment. Between group differences and interactions (2-way ANOVA) were 
investigated for urban vs. rural environment over time (baseline vs. 1 yr).
Results: All stated differences are p < 0.05. Urban had overall greater weight (93.3+1.4 vs. 
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1012-128 Sustaining Excellence in Three Major Areas of Cardiac 
Care Over Three Years: Can Any Hospital Be a Top 
Performer Over Time and Does it Matter?
Aaron D. Kugelmass, Phillip P. Brown, David J. Cohen, Matthew R. Reynolds, April W. 
Simon, Steven D. Culler, Emory University, Atlanta, GA, Cardiac Data Solutions, Inc., 
Atlanta, GA
Background: This study examines if hospitals can sustain excellence in three major areas 
of care (AMI, PCI, and CABG).
Methods: A retrospective analysis was conducted using MedPar data for fiscal years 
2003 thru 2005. The study sample consists of 710 US hospitals that treated at least 52 
Medicare beneficiaries (MB) per fiscal year in each of the care areas. Logistic regressions 
were estimated to predict in-hospital mortality for each type of hospitalization annually. 
For each care area, hospitals were ranked into quartiles (from best to worst) annually, 
based on the difference between a hospital’s risk-adjusted expected number of deaths 
and its observed number of deaths. Hospitals were assigned annual performance scores 
based on their quartile rankings as follows: 1 - top quartile in all three; 2 - averaged 
ranking between 1 and 2; 3 - averaged between 2 and 3; 4 - averaged between 3 and 4; 
and 5 bottom quartile in all three.
Results: Only 46 hospitals achieved a cumulative performance score of 5 or less (a score 
of 1 in at least 1 year and no lower than a 2 in the other years). The table reports the 
average lives saved and average risk-adjusted mortality rates for each type of service 
by year for the 46 hospitals versus the other 664 study hospitals. All differences were 
statistically significant (p<0.001) between the two study groups.
Conclusion: Sustained top performance in all three care areas is rare. However, those hospitals 
that do, save significantly more lives on average than all other hospitals treating MBs. 
FY-2003 FY-2004 FY-2005
46 Top Performers:
Total Volume (All Services) 1,216 1,231 1,178
Lives Saved (CABG) +2.7 +3.2 +2.3
Lives Saved (PCI) +3.7 +3.6 +3.2
Lives Saved (AMI) +8.7 +9.6 +9.2
RA Mortality (CABG) 2.11% 1.92% 1.74%
RA Mortality (PCI) 0.82% 0.87% 0.88%
RA Mortality (AMI) 7.74% 6.99% 6.45%
All Other Study Hospitals (664 Hospitals):
Total Volume (All Services) 876 875 843
Lives Saved (CABG) -0.18 -0.20 -0.22
Lives Saved (PCI) -0.16 -0.25 -0.23
Lives Saved (AMI) -1.07 -1.00 -0.89
RA Mortality (CABG) 3.70% 3.73% 3.38%
RA Mortality (PCI) 1.62% 1.56% 1.49%
RA Mortality (AMI) 10.55% 10.11% 9.64%
3:00 p.m.
1012-129 Primary Percutaneous Coronary Intervention in Acute 
Myocardial Infarction With or Without Thrombectomy: a 
Meta-Analysis
François-Pierre Mongeon, Patrick Bélisle, Lawrence Joseph, Mark J. Eisenberg, 
Stéphane Rinfret, Divisions of General and Interventional Cardiology, Centre Hospitalier 
de l’Université de Montréal, Montreal, QC, Canada, Division of Clinical Epidemiology, 
McGill University, Montreal, QC, Canada
Background: In available trials, mechanical removal of thrombus from the coronary 
artery inconsistently improves outcomes of percutaneous coronary intervention (PCI) 
for acute myocardial infarction (MI). We performed a meta-analysis of randomized trials 
of adjunctive thrombectomy in primary PCI to determine if it leads to better myocardial 
perfusion and lower mortality and reinfarction rates.
Methods: A systematic literature search aimed to identify all randomized clinical trials in 
the specific setting of acute ST-segment elevation myocardial infarction. The outcomes 
examined were the rates of death, recurrent MI, stroke and post procedure rates of 
Thrombolysis in Myocardial Infarction (TIMI) 3 flow, TIMI myocardial perfusion grade 3, 
ST segment resolution > 50%, no reflow and distal embolization. We also compared the 
impact of thrombectomy on procedure time, symptom onset to balloon time, post-MI left 
ventricular ejection fraction (LVEF) and left ventricular volumes.
Results: We identified 16 eligible trials involving 2,944 patients. Adjunctive thrombectomy 
yields significantly less no reflow (odds ratio 0.35, 95% credible interval 0.10-0.95), more 
ST segment resolution > 50% (2.24, 1.40-3.82) and more TIMI myocardial perfusion grade 
3 (2.45, 1.11-5.81) There was no excess of death, recurrent MI, stroke with thrombectomy 
(1.16, 0.59-2.41). The meta-analysis shows no effect on post procedure TIMI 3 flow (1.32, 
0.84-2.28) and distal embolization (0.58, 0.19-1.45). There is no significant difference in 
procedure time and symptom onset to balloon time between thrombectomy and control 
groups. Thrombectomy does not improve post-MI LVEF, but may reduced left ventricular 
remodeling at 6 months.
Conclusions: Adjunctive thrombectomy significantly improves surrogate markers of 
reperfusion after primary PCI. However, this effect does not extend to a reduction in clinical 
events rates. Available studies are limited by their small sample size, which translates in 
large credible intervals. Randomized trials powered to study clinical outcomes and with 
longer follow-up are needed.
3:00 p.m.
1012-130 Symptoms of depression, antidepressant use, and risk 
of sudden cardiac death and coronary events among 
women
William Whang, Laura D. Kubzansky, Ichiro Kawachi, Kathryn M. Rexrode, Candyce H. 
Kroenke, Hasan Garan, Christine M. Albert, Columbia University Medical Center, New 
York, NY, Brigham and Women’s Hospital, Boston, MA
Background: Depression has been identified as a risk factor for the development of 
cardiovascular disease and for recurrent cardiac events and mortality among those 
with established coronary artery disease. Several studies have suggested a possible 
arrhythmic mechanism.
Methods: We studied the relationship between symptoms of depression, antidepressant 
use, and cardiac events in the Nurses’ Health Study. Questionnaires in 1992, 1996, and 
2000 assessed depressive symptoms with the Mental Health Index (MHI-5), a five-item 
subscale of the Short-Form 36 health status survey, as well as other coronary heart 
disease (CHD) risk factors. Depression was defined as an MHI-5 score of <53, based on 
data from this and other studies. Antidepressant use was assessed in 1996 and 2000. 
Primary endpoints included 142 sudden cardiac deaths (SCD), 463 fatal CHD events, and 
1,189 non-fatal myocardial infarctions (MI).
Results: Among 63,191 women without prior CHD or stroke in 1992, 7.9% had depression 
by MHI-5 score. Women with MHI-5 depression were older and had higher prevalence 
of hypertension, diabetes, high cholesterol, and cigarette use. In multivariable Cox 
proportional hazard analyses that adjusted for these CHD risk factors, MHI-5 depression 
was significantly associated with fatal CHD (HR=1.40, 95% CI 1.04-1.89) but not with non-
fatal MI (HR=1.14, 0.90-1.45). In these models, MHI-5 depression was not associated with 
SCD (HR=1.20, 0.66-2.18) but was associated with other fatal CHD events (HR=1.57, 
1.13-2.17). When antidepressant use was added to these models beginning in 1996, the 
relationship between MHI-5 depression and other fatal CHD events persisted. In contrast, 
antidepressant use was associated with a higher risk of SCD (HR=3.24, 1.97-5.32) but 
not other fatal CHD events (HR=0.66; 0.39-1.10).
Conclusions: In this cohort of women without baseline CHD, symptoms of depression 
were associated with total fatal cardiac events, and antidepressant use was specifically 
associated with SCD. Although antidepressant use may be a marker of depression 
severity, its association with elevated risk of sudden cardiac death merits further study.
3:00 p.m.
1012-131 Clinical Outcomes in Patients for Whom Precertification 
for Myocardial Stress Perfusion Imaging Was Not 
Obtained Using Algorithms Based On ACC/AHA/ASNC 
Guidelines and Appropriateness Criteria
Nathaniel Reichek, David Grossman, Russell Amico, Gary Gerstenblith, Jeffrey A. 
Brinker, Stephen Winters, Hugh Calkins, Jing Han, John Covert, Joseph Levine, St. 
Francis Hospital, Roslyn, NY, Johns Hopkins Medical Institutions, Baltimore, MD
Background: Pre-certification algorithms for outpatient myocardial stress perfusion 
imaging (sMPI) can limit utilization, but little data exists on outcomes in patients for whom 
sMPI is not approved using a precertification process.
Methods: Algorithms for pre-certification of sMPI based on ACC/AHA/ASNC practice 
guidelines and appropriateness criteria were developed by CareCore Cardiology 
Management and applied in a population of 829,360 covered lives beginning 2/06. For 
patients whose MPI pre-certifications were not approved from 2/3/06 to 5/30/06, we 
reviewed all services provided to 9/01/06 using ICD9 and CPT codes to identify cardiac 
events, including acute myocardial infarction, revascularization, resuscitation from sudden 
death and coronary angiography. The Social Security Death Index and New York State 
Bureau of Vital Statistics records were also searched for deaths.
Results: There were 9311 requests for sMPI of which 2056(22.1%) were initially 
unapprovable. Appeals were made in 120(5.8%) and of these 77(64%) were then approved 
for sMPI. Thus 1979 patients were “at risk” and comprise the study group. Mean follow-up 
was155.7+ 34.0 days during which there were no deaths, acute myocardial infarctions 
or cardiac resuscitations. In 20 patients(1.0%) coronary angiography was subsequently 
performed and 6 of these (0.3% of the study group) underwent revascularization(4 PCI, 
2 CABG). Angiography and revascularization occurred without intercurrent services 
or any appeal of the initial sMPI precertification disapproval in each patient: within 1 
week of initial denial in 3 patients and 21, 25 and 82 days after initial disapproval in the 
remainder. Thus no patient unapproved for sMPI had an adverse event and only 0.3% had 
subsequent revascularization.
Conclusions: Use of ACC/AHA/ASNC-based precertification algorithms reduced sMPI 
utilization, avoided unnecessary radiation exposure and resulted in a substantial reduction 
in health care costs without any major adverse cardiac events in this population.
3:00 p.m.
1012-132 Diastolic Dominant Pulmonary Vein Flow Predicts 
Hospitalization for Heart Failure and Mortality in 
Ambulatory Patients with Coronary Heart Disease
Xiushui Ren, Beeya Na, Bryan Ristow, Mary A. Whooley, Nelson B. Schiller, VA Medical 
Center, San Francisco, CA, University of California, San Francisco, San Francisco, CA
Background: Diastolic dominant pulmonary vein Doppler flow pattern, combined with 
mitral inflow, identifies diastolic dysfunction with poor prognosis. We hypothesized that 
diastolic dominant pulmonary vein flow as a stand alone variable predicts heart failure 
(HF) hospitalizations and cardiovascular (CV) death.
Methods: Standard transthoracic echocardiograms were obtained in 906 subjects from 
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the Heart and Soul Study, a prospective study of patients with stable coronary heart 
disease. Pulmonary vein flow pattern was determined by the dominant velocity time 
integral. Cardiac events were determined by two independent adjudicators and Cox 
proportional hazards models were applied.
Results: During an average 3 years of follow-up, subjects with diastolic dominant 
pulmonary vein flow had a 25% rate of HF hospitalization and 9% rate of CV death. After 
multivariate adjustment, diastolic pulmonary vein flow was associated with a 4-fold risk for 
HF hospitalization (p<0.0001) and a 2-fold risk for HF hospitalization or death (p=0.0002). 
(Figure) Compared with combined Doppler indices of diastolic dysfunction, pulmonary 
vein flow pattern was equally predictive.
Conclusions: These data support our hypothesis that pulmonary vein flow pattern can be 
used as a stand alone predictor of adverse cardiac events. Diastolic dominant pulmonary 
vein flow pattern is associated with significantly higher rates of HF hospitalizations and 
CV death and compares favorably with more complex Doppler indices. 
3:00 p.m.
1012-133 Relation of Angiographic Patterns and Ejection Fraction 
to Clinical Outcomes in the COURAGE Trial
G. B. John Mancini, Pamela M. Hartigan, David J. Maron, Leslee Shaw, Daniel Berman, 
Bernard Chaitman, Eric R. Bates, William Kostuk, Merrill Knudtsen, Marcin Dada, Koon 
K. Teo, Robert A. O’Rourke, William E. Boden, University of British Columbia, Vancouver, 
BC, Canada, COURAGE Investigators, West Haven, CT
Background: COURAGE randomized patients to elective percutaneous coronary 
intervention (PCI) plus optimal medical therapy (OMT) or OMT alone. We hypothesized 
that more severe angiographic coronary artery disease (CAD), and depressed ejection 
fraction (EF) would identify higher risk patients with improved outcome from PCI + OMT 
compared with OMT alone.
Methods: We analyzed death/myocardial infarction (MI), MI, and acute coronary syndrome 
(ACS) in 2,275 patients. Peri-procedural MI was excluded. Vessel disease was defined by 
core analysis as > 50% DS in major segments/branches. Proximal LAD (pLAD) disease 
either isolated or in combination with other vessel disease was also evaluated. Low EF 
was defined as < 50%. Cox regression analysis was undertaken using terms for treatment 
assignment, Low EF, number of vessels, pLAD and interaction terms.
Results: 
Outcome Variables Hazard Ratio 95% CI p value
Death/MI Treatment 0.95 0.85, 1.057 0.40
(372 events Number of stenotic vessels 1.44 1.27, 1.64 <0.001
overall) Low EF 1.49 1.18, 1.90 0.001
Interaction of treatment & vessels 1.00 0.94
Interaction of treatment & Low EF 0.90 0.40
MI Treatment 0.92 0.89, 1.06 0.25
(229 events Number of stenotic vessels 1.55 1.31, 1.83 <0.001
overall) Low EF 1.16 0.84, 1.61 0.38
Interaction of treatment & vessels 0.99 0.86
Interaction of treatment & Low EF 1.05 0.77
ACS Treatment 1.03 0.90, 1.18 0.64
(258 events Number of stenotic vessels 1.24 1.06, 1.45 0.007
overall) Low EF 1.06 0.77, 1.46 0.73
Interaction of treatment & vessels 1.01 0.92
Interaction of treatment & Low EF 1.01 0.92
Isolated pLAD or pLAD associated with other disease was not predictive of any end-
point. Moreover, addition of PCI to OMT did not reduce the risk of events compared with 
OMT alone in any subgroup. Conclusions: Increasing number of stenotic vessels is the 
most consistent predictor of events and low EF also identified patients at greater risk of 
death/MI. pLAD disease was not predictive of events. This analysis is limited by the size 
of individual groups and the post-hoc nature of the analysis. But the findings suggest that 
trials comparing OMT to PCI + OMT in chronic stable angina should be limited to patients 
with multivessel disease and impaired EF.
3:00 p.m.
1012-134 Treatment and Outcome of Diabetic Patients with 
an Acute Coronary Syndrome: Has There Been any 
Improvement Over Time? The GRACE Registry
Joel M. Gore, Michel Marre, Ph Gabriel Steg, David Brieger, Ann Quill, Shaun G. 
Goodman, for the GRACE Investigators, UMASS Medical School, Worcester, MA, 
Hopital Bichat, Paris, France
Background: Improvements in the management of acute coronary syndrome (ACS) are 
associated with short-term reductions in adverse outcomes. Whether diabetic patients 
with an ACS - a higher risk group - have seen the same improvement is unknown.
Methods: GRACE is a prospective observational study of patients hospitalized with 
ACS at 113 sites in 14 countries. We report on data from 46,576 patients. Using logistic 
regression, temporal trends in treatment and outcomes were analyzed for seven 1-year 
intervals starting in July 1999.
Results: Approximately 1 in 4 patients (11,550) presenting with ACS was diabetic. Patients 
with diabetes were older, more often female, had a greater prevalence of comorbidities, 
and a higher GRACE risk score. Rates of use of catheterization and percutaneous 
coronary intervention increased over time, but less so in diabetic individuals. Diabetic 
patients had slightly higher rates of CABG. Hospital mortality rates were higher in diabetic 
than non-diabetic patients. Over the 7-year study, hospital mortality and the combined 
endpoint of 6-month MI, stroke, or death declined in non-diabetic patients with an ACS 
but remained unchanged in the diabetic cohort. 
In-hospital interventions and clinical outcomes
Jul 99-
Jun 00 
(n=7228)
Jul 00-
Jun 01 
(n=6802)
Jul 01- 
Jun 02 
(n=6807)
Jul 02- 
Jun 03 
(n=7288)
Jul 03- 
Jun 04 
(n=)7256
Jul 04- 
Jun 05 
(n=6203)
Jul 05- 
Jun 06 
(n=5346)
P 
value* 
for 
trend
Diabetic 
patients 
(%)
24 24 26 25 26 26 27 <.001
In-hospital (%)
Cath - 
diabetics
48 54 55 56 59 62 62 <.001
Cath - non-
diabetics
46 53 57 60 63 68 68 <.001
PCI - 
diabetics
23 29 30 32 34 38 36 <.001
PCI - non-
diabetics
23 31 36 37 40 45 46 <.001
CABG - 
diabetics
7.4 5.5 6.3 5.9 4.4 5.6 5.0 0.01
CABG 
- non-
diabetics
5.1 4.2 4.6 4.5 4.3 4.4 3.8 0.02
Death - 
diabetics
5.8 6.9 6.6 5.1 6.3 6.3 5.1 0.24
Death 
- non-
diabetics
4.4 4.4 5.0 4.1 3.6 3.8 3.3 <.001
Post-discharge (%)
6-month 
MI, stroke, 
or death - 
diabetics
7.9 10 11 8.5 9.4 8.5 7.1 0.06
6-month MI, 
stroke, or 
death - non-
diabetics
6.1 7.4 8.5 6.5 5.6 5.5 4.9 <.001
Conclusions: Diabetic patients with ACS are treated less aggressively than non-diabetic 
patients. These observational data show improvements in both hospital and 6-month 
outcomes in non-diabetic patients with an ACS but no changes in outcomes among those 
with diabetes.
3:00 p.m.
1012-135 Communication Strategies To Reduce Cardiovascular 
Disease Risk In Underserved Communities
Alfred A. Bove, William P. Santamore, Carol J. Homko, Timothy McConnell, Gail Shirk, 
Robert Cross, Abul Kashem, Francis Menapace, Temple University, Philadelphia, PA, 
Geisinger Medical Center, Danville, PA
We used two strategies (clinical only-C, clinical plus telemedicine-T) to inform patients in 
a rural and an urban underserved community about their cardiovascular disease (CVD) 
risk based on the Framingham score, and provide feedback to help in reducing CVD risk. 
388 patients (183 Urban, 285 rural, 211 male, 59% white, 37% African American, 4% 
Hispanic, average income $17.4K Urban, $35.4K) with a Framingham risk > 15%, and no 
evidence of CVD were randomized to a communication strategy involving either 4 clinical 
encounters in one year, or 4 clinical encounters plus unlimited access to their health care 
system via an Internet-based telemedicine system. All subjects measured home blood 
pressure, weight, steps per day with a pedometer, and reported at their clinic visits (C 
group), or as desired via Telemedicine (T group). The T group reported 6.3±8.8 health 
measures per month via the Internet, and received a response from the practice via 
the Internet for each report. After one year, risk score for the entire cohort was reduced 
by 2.6%±6.8 (p< 0.001), there was no difference between the groups (C: -2.7±7.3, T: 
+2.5±6.3 p=0.75). Reductions in total Cholesterol (C: -10.2±36.6, T: -9.7±35.6, p< 0.001 
for both), LDL (C: -7.2 ±32.5, T: -6.7±3 0.4, p< 0.001), and Triglycerides (C: -29.6±133.2, T: 
-14.9 ±73.4, p< 0.001) were significantly in both groups, HDL (C: +2.0±9.6, T: -0.10±7.8) 
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was unchanged. Systolic BP was lowered more in T (C: -9.1 ±20.7, T: -12.1±19.1, p< 
0.001), while Diastolic BP was reduced equivalently in both groups (C: -4.1±12.1, T: -
5.2±11.2, p<0.001). The T group had more diabetics (T- 42%, C- 51%), and showed a 
greater drop in FBG (C: -5.2 ±37.4, T: -7.0±37.3, p<0.001), and A1C (C: +0.016±0.987, T: 
-0.190±1.102, p< 0.001). 67% of subjects in both groups showed an improvement in CVD 
risk,, both groups showed an increase in 6-minute walk distance (C: +25±256, T: +25±228 
feet). Frequent communications in an asymptomatic underserved cohort at increased risk 
for CVD can lower blood pressure, blood lipids,, and CVD risk score. Adding an internet-
based telemedicine system allows frequent access to health care providers and provides 
some advantage over frequent office visits alone.
3:00 p.m.
1012-137 NT-proBNP and Incident Heart Failure (HF) in 
Community-Dwelling Older Adults: the Cardiovascular 
Heart Study (CHS)
Stephen L. Seliger, Christopher R. DeFilippi, Robert H. Christenson, Willem J. Kop, John 
S. Gottdiener, University of Maryland School of Medicine, Baltimore, MD
Background: The role of NT-proBNP in predicting incident HF in asymptomatic patients is 
not clear, especially among older adults with a high burden of co-morbidity.
Methods: We measured NT-proBNP (Roche Elecsys) in the CHS, a multi-center study 
of cardiovascular risk factors in community-dwelling older adults, in sera collected in 
1989-90 or 1992-93 (at entry into CHS). Incident HF was determined prospectively by 
expert review of inpatient and outpatient records. Cox proportional hazards regression 
was used to estimate the association of NT-proBNP and incident HF, after adjusting for 
demographic factors and other HF risk factors (blood pressure, coronary heart disease, 
diabetes, smoking, lipid levels and renal function).
Results: NT-proBNP was measured in 4,312 (76.8%) CHS subjects without prevalent HF 
at baseline. Median age was 71 years, 18% had coronary disease, 59% had hypertension, 
and 21.5% had estimated GFR<60 cc/min/1.73m2. Rate of incident HF was 2.5 per 100 
person-years over a median 10.5 years of follow up. Increasing levels of NT-proBNP were 
associated with a significantly greater risk of incident HF after multivariate adjustment, 
with a 3-fold risk among those in the highest quintile (Table). The association did not 
differ between those with GFR<60 cc/min(HR=1.56) and >60 cc/min (HR=1.65; p=0.4 
for interaction). 
Association of NT-proBNP and Incident Heart Failure
Demographic-Adjusted Fully-Adjusted
Hazard Ratio (95% CI)
ln(NT-proBNP) 1.68 (1.59, 1.79) 1.58 (1.48, 1.61)
Quintiles 
(Range, pg/mL)
Q1 (<5-47.5) Ref Ref
Q2 (47.5-86.8) 1.04 (0.83, 1.32) 1.01 (0.80, 1.29)
Q3 (86.9-143.1) 1.32 (1.06, 1.66) 1.24 (0.99, 1.55)
Q4 (143.2-267.5) 1.93 (1.55, 2.40) 1.79 (1.43, 2.22)
Q5 (267.7-23,445) 3.84 (3.12, 4.73) 3.16 (2.54, 3.93)
Test for trend <.001 <.001
Conclusions: NT-proBNP is a strong predictor of incident HF in a community-based elderly 
population, independent of renal function and common cardiovascular risk factors.
3:00 p.m.
1012-138 The 2006 AHA/ACC Cardiovascular Disease Prevention 
Guideline Recommendations: Impact of Pharmacologic 
versus Therapeutic Lifestyle Interventions on All-Cause 
Mortality
Shervin Eshaghian, Sameer Amin, Jayanta R. Das, Donna Polk, Prediman K. Shah, 
George A. Diamond, Sanjay Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: Traditionally pharmacologic interventions like aspirin, beta blockers, ACE-I, 
and statins have garnered greater attention than therapeutic lifestyle interventions like 
diet, exercise, and smoking cessation for cardiovascular risk prevention.
Objective: To evaluate the relative effectiveness of pharmacologic vs. therapeutic lifestyle 
recommendations of the 2006 AHA/ACC Cardiovascular Disease Prevention Guidelines.
Methods: Evidence for total mortality benefit associated with 7 recommendations was 
evaluated and summary estimates (odds ratio) were derived via a random-effect meta-
analysis of trials. Posterior probabilities (Pr) that risk reduction is greater than threshold 
value for clinical importance (d>0%, 5%, 10%, 15%), were derived from a Bayesian 
analysis using an uninformative prior (μ = 0, σ =10).
Results: Table illustrates a comparative analysis of therapeutic benefit. Although 
Pr(d>0%) approaches 100% for all recommendations (consistent with statistically 
significant p values), the Pr d>5%, >10%, and >15% benefit is >90% for 6, 4, and 3 
recommendations, respectively. With the exception of aspirin, the Pr d>15% benefit 
is much greater for lifestyle interventions (>75% in all 3) compared to pharmacologic 
interventions (<30% in 3 of 4).
Conclusions: The probability of a clinically important mortality benefit is higher for lifestyle 
compared to pharmacologic interventions, thereby highlighting the relative importance of 
the former in modulating cardiovascular risk.
Category Sample 
size
# of 
trails
Summary OR 
(95% CI)
p  
value
Pr  
d>0%
Pr  
d>5%
Pr  
d>10%
Pr  
d>15%
Aspirin 2,856 4 0.42 (0.26-0.69) 0.0004 100% 100% 100% 100%
Beta 
blocker 52,465 4 0.87 (0.80-0.94) 0.0006 100% 99.9% 80% 28%
Converting 
enzyme 
inhibitor
98,483 4 0.93 (0.89-0.98) 0.004 99.8% 80% 10% 0%
Cholesterol 
lowering 
(statin)
90,056 14 0.88 (0.84-0.91) <0.0001 100% 100% 87% 4%
Diet (Lyon 
Diet Heart 
Study)
423 1 0.44 (0.21-0.94) 0.030 98.5% 98% 97% 96%
Exercise 8,432 48 0.80 (0.68-0.93) 0.005 99.8% 98% 93% 78%
Smoking 
Cessation 5,878 12 0.54 (0.46-0.62) <0.0001 100% 100% 100% 100%
3:00 p.m.
1012-139 Functional Decline After an Acute Myocardial Infarction: 
Do Elderly Patients Have Different Rates and Predictors 
Than Younger Patients?
Suzanne V. Arnold, Karen P. Alexander, Frederick A. Masoudi, P. Michael Ho, Lan Xiao, 
Susmita Parashar, John A. Spertus, Mid America Heart Institute, Kansas City, MO
Background: Functional decline is a powerful predictor of morbidity and mortality. It also 
adversely affects quality of life and can be a threat to independence, particularly in the 
elderly. The rates of and factors contributing to functional decline post-MI in young and old 
pts are poorly described, thus limiting the ability to target at-risk pts.
Methods: A 19-site US registry of post-MI pts was analyzed to identify predictors of 
functional decline following hospitalization. Decline in function was defined as either a 
>5 point decrease in SF-12 Physical Components Scale (PCS) from baseline or being 
“too ill” to follow-up at 1 yr. Multivariable regression identified factors associated with 
decline in function at 1 yr in old (>70 yrs) and young (<70 yrs) pts. To assess for a ‘floor’ 
effect, a secondary analysis excluding pts with very low baseline function (PCS<25) was 
performed.
Results: Of 1789 pts who survived to 1 yr, 471 (26%) were >70 yrs. Baseline PCS was 
higher in young vs. old pts (44.7 vs. 41.4, p<0.001). Similar proportions of young and old 
pts had functional decline at 1 yr (29% vs. 30%, p=0.55). Factors significantly associated 
with functional decline are shown in the Figure. Excluding pts with very low baseline 
function did not change the results.
Conclusion: One in 4 post-MI survivors experience clinically significant functional decline 
at 1 yr. Although this occurs equally in young and old pts, the predictors of decline vary by 
age, with low education more important in young and race more important in old pts.
3:00 p.m.
1012-140 Factors Related to Heart Rupture in Acute Coronary 
Syndromes. The Global Registry of Acute Coronary 
Events
Jose Lopez-Sendon, Enrique P. Gurfinkel, Esteban Lopez de Sa, Giancarlo Agnelli, Joel 
M. Gore, Ph Gabriel Steg, Gordon FitzGerald, Christopher B. Granger, for the GRACE 
Investigators, Hospital Universitario La Paz, Madrid, Spain, Duke University Medical 
Center, Durham, NC
Background: Heart rupture (HR) after MI is a life-threatening complication.
Objective: To determine the incidence and factors associated with HR in ACS patients.
Methods: Data from 56,314 patients were analyzed. Diagnosis of HR included free wall 
(VR) (n=114) and ventricular septal rupture (VSR) (n=150). Predictors were determined 
by logistic regression. Candidates included GRACE risk score variables, hospital clusters, 
ACS type and clinical variables with P<0.25 in univariate analysis.
Results: 265 (0.47%) patients with HR were identified (hospital mortality 57%, vs 4.5% 
without rupture), representing 5.6% of all hospital deaths. The incidence was 0.9% for 
STEMI, 0.2% for NSTEMI and 0.3% for UA, and varied across the 18 clusters (mean 
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0.47%; range 0.0-1.47). The incidence was lower in STEMI pts with primary PCI than in 
those without (0.7 vs 1.1%, P=.01); primary PCI was not independently related to HR in 
adjusted analysis (P=.20). Independent variables associated with HR are shown below 
(C statistic 0.8): 
Odds ratio 95% confidence interval P-value
Male sex 0.63 0.47-0.85 0.02
Previous CAD 0.59 0.38-0.90 0.01
ST deviation 1.51 0.99-2.30 0.05
Age per 10-year increase 1.37 1.22-1.55 0.001
Pulse per 30-bpm increase 1.34 1.13-1.58 <0.001
Systolic blood pressure per 20-mmHg 
decrease 1.19 1.08-1.30 <0.001
Beta-blocker in 1st 24 h 0.58 0.43-0.78 <0.001
LMWH in 1st 24 h 0.58 0.42-0.79 <0.001
Conclusions: In the reperfusion era, HR is a rare complication in ACS, although the real 
incidence is probably underestimated in this retrospective study. HR is more common 
with, but not exclusive in ACS with ST elevation. There are significant variations in 
incidence between hospitals. Sex, age, ST elevation at presentation and heart rate are 
independently related to HR; history of ischemic disease and early use of beta-blockers 
and low-molecular-weight heparin were associated with lower incidence.
3:00 p.m.
1012-141 Disparities in the Initial Assessment of Acute Chest 
Pain in the Emergency Department
Harold Bowker, Kimberly A. Selzman, Sergio Rabinovich, Jr., Mauricio Cohen, Abhishek 
Mehrotra, University of North Carolina, Chapel HIll, NC
Background: It remains unclear why female gender and ethnic minority status are 
independent predictors of worse outcomes in patients who are treated for acute coronary 
syndrome. Time to initial electrocardiogram (EKG) has been linked to outcomes in cardiac 
patients. We sought to determine the relationship between time to EKG and gender, 
ethnicity, and age.
Methods: A retrospective analysis of the EKG database at a tertiary care university hospital 
emergency department (ED) was performed. All patients > 18 years old presenting to the 
ED from January 1, 2005, to June 30, 2005 with a chief complaint suggestive of cardiac 
symptoms such as chest pain or dyspnea were included. The time elapsed between 
patient arrival to the ED and EKG acquisition was analyzed. The relationship between 
time to EKG and age, gender, and race was determined with a multiple regression model. 
A Pearson’s coefficient test assessed for correlation between age and time to EKG.
Results: A total of 1540 patients were included with a mean age of 52.6 years (ranging 
from 18 to 101 years). 53.2% were women and 34.4% were African American. The mean 
time from arrival to EKG was 30.7 minutes (min) for all patients. Women tended to be 
slightly older than men (53.4 vs. 51.7 years, p=0.035) and African Americans were more 
likely to be younger than white patients (50.0 vs. 54.7 years, p=0.00001). Women had 
an increase in time to EKG compared to men (32.7 vs. 28.3 min, p=0.001). Age was 
inversely correlated to EKG time (p=0.0001). The multiple regression analysis showed 
that female gender, racial minority status, and younger age all independently contribute 
to a longer time to EKG.
Conclusions: Time to initial EKG in the ED is longer for females, African Americans, and 
younger patients. These results suggest that strategies aimed at improving arrival to EKG 
acquisition time are needed for all patients and might narrow the outcomes gap in cardiac 
patients.
3:00 p.m.
1012-142 Proteinuria is a Risk Factor for Adverse Events in Heart 
Failure Independent of a Reduced Glomerular Filtration 
Rate
Inderjit S. Anand, Michael Kuskowski, Areef Ishani, Thomas Rector, Kalkidan Bishu, Jay N. 
Cohn, VA Medical Center, Minneapolis, MN, University of Minnesota, Minneapolis, MN
Background: Whether proteinuria (PU), with or without a reduction in estimated 
glomerular filtration rate (eGFR), is a risk factor for adverse events in heart failure is 
unclear. Methods: Patients (n=5010) randomized in Val-HeFT were retrospectively 
divided into subgroups with high or low eGFR using a cut off of 60 ml/min/1.73m2, and into 
subgroups with or without PU (dipstick) at baseline. Cox proportional hazards regression 
analyses for all-cause mortality were conducted. Results: PU was seen in 8% (405/4551) 
patients. Patients with PU were more likely to have hypertension, diabetes, higher NYHA 
class, higher systolic blood pressure (SBP), lower eGFR, higher hsCRP, norepinephrine, 
BNP, PRA, and higher use of digoxin and diuretics (all p<0.01). PU correlated (p<0.001) 
weakly with the presence of diabetes (rho=0.16), albumin (-0.17), BNP (0.16), SBP (0.11), 
CRP (0.11), and eGFR (0.09) and was not related to LVEF (-0.025). The risk of death was 
increased in presence of PU (HR 1.61, 95% CI 1.33-1.95) or low eGFR (HR 2.0, 95% CI 
1.74-2.31). To show the additional prognostic information provided by PU, patients were 
categorized into 4 sub-groups by the presence of either one or both risk factors (Figure). 
The presence of PU was associated with increased mortality in the subgroups with high 
eGFR (HR = 2.1, 95% CI 1.4-3.1) or low eGFR (HR = 3.1, 95% CI 2.4-4.0). Conclusions: 
The presence of PU is a prognostic marker in HF, independent of a reduction in eGFR, 
suggesting these two measures of CKD provide distinct information. 
3:00 p.m.
1012-143 A Meta-Analysis of the Effect of Weight Loss 
Pharmacotherapies on Metabolic Outcomes
Susan M. Wakil, Kristian B. Filion, Jacques Genest, Lawrence Joseph, Louise Pilote, 
Paul Poirier, Stéphane Rinfret, Ernesto Schiffrin, Mark J. Eisenberg, Jewish General 
Hospital / McGill University, Montreal, QC, Canada
Background: Orlistat, rimonabant, and sibutramine are the only three weight loss agents 
approved for the long term management of obesity worldwide.
Objectives: The objective of this study was to examine the efficacy of these three agents 
on weight loss and metabolic outcomes.
Methods: We identified double-blind, placebo-controlled randomized clinical trials (RCTs) 
through a systematic review of the literature. We limited our search to RCTs that examined 
weight loss and metabolic outcomes at 6 and/or 12 months. Data were pooled using a 
random effects model.
Results: A total of 63 RCTs were identified, including 33 for orlistat (n=14,650), 4 for 
rimonabant (n=6,625), and 26 for sibutramine (n=5,165). All three pharmacotherapies 
were associated with weight loss and improvement in some metabolic factors (Table). 
Difference in Mean Change [95% CI]
Outcomes Orlistat Rimonabant Sibutramine
Weight Loss (kg) -2.70 [-3.18, -2.22] -3.02 [-4.54, -1.50] -5.00 [-5.91, -4.10]
Waist Circumference 
(cm) -2.45 [-3.31, -1.59] -2.61 [-3.90, -1.32] -4.82 [-6.10, -3.54]
Fasting Glucose 
(mmol/l) -0.38 [-0.59, -0.17] -0.14 [-0.27, 0.00] -2.31 [-5.74, 1.13]
Total Cholesterol 
(mmol/l) -0.40 [-0.48, -0.33] -0.02 [-0.08, 0.03] -0.05 [-0.20, 0.10]
LDL Cholesterol 
(mmol/l) -0.32 [-0.38, -0.27] -0.05 [-0.10, 0.00] 0.07 [-0.04, 0.18]
HDL Cholesterol 
(mmol/l) -0.04 [-0.07, -0.02] 0.07 [0.04, 0.11] 0.08 [0.06, 0.10]
Triglycerides (mmol/l) -0.03 [-0.10, 0.03] -0.20 [-0.35, -0.05] -0.31 [-0.48, -0.14]
Systolic Blood 
Pressure (mmHg) -1.45 [-2.95, 0.06] -1.27 [-2.16, -0.37] 0.88 [0.08, 1.69]
Diastolic Blood 
Pressure (mmHg) -1.34 [-2.54, -0.14] -0.67 [-1.29, -0.05] 1.44 [0.80, 2.09]
Conclusion: Orlistat, rimonabant, and sibutramine are all effective weight loss agents; 
however, they have heterogeneous effects on metabolic outcomes. Sibutramine may be 
the most effective at reducing weight and fasting glucose. However, it also appears to be 
associated with an increase in LDL and blood pressure.
3:00 p.m.
1012-144 Moderate Drinkers Show Improved Post Myocardial 
Infarction Long Term Outcomes Compared to Quitters
Josh Valtos, John H. Lee, John A. Spertus, Eric D. Peterson, Fengming Tang, Kimberly J. 
Reid, Donna M. Buchanan, James H. O’Keefe, Jr., Mid America Heart Institute, Kansas 
City, MO, University of Missouri-Kansas City, Kansas City, MO
Background: Drinkers (Ds) of moderate amounts of alcohol have been associated with a 
lower risk of myocardial infarction (MI) and mortality. However, there are limited data on 
changes in drinking behaviors after MI and the association of such changes with long-
term outcomes.
Methods: Among 2,498 pts in the 19-center PREMIER study, 362 pts were considered 
moderate drinkers by drinking at least weekly without binge drinking. Of these, 64 (18%) 
quit after their MI and 298 continued. The Seattle Angina Questionnaire (SAQ) and SF-
12 physical and mental component summary scales (PCS and MCS) were employed 
to assess freedom from angina and quality of life at baseline and 1 year later. 3-year 
mortality, 1-year re-hospitalization, and a combined adverse outcome of mortality, re-
hospitalization, and the presence of angina at 1 year were also assessed. Multivariable 
regression models adjusted for baseline health status, age, gender, Caucasian race, 
smoking, diabetes, renal failure, and congestive heart failure.
Results: As compared with those who quit, moderate Ds who continued drinking had 
significantly better outcomes (figure).
Conclusion: A significant proportion of moderate drinkers quit after a MI and this is associated 
with worse outcomes as compared with moderate drinkers who continue to drink. 
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3:00 p.m.
1012-145 Correlates of Frailty in Patients with Coronary 
Heart Disease Undergoing Percutaneous Coronary 
Interventions
Mandeep Singh, Veronique Roger, Charanjit Rihal, Ryan Lennon, Jeff Sloan, Amir 
Lerman, Arshad Jahangir, Sreekumaran Nair, John Spertus, Mayo Clinic, Rochester, MN
Background: Coronary heart disease (CHD) is the leading cause of death in the United 
States. With the shift of CHD burden towards elderly, assessment of frailty assumes 
importance. Patient factors associated with frailty among older patients undergoing PCI 
are unknown.
Methods and Results: We prospectively measured frailty including unintended weight 
loss (>10 lb in the preceding year), exhaustion, physical activity, walk time (15 feet 
criteria), and grip strength in 314 patients, ≥ 65 years at the time of PCI,. Patients with ≥ 
3 core elements were frail, and those with 1 or 2 elements had intermediate frailty. The 
prevalence of frailty was 20% and more than half of the subjects (56%) had intermediate 
frailty. Multiple ordinal logistic regression analysis determined correlates of frailty and 
intermediate frailty. Female gender (OR 3.2; 95% CI 1.9-5.; P<0.001), chronic kidney 
disease (CKD) (3.8; 95%CI 2.0-7.3), a history of smoking (2.3; 95% CI 1.4-3.7), an 
unexpected fall in the past 6 months (3.6; 95% CI 1.7-7.3), and sex-standardized height 
(0.7 per standard deviation; 95% CI 0.5-0.8) were associated with frailty as compared with 
patients not frail or with intermediate frailty. The c-statistic was 0.72 for the model.
Conclusions: Frailty and intermediate frailty are highly prevalent among subjects with 
CHD undergoing PCI. The association of frailty and the use of these predictors to identify 
high-risk elderly patients warrant further investigation.
3:00 p.m.
1012-146 Drug eluting stent among diabetics: A propensity 
analysis of a large population-based cohort
Dennis T. Ko, Maria Chiu, Peter Austin, James Bowen, Eric Cohen, Jack Tu, Institute for 
Clinical Evaluative Sciences, Toronto, ON, Canada
Background: Diabetic patients frequently receive drug eluting stents (DES) during 
percutaneous coronary interventions (PCIs) but recent data have raised concerns as 
to whether DES are associated with increased risk of myocardial infarction or death. 
Accordingly, we sought to evaluate the long-term safety and effectiveness of diabetic 
patients who received DES.
Methods: We used a propensity score matching method to create and analyze a well-
balanced cohort that included 2,374 diabetic patients who received DES in Ontario, Canada 
from December 1, 2003 to March 31, 2005. Primary outcomes of interest were repeat target 
vessel revascularization, myocardial infarction, and death after the index PCI.
Results: The mean age of our diabetic cohort was 64 years and 68% of the patents were 
male. At 2-years, rates of repeat target vessel revascularization were significantly lower 
among diabetic patients treated with DES compared with those treated with BMS (7.1% 
vs. 14.4%, P <0.001). Myocardial infarction rates were not significantly different between 
the two groups after 2 years (6.6% in DES group vs. 4.5% in BMS group, p = 0.45). In 
addition, mortality was not statistically different among diabetics treated with DES (7.6%) 
and BMS (9.5%) (P=0.086).
Conclusions: Drug-eluting stents are effective among diabetic patients in substantially reducing 
the need of repeat target vessel revascularization. Although the overall rates of myocardial 
infarction were not significantly different between DES and BMS, we cannot completely 
exclude small risks associated with DES at longer-term follow-up. Nevertheless, mortality of 
diabetic patients who received DES was not significantly increased compared with BMS.
3:00 p.m.
1012-147 Self-assessment of health status is associated with 
immune and neurohormonal activation, and predicts 
long-term outcome in outpatients with chronic heart 
failure
Dimitrios Farmakis, Maria Nikolaou, John Parissis, Vasiliki Bistola, Vasilios Gogas, Koula 
Venetsanou, Gerasimos Filippatos, Dimitrios Kremastinos, Attikon University Hospital, 
Athens, Greece
Background: Clinicians lack a generally accepted means for functional capacity and 
health status assessment in chronic heart failure (CHF). To investigate the correlation 
between self-rated health status and inflammation burden, neurohormonal profile and 
depressive disorders as well as its long-term prognostic value in CHF outpatients.
Methods: Kansas City Cardiomyopathy Questionnaires (KCCQ) was completed by 137 
CHF outpatients (aged 64±12 years, mean left ventricular ejection fraction 27±7%). 
Inflammatory/apoptotic markers (IL-6, IL-10, TNF-α, soluble Fas, soluble Fas ligand, 
soluble ICAM-1, VCAM-1), plasma B-type natriuretic peptide (BNP), 6-minute walking test 
(6MWT), Zung self-rated depression scale (SDS) and Beck Depression Inventory (BDI) 
were also assessed. Patients were followed for major cardiovascular events, including 
death or hospitalization due to cardiovascular causes, for up to 250 days.
Results: Patients with worse KCCQ-summary score (KCCQ-s <50%) had higher Zung 
SDS (46±10 vs 34±9, p<0.001), worse NYHA class (p<0.05), lower 6MWT (259±200 
vs 363±110 meters, p<0.05), higher BNP (p<0.05), IL-6 (12.7±7.2 vs 8.5±6.4 pg/ml, 
p<0.05), soluble Fas, soluble Fas ligand, and soluble VCAM-1 and lower anti-inflammatory 
cytokine IL-10 (6.1±3.2 vs 9.4±5.4 pg/ml, p<0.05) than those with KCCQ-s ≥50%. Worse 
health status was also associated with shorter event-free survival (115±12 days for 
KCCQ-s<50% vs 214±15 days KCCQ-s ≥50%, p=0.0179). Separating patients according 
KCCQ-functional score (KCCQ-f, cut-off 50%) showed similar results. In multivariate Cox 
regression analysis, including all parameters univariately related with outcome, only LVEF 
(HR=0.637, 95% CI=0.450-0.900, p=0.011) and KCCQ-f (HR=0.035, 95% CI=0.002-
0.824, p=0.037) were independent predictors of event-free survival at 250 days.
Conclusions: KCCQ reflects neurohormonal and inflammatory burden and depressive 
symptoms in CHF outpatients. KCCQ-f is an independent predictor of long-term event-
free survival in these patients.
3:00 p.m.
1012-148 Impact of a Compliance Program on Cholesterol 
Control: Results of the Randomized ORBITAL Study in 
8,108 Patients Treated With Rosuvastatin in Germany
Stefan N. Willich, Jacqueline Mueller-Nordhorn, Heike Englert, Frank Sonntag, Heinz 
Voeller, Norbert van den Boom, Wolfgang Meyer-Sabellek, Karl Wegscheider, Eberhard 
Windler, Hugo Katus, Charité University Medical Center, Berlin, Germany
Background: Compliance with statin therapy is closely related to achievement of low-
density lipoprotein (LDL-C) goals in patients with dyslipidemia. In the present study we 
determined whether a compliance-enhancing program could increase the level of lipid 
control in patients treated with rosuvastatin.
Methods: A total of 8,108 patients (56% men, mean age 59 years and 44% women, 
63 years) with LDL-C ≥115 mg/dL (3.0 mmol/L) if statin-naïve or else ≥125 mg/dL (3.2 
mmol/L) were randomized to receive rosuvastatin 10 mg daily either with or without a 
compliance-enhancing program for 12 months. Patients not achieving goal after 3 months 
were to be up-titrated to rosuvastatin 20 mg daily thereafter.
Results: At 3, 6, and 12 months, rosuvastatin plus compliance initiatives was similarly 
effective to rosuvastatin alone in terms of 1998 European LDL-C goal (<115 mg/dL [3.0 
mmol/L]) achievement (72% vs 70%; 71% vs 69%; 68% vs 68%, respectively) and changes 
in the lipid profile. Significant differences were observed in the subgroup of statin-naïve 
patients (at 3 and 6 months, 80% vs 76%, P<0.01 and 78 vs 73%, P<0.001, respectively). 
The frequency of adverse events and clinically important changes in laboratory data were 
consistent with the known safety profile of rosuvastatin.
Conclusions: Rosuvastatin 10/20 mg daily enables the majority of patients to achieve 
LDL-C <115 mg/dL within 3 months and provides a sustained improvement of their lipid 
profile. The compliance-enhancing program was only effective in statin-naïve patients at 
early timepoints, but had no overall effect over 12 months.
3:00 p.m.
1012-149 The Relationship Between Sex, Mortality and 
Cardiovascular Events Among Patients with 
Established Cardiovascular Disease: A Meta-Analysis
Jeffrey S. Berger, Deepak L. Bhatt, Zhengming Chen, J B Jones, Shamir R. Mehta, Marc 
S. Sabatine, Steven R. Steinhubl, Eric J. Topol, Peter B. Berger, Duke University Medical 
Center, Durham, NC, Geisinger Medical Center, Danville, PA
Background: The risk of death and other adverse events may differ between women and 
men with cardiovascular (CV) disease.
Methods: We performed a meta-analysis of 76,174 pts (29% women) with established 
CV disease from 5 randomized trials (CURE, CREDO, CLARITY, COMMIT and those 
with CVD from CHARISMA) performed between 2001-06 to compare the risk of adverse 
events in women and men across a wide spectrum of clinical scenarios. Data from the 
5 trials were analyzed; odds ratios (OR) and 95% confidence intervals (CI’s) for the 
incidence of CV events (CV mortality, non-fatal MI or non-fatal stroke) and all-cause 
mortality were calculated for women vs. men using random-effects modeling.
Results: In the overall cohort, no significant differences were noted for CV events between 
women and men (OR 1.20, 95% CI 0.84-1.73), all-cause mortality (OR 1.45, 95% CI 0.93-
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2.25), MI (OR 0.94, 95% CI 0.74-1.19), stroke (OR 1.18, 95% CI 0.92-1.52), ischemic 
stroke (OR 1.20, 95% CI 0.96-1.51), and hemorrhagic stroke (OR 1.24, 95% CI 0.67-
2.31) (although women tended to have a greater frequency of these events). However, 
there were differences in the event rates between the sexes in different clinical situations. 
Among 49,304 patients with STEMI, women had increased rates of any CV event (OR 
1.77, 95% CI 1.67-1.89), all-cause mortality (OR 2.08, 95% CI 1.77-2.44), MI (OR 1.20, 
95% CI 0.98-1.46), and hemorrhagic stroke (OR 1.97, 95% CI 1.39-2.80). No differences 
between the sexes existed for the frequency of ischemic stroke. Among the 26,870 
patients with CV disease excluding those with STEMI, women had a lower risk of MI than 
men (OR 0.83, 95% CI 0.72-0.97). No differences existed in the frequency of CV events, 
all-cause mortality or stroke. There was no evidence of statistical heterogeneity for the 
effect of clopidogrel in women vs. men.
Conclusion: Among patients with CV disease, women with STEMI, but not other 
manifestations of CV disease, have higher rates of CV events and all-cause mortality 
than men. Conversely, women who present with other manifestations of CV disease 
have lower rates of MI than men. Understanding these differences may lead to better risk 
stratification and treatment of patients with CV disease.
3:00 p.m.
1012-150 Does Interruption of Antiretroviral Therapy Change 
the Risk of Cardiovascular Disease in HIV-1 Patients? 
Results From the SMART Trial
Daniel A. Duprez, Andrew N. Phillips, Andrew Carr, Jacquie Neuhaus, Fehmida 
Visnegarwala, Ronald Prineas, William Burman, Ian Williams, Fraser Drummond, Jens 
Lundgren, University of Minnesota, Minneapolis, MN
Background: Use of combination of antiretroviral therapy (ART) in HIV-1 patients has 
been shown in cohort studies to be associated with increased cardiovascular disease, 
potentially related to increase of lipid levels induced by antiretroviral drugs. We compared 
in the SMART trial the cardiovascular events and lipid changes between strategies of 
continuous (viral suppression arm; VS) and CD4 count guided (drug conservation arm; 
DC) antiretroviral therapy.
Methods: A total of 5,472 HIV patients were randomized either on a VS or a DC therapy. Cox 
models were used to assess the association between treatment arm and cardiovascular 
disease (CVD) risk. Mean changes in lipids were assessed between baseline and year 1.
Results: A total of 79 patients developped major CVD events. The hazard ratio (HR) for risk 
of CVD events for DC vs VS was 1.57 (95% CI, 1.00-2.46, P = 0.05). For a subset (84% of 
subjects) on ART at baseline the HR was 1.37 (0.85-2.21), P = 0.20, compared with 4.41 (0.94-
20.8), P = 0.06 for those off ART at baseline; P-value for interaction = 0.16. There was no 
evidence that being off ART (as a time-updated covariate) was associated with increased risk 
of CVD events (HR for being on ART vs off 0.96 (0.60-1.54), P = 0.90), nor was a higher current 
viral load associated with increased risk of CVD. Among those on ART at baseline, the raised 
risk in DC patients was restricted to those on Non-Nucleoside Reverse Transcriptase Inhibitors 
(NNRTI) or nucleoside-only regimens. Total and LDL-cholesterol were reduced as a result of 
interruption in DC patients, but so was HDL-cholesterol, leading to a net unfavorable change in 
total/HDL-cholesterol ratio, particularly in those on NNRTI or nucleoside-only regimens.
Conclusions: There is no clear evidence to suggest that interruption of ART and the 
consequent increase in viral load immediately increases risk for CVD. On balance, lipid 
changes were less favorable in patients using CD4 count-guided ART, particularly those 
on NNRTI regimens at baseline and this may partially explain the observed excess risk.
3:00 p.m.
1012-151 Impact of a Sophisticated Computer Based Telephonic 
Heart Failure Monitoring System on Quality-of-Life in 
Patients With Heart Failure
Ozlem Z. Soran, Ileana L. Piña, Gervasio A. Lamas, Sheryl F. Kelsey, Faith Selzer, John 
Pilotte, Arthur M. Feldman, University of Pittsburgh, Pittsburgh, PA
Background: Disease management programs directed by cardiologists at academic 
centers have shown to improve the quality-of-life (QoL) of patients with heart failure. 
However, questions remain regarding the utility of these programs for women, racial and 
ethnic minorities, and the elderly. Moreover, long-term, well-controlled, community-based 
studies have not been reported. The present study was designed to address these gaps 
in knowledge.
Methods: This was a multicenter, randomized, controlled trial of enhanced (Alere day link 
heart failure monitoring System; AS) vs standard heart failure care (SC) in patients with heart 
failure and systolic dysfunction. Both groups received patient one on one education, education 
to clinicians and an effort to use optimal medical care. AS patients received an electronic 
scale and an individualized symptom response system linked to a computerized data base 
operated by trained nurses. The Medical Outcome Study 12 Item Short Form (SF-12) and the 
Kansas City QoL Questionnaire (KCCQ) were administered to assess the QoL.
Results: 315 patients were randomized: 160 to the AS and 155 to SC. The patients were 
65% women with mean ejection fraction of 23±9%. Baseline characteristics, laboratory 
evaluations were equivalent in both treatment groups. Baseline mean SF-12 physical 
functioning and mental functioning scores and all KCCQ domains were similar by 
treatment arm. All change scores for both QoL instruments were positive at 6-moth follow 
up. However, there were no statistically significant differences in mean change scores 
for all QoL measures by treatment arm. The mean follow-up scores for each domain 
were calculated adjusting for baseline values and comparisons by treatment arm were 
all similar. The mean 6-month scores for the SF-12 physical functioning and mental 
functioning adjusting for baseline scores were also similar by treatment group.
Conclusion : QoL scores improved at 6- month comparing to baseline in both groups 
however, there was no measurable QoL benefit in the intensively followed population. 
The lack of effect may indicate that sophisticated heart failure monitoring devices aren’t 
necessarily helpful in all heart-failure populations.
3:00 p.m.
1012-152 Risk Factors for Gastrointestinal Bleeding in Post-
Myocardial Infarction Patients: Results From the 
VALIANT Trial
George V. Moukarbel, James E. Signorovitch, Marc A. Pfeffer, John J. V. McMurray, 
Harvey D. White, Aldo P. Maggioni, Eric J. Velazquez, Robert M. Califf, Scott D. Solomon, 
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background: Gastrointestinal (GI) bleeding limits the use of antiplatelet drugs in heart 
disease patients. We sought to identify potential risk factors for GI bleeding in patients 
post myocardial infarction (MI).
Methods: VALIANT followed 14,703 post MI patients with LV dysfunction and/or heart 
failure for a median of 24.7 months. GI bleeding events were determined from the 
VALIANT serious adverse event database. We identified risk factors from medical history, 
demographics, baseline clinical profile and medications. We used stepwise selection to 
build a multivariate Cox proportional hazards model from significant (p<0.05) univariate 
predictors.
Results: During study period, 98 (0.7%) patients had a serious GI bleeding event. These 
patients were older, had more comorbidities, were more likely to take antihypertensive, 
antiplatelet and antidiabetic drugs, and had worse LV systolic and renal function. Forty 
(41%) events occurred within 3 months after the index MI. Independent predictors of 
increased risk of GI bleeding were: age, male gender, nonwhite race, heart failure, 
diabetes, renal dysfunction, NYHA class, history of alcohol abuse, dual antiplatelet 
therapy at baseline, but not NSAID use (Table). Of note, 3,301 (22%) patients were on 
dual antiplatelet therapy which was associated with an 85% higher adjusted risk.
Conclusion: Clinical characteristics can identify post MI patients at higher risk of GI 
bleeding. Whether these patients would benefit from GI prophylaxis therapy remains 
unknown. 
Independent predictors of increased risk of GI bleeding.
Hazard Ratio 95% CI Z-Score P-Value
Age (10-year increment) 1.71 1.38 - 2.13 4.85 <0.001
Nonwhite Race 3.41 2.03 - 5.71 4.66 <0.001
History of Alcohol Abuse 4.40 1.90 - 10.21 3.45 0.001
Dual Antiplatelet Therapy 1.85 1.20 - 2.86 2.79 0.005
Male Gender 1.97 1.22 - 3.18 2.76 0.006
Diabetes 1.66 1.08 - 2.54 2.33 0.020
eGFR (10 mL/min/1.73m2 decrement) 1.13 1.01 - 1.27 2.17 0.030
Congestive Heart Failure 1.68 1.05 - 2.68 2.16 0.031
NYHA class 3 or 4 1.55 1.01 - 2.37 2.00 0.045
eGFR = estimated glomerular filtration rate; NYHA = New York Heart Association; CI = 
confidence interval.
3:00 p.m.
1012-153 The Impact of Homocysteine-Lowering Therapy on 
Cardiovascular Outcomes: An Updated Meta-Analysis 
of 13 Trials
Jayanta Das, George A. Diamond, Shervin Eshaghian, Sameer Amin, Prediman K. 
Shah, Sanjay Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: Epidemiological evidence has shown strong associations between 
homocysteine (Hcy) levels and cardiovascular disease. However, efficacy of 
homocysteine-lowering therapy to reduce cardiovascular risk hasn’t been confirmed 
by randomized trials. One possible explanation may be lack of sufficient power due to 
inadequate sample size.
Objective: To perform a meta-analysis of randomized trials to determine the impact of 
homocysteine-lowering therapy on outcomes.
Methods: Thirteen studies (n=25,000) with follow-up ranging from 6 months to 7.2 years 
were pooled using a random-effects model and summary risk ratios (RR) were derived. 
Heterogeneity was assessed using Cochran’s Q (P<0.1) and I2 statistic (>50%).
Results: The results shown in the figure demonstrate a nonsignificant reduction in the 
risk of stroke and virtually a null effect on coronary heart disease (CHD). Similar results 
were observed with regards to all-cause mortality (RR of 0.96, p=0.48). No statistically 
significant heterogeneity was observed across the trials.
Conclusions: Current evidence suggests a low likelihood of coronary benefit and a 
possible likelihood of stroke benefit with homocysteine-lowering therapy. These data are 
consistent with epidemiologic observations of a stronger association of elevated Hcy with 
stroke compared to CHD. Until further trials demonstrate definitive evidence of benefit, 
routine screening and treatment of hyperhomocysteinemia cannot be recommended for 
cardiovascular risk prevention. 
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3:00 p.m.
1012-154 DHEA-S Levels and Cardiovascular Mortality in Post-
Menopausal Women: Results From the National 
Institutes of Health - National Heart, Lung, and Blood 
Institute (NHLBI) - Sponsored Women’s Ischemia 
Syndrome Evaluation (WISE)
Philip Bretsky, B. Delia Johnson, Leslee J. Shaw, Ricardo Azziz, Glenn D. Braunstein, 
Carl J. Pepine, Vera Bittner, Diane A. Vido, C. Noel Bairey Merz, Cedars Sinai Medical 
Center, Los Angeles, CA, University of Pittsburgh, Pittsburgh, PA
Background: DHEA-S is a major circulating sex steroid prohormone. Low levels 
are associated with an elevated cardiovascular disease (CVD) risk, although not 
consistently.
Methods: African-American (AA) and White women in this study are participants in the 
Women’s Ischemia Syndrome Evaluation (WISE) study. Among 855 women, 374 (43.7%) 
were postmenopausal, non-hormone therapy and non-oral contraceptive users. Logistic 
regression models evaluated the effect of DHEA-S, adjusting for CVD risk factors. The 
primary endpoint was death due to CVD causes. Kaplan-Meier life-table analyses 
constructed survival curves. CVD event, any major event and obstructive CAD were 
considered secondarily. Follow-up was complete in >95% of surviving patients through 
6 years.
Results: Circulating levels of DHEA-S did not differ by race. Higher levels of DHEA-S were 
associated with a reduced risk of CVD mortality (OR: 0.61, 95%CI: 0.42, 0.88, p=0.008). 
Survival analyses revealed that the lowest DHEA-S tertile had the poorest outcomes (log 
rank p=0.0114). Risk reductions of similar magnitude were observed when considering 
any CVD event and any major event; no significant risk modification was noted for 
obstructive CAD.
Conclusions: Higher circulating DHEA-S levels among post-menopausel women with 
suspected ischemia are associated with lower CVD events.
3:00 p.m.
1012-155 Clinical and Prognostic Implications of Duke’s Activity 
Status Index in Chronic Heart Failure
John Parissis, Dimitrios Farmakis, Maria Nikolaou, Vasiliki Bistola, Kallirhoe Kourea, 
Katerina Fountoulaki, Gerasimos Filippatos, Dimitrios Kremastinos, Attikon University 
Hospital, Athens, Greece
Background: The Duke’s Activity Status Index (DASI) provides an accurate estimate of 
functional capacity in chronic heart failure (CHF) patients and correlates closely with the 
peak oxygen consumption measured in cardiopulmonary stress test.
Methods: We evaluated the prognostic value of baseline DASI against well established 
prognostic factors and Kansas City Cardiomyopathy Questionnaire (KCCQ) in 130 
consecutive hospitalized CHF patients (aged 64±12 years, mean left ventricular ejection 
fraction 26±7%) at discharge, followed for 9 months for major cardiovascular events, 
defined as death or hospitalization for heart failure decompensation.
Results: During follow-up, 77 of 130 patients (59%) experienced a major cardiovascular 
event after a median time of 60 days (range, 5-220). Patients with an eventful course 
had worse New York Heart Association functional class (p=0.001), lower 6-min walked 
distance (259±196 vs 346±139 m, p=0.041), lower ejection fraction (24±6 vs 29±6%, 
p<0.001), higher B-type natriuretic peptide (BNP, 933±913 vs 404±312 pg/mL, p<0.001), 
lower DASI score (16±12 vs 25±17, p=0.003), lower summary KCCQ (30±16 vs 42±21, 
p<0.001) and functional KCCQ (39±17 vs 54±20, p<0.001) scores and higher frequency 
of depressive symptoms, defined by a Zung self-rated depression scale >40 (p=0.021). 
In multivariate Cox regression analysis including all the above variables, BNP (p=0.006) 
and DASI (p=0.047) were independently associated with event-free survival. A BNP 
cut-off of 697 pg/mL predicted future events with a 59% sensitivity and 86% specificity, 
while a DASI cut-off of 8 had a 76% sensitivity and 25% specificity. The combination of 
the two cut-offs predicted events with a 33% sensitivity and 95% specificity. Event-free 
survival was significantly lower in patients with both markers positive (BNP>697 pg/mL 
and DASI<8) compared to those with both markers negative (63±27 vs 183±15 days, log 
rank p<0.0001).
Conclusion: Functional status assessment by the DASI bears a prognostic value and its 
combination with BNP may provide quite a specific risk stratification in CHF patients.
3:00 p.m.
1012-156 Long-Term Clinical Prognosis of Provocation Positive 
Variant Angina
Sang Yeub Lee, Jin-Ho Choi, Seung Min Choi, Bong Gun Song, Soo Jin Cho, Joo-Yong 
Hahn, Seung-Hyuk Choi, Hyeon-Cheol Gwon, Sang Hoon Lee, Division of Cardiology, 
Cardiac and Vascular Center, Samsung Medical Center, Sungkyunkwan University, 
seoul, South Korea
Background: Although coronary vasospasm provocation test is widely performed in daily 
clinical practice, data regarding the long term prognosis of variant angina is still limited.
Methods: We retrospectively investigated clinical consequence of 1,736 patients who 
underwent elective diagnostic coronary angiography and vasospasm provocation test for 
the evaluation of chest pain from Sep 1994 to Dec 2006. Variant angina was defined by 
decrease of anterograde coronary flow less than TIMI 2, or new development of severe 
coronary stenosis (diameter stenosis > 90%) accompanied by typical angina pain and 
corresponding EKG changes provoked by ergonovine intracoronary infusion, followed by 
nitroglycerin infusion and resolution of vasospasm. Patients who developed spontaneous 
spasm without provocation or underwent revascularization were excluded.
Results: Provocation test was positive in 723 patients and negative in 1,013 patients. 
Median follow-up period was 1452 days (interquartile range: 711 - 2606), which was not 
different between two groups. 5-year all major adverse cardiac event (MACE)-free, death-
free, and revascularization-free survival was significantly lower in positive provocation 
group compared to negative group (90.0% versus 95.4%, 92.9% versus 95.7%, 96.8% 
versus 99.6%, p<0.05, respectively), and cardiac death-free survival was marginally 
lower in positive provocation group (96.9% versus 98.7%, p=0.051). Although positive 
provocation group showed higher incidence of smoking, diabetes, hypertension, and 
significant fixed stenosis in major coronary arteries (frequency: 19.4% versus 8.2%), 
multivariate analysis using Cox proportional hazard model revealed that positive 
provocation test was still an independent predictor of MACE (p<0.001).
Conclusions: Our result showed that positive provocation test might be associated with 
adverse outcome in chest pain patients. It suggests that long term medical care should 
be provided for patients with positive provocation test.
ACC.POSTER CONTRIBUTIONS
1019 
Outcomes Assessment II
Monday, March 31, 2008, 9:00 a.m.-12:30 p.m.
McCormick Place, South Hall 
11:00 a.m.
1019-127 NT-proBNP Predicts Long-Term Risk of Cardiac Death 
in Patients With Dilative Cardiomyopathy: A Ten-Year 
Follow-up Trial
Florian Krackhardt, Hans-Dirk Duengen, Peter Schlattmann, Katrin Kehrt, Sabine 
Hassfeldt, Rainer Dietz, Wilhelm Haverkamp, Charite, Department of Cardiology, 
Universitätsmedizin, Berlin, Germany
Background: Few data exist regarding the long term outcome of patients with elevated NT-
proBNP serum levels in heart failure caused by dilative cardiomyopathy. A major limitation 
of former trials is a short follow-up period (usually not exceeding 3 years). In addition, 
mainly patients with coronary artery disease were studied.
Methods: In a prospectively designed 10-year follow-up trial plasma levels of NT-proBNP 
were measured in 155 consecutive patients with dilative cardiomyopathy (age 56±9.5 
years, 83% male, left ventricular ejection fraction (LVEF) 33±13%). NT-proBNP was 
tested for its predictive value with respect to cardiac death and compared with other 
established prognostic indicators.
Results: Eighty-three patients (53.5%) survived, 10 patients (6.5 %) underwent heart 
transplantation, and 62 patients (40.0%) died. Cause of cardiac death was pump failure 
in 30 patients (58.9 %) and sudden cardiac death in 21 patients (41.1 %). Eleven patients 
died from other causes. Non-survivors had higher NT-proBNP-levels than survivors 
(3.1±0.6 vs. 2.8±0.5). NT-proBNP-levels were higher in patients dying due to cardiac 
as compared to non-cardiac causes (3.3±0.6 vs. 2.6±0.6). By cox proportional hazard 
regression analyses, NT-proBNP was identified as a strong and independent predictor 
in cardiac death. It was shown to provide valuable additional information even when 
adjusting for other established prognostic indicators.
Conclusions: NT-proBNP is a strong predictor of outcome in patients with chronic heart 
failure due to dilative cardiomyopathy. The present analysis affirms the superiority of this 
peptide compared with other clinical variables known as powerful predictors of mortality.
11:00 a.m.
1019-128 Representation of Women in Randomized Clinical Trials 
of Cardiovascular Disease Prevention
Chiara Melloni, Tracy Y. Wang, Karen S. Pieper, Jeffreys S. Berger, Rowena J. Dolor, 
Daniel B. Mark, Kristin L. Newby, Duke Clinical Research Institute, Durham, NC
Background: The 2007 evidence-based guidelines for cardiovascular disease prevention in 
women drew heavily upon data from randomized clinical trials (RCTs), but representation 
of women in these trials has not been systematically assessed.
Methods:We abstracted RCTs supporting the prevention guidelines for women to 
determine female representation over time and by clinical indication, prevention type 
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(primary or secondary), trial location, and funding source.
Results: Overall, women represented 30.6% of RCTs enrollment. Proportional enrollment 
of women increased significantly over time (Figure). Representation of women differed 
substantially by clinical indication, and was highest among trials in hypertension (41%), 
diabetes (39%), and stroke (37%) and lowest for trials of heart failure (29%), coronary 
disease (24%), and hypercholesterolemia (17%). Enrollment of women was higher in 
United States vs. International trials (55% vs. 26%, P<0.0001), in primary vs. secondary 
prevention trials (37% vs. 29%, P<0.001) and in Government/Foundation vs. industry 
funded trials (33% vs. 29%, P<0.001).
Conclusions: Enrollment of women in RCTs has increased over time, but efforts are still 
needed to reach a level of representation that is adequate to ensure evidence-based 
sex-specific recommendations. 
11:00 a.m.
1019-129 Early Enalapril Therapy Reduced Long-Term 
Cardiovascular Morbidity and Mortality in Patients With 
Asymptomatic Left Ventricular Systolic Dysfunction: 
An Extended Follow-Up of SOLVD
Philip Jong, Sylvie A. Ahn, Michel F. Rousseau, University of Louvain, Brussels, 
Belgium, University of Toronto*, Toronto, ON, Canada
Background: Sparse data exist on the long-term outcomes of patients treated early with 
ACE inhibitors who had left ventricular systolic dysfunction but without clinical heart 
failure. In an extended follow-up of the Studies of Left Ventricular Dysfunction (SOLVD), 
we reported the 15-year post-trial morbidity and mortality outcomes of patients previously 
enrolled in the prevention arm of SOLVD.
Methods: Among the 398 patients originally enrolled in the SOLVD Prevention Trial from 
Belgium, post-trial morbidity and mortality data were prospectively collected on all 336 
survivors (165 enalapril vs. 171 placebo) at trial closeout. All patients were placed on 
enalapril after the trial. Use of enalapril was classified as either “early” if started in trial 
or “delayed” if started post trial. The median delay in therapy was 3.3 years. No patients 
were lost to follow-up.
Results: The median duration of follow-up was 18.8 years from the time of randomization 
or 15.8 years from the time of closeout. The overall 5-year, 10-year, and 15-year 
cumulative post-trial survival rates were 66%, 42%, and 26% respectively. All-cause 
mortality was significantly reduced among patients who received early enalapril therapy 
as compared to those who received delayed therapy (73% vs. 77%, Wilcoxon p=0.01). 
Cardiac mortality was also significantly reduced (47% vs. 58%, p=0.003). Early enalapril 
therapy was associated with a significant 28% risk reduction in the composite outcome 
of all-cause deaths or cardiovascular morbid events over the post-trial period (95% CI 
9-42%, p=0.006). Life expectancy (after censoring those who had heart transplantation) 
was significantly increased by 34.1 months (95% CI 4.6-73.5 months) among patients 
who were treated early with enalapril over those who were treated late (p=0.02). Post-trial 
use of ACE inhibitors (81%) was similar between the two groups.
Conclusions: Long-term survival was low among patients with left ventricular systolic 
dysfunction who were initially asymptomatic. Delay in ACE inhibitor therapy by just a 
few years significantly increased the late risks of serious cardiovascular morbidity and 
mortality in these patients.
11:00 a.m.
1019-130 Extent of Late Gadolinium Enhancement in Cardiac 
Magnetic Resonance as an Independent Prognostic 
Factor in Patients With Hypertrophic Cardiomyopathy
WooIn Yang, Jong-Won Ha, Dae-Sik Choi, SungAi Kim, Byoungwook Choi, Young Jin 
Kim, Chi Young Shim, Byung Ho Lee, Eui-Young Choi, Namsik Chung, Cardiology 
Division, Yonsei University College of Medicine, Seoul, South Korea, Department of 
Radiology, Yonsei University College of Medicine, Seoul, South Korea
Background: Late gadolinium enhancement (LGE) in cardiac magnetic resonance (CMR) 
has been proposed to detect myocardial fibrosis in hypertrophic cardiomyopathy (HCM). 
We sought to investigate whether the extent of LGE has a prognostic significance in 
patients with HCM at long-term follow up.
Methods: Seventy-two consecutive patients with non-apical HCM (46 male, mean 
age 56±14) underwent CMR and echocardiography. Cardiac events were defined as 
hospitalization due to worsening of heart failure (HF), cardiac transplantation and 
cardiovascular deaths.
Results: LGE was found in 58 patients (80.6%) ranging 1.4 to 81% of the left ventricular 
(LV) mass. During the mean follow-up of 30 ± 11 months, there was no event in patients 
without LGE, whereas 11 events (5 deaths, 6 hospitalizations due to worsening of HF) in 
patients with LGE. Receiver operating curves showed a threshold of LGE % of LV mass 
> 15% as a predictor of poor outcome (area under the curve [AUC] 0.77, 95% CI 0.65-
0.87),and this cutoff value had an 81% sensitivity and a 69% specificity for predicting 
cardiac events. The univariate analysis revealed that not only the LGE % > 15% but 
also the presence of LV outflow tract obstruction, elevated E/E’, increased left atrial (LA) 
volume index were related with cardiac events. Multivariate Cox regression analysis 
showed that the LGE % > 15% (p=0.04, HR;9.87, 95% CI;1.09-88.9) was the most potent 
predictor in addition to LA volume index (p=0.04, HR=1.04, 95% CI;1.01-1.08) in the 
prognostic outcome of HCM. Moreover, addition of LGE % > 15% had an incremental 
prognostic value in the model including LV outflow tract obstruction, E/E’, and LA volume 
index (p=0.01 for change in χ2).
Conclusions: The presence and the extent of LGE in CMR have a prognostic significance 
in patients with HCM.
11:00 a.m.
1019-131 Incidence of Death and Myocardial Infarction 
Associated With Stopping Clopidogrel After Acute 
Coronary Syndrome: Evidence Supporting a Rebound 
Effect
P. Michael Ho, Eric D. Peterson, Li Wang, David J. Magid, Stephan D. Fihn, Greg C. 
Larsen, Robert A. Jesse, John S. Rumsfeld, Denver VA Medical Center, Denver, CO, 
University of Colorado Health Sciences Center, Aurora, CO
Background: It is unknown if a ‘rebound’ phenomenon of increased thrombotic events 
occurs after stopping clopidogrel. We assessed rates of adverse events after stopping 
clopidogrel in a national sample of acute coronary syndrome (ACS) patients.
Methods: This was a retrospective cohort of 2,524 ACS patients discharged on clopidogrel 
from 127 VA hospitals from 2003-2004. The primary outcome was death or myocardial 
infarction (MI) after stopping clopidogrel. Multivariable Poisson regression assessed 
the association between risk of death/MI in the 0-90 day interval versus the 91-180 
day interval after stopping clopidogrel adjusting for demographics, co-morbidities, ACS 
presentation and treatment factors and duration of clopidogrel treatment.
Results: Mean follow-up after stopping clopidogrel was 220±154 days for medically-treated 
(n=1,247) and 222±145 days for PCI treated (n=1,277) ACS patients. Among medically 
treated patients, mean duration of clopidogrel treatment was 320±150 days and death/MI 
occurred in 17.0% (n=212) of patients with 55.7% of events occurred during 0-90 days, 
21.7% during 91-180 days and 12.3% during 181-270 days after stopping clopidogrel. In 
multivariable analysis, the first 90 day interval after stopping clopidogrel was associated with 
significantly higher risk of adverse events compared with 91-180 day interval (incidence rate 
ratio [IRR] 1.95; 95% CI 1.39-2.75). Among PCI-treated ACS patients, mean duration of 
clopidogrel treatment was 320±150 days and death/MI occurred in 7.8% (n=100) of patients 
with 56.0% of events occurred during 0-90 days, 25.0% during 91-180 days and 7.0% 
during 181-270 days after stopping clopidogrel. In multivariable analysis, the first 90 day 
interval after stopping clopidogrel was also associated with higher risk of adverse events 
compared with 91-180 day interval (IRR 1.78; 95% CI 1.10-2.88).
Conclusions: We observed a clustering of adverse events in the initial 90-days after 
stopping clopidogrel among both medically treated and PCI treated ACS patients, 
supporting a possible clopidogrel rebound effect. Additional studies are needed to further 
confirm this phenomenon as well as to identify strategies to attenuate this effect.
11:00 a.m.
1019-132 Stroke in Coronary Artery Bypass Grafting (CABG) 
Versus Percutaneous Coronary Intervention (PCI): A 
Meta-Analysis of Randomized Trials
Anishee K. Shah, Alexandra K. Retana, Thomas Trikalinos, John B. Wong, Tufts-New 
England Medical Center, Boston, MA
Background/Aim: Randomized trials have not identified CABG as having a higher risk of 
stroke than PCI, perhaps because of insufficient power. Our aim was to perform a meta-
analysis of stroke in randomized trials of PCI versus CABG.
Methods: A Medline search from 1993-2007 and a review of published meta-analyses and 
bibliographies were used to identify randomized trials of CABG and PCI reporting stroke 
event rates. Using the DerSimonian and Laird random effects model, we determined the 
odds ratio (OR) and 95% CI of in-hospital and long-term stroke incidence with PCI versus 
CABG. Subgroup analysis considered stroke incidence after PCI with mostly stent or 
balloon only. When appropriate, we confirmed results with the Mantel-Haenszel fixed 
effects model and Bayesian methods.
Results: Our systematic review identified 10 randomized trials of PCI and CABG reporting 
stroke event rates. The trials involved 6021 patients all with multivessel coronary disease: 
mean age 54-64, 67%-81% men, 3-vessel disease 22%-58%, ejection fraction 57%-
77%. In 6 studies reporting in-hospital stroke, 4 involved PCI with balloon only, and in 5 
studies reporting long-term stroke, 4 involved PCI with stent. PCI was associated with a 
statistically significantly reduced risk of in-hospital stroke (n=6 studies, 3278 pts) when 
compared with CABG (OR 0.36, 0.13-0.98). When considering PCI with balloon only 
versus CABG (n=4, 2707 pts), the OR for in-hospital stroke was 0.36 (0.13-1.00). After 
1-5 years (n=5, 2598 pts), however, the OR for stroke with PCI versus CABG was 1.04 
(0.63-1.72). Similarly, for PCI with stent versus CABG (n=4, 2722 pts), the OR for stroke 
after 1-5 years of follow-up was 0.91 (0.58-1.43). Lastly, for PCI versus CABG, the OR for 
any stroke in-hospital or in follow-up was 0.36 (0.13-0.98) for balloon only (n=5, 2849 pts) 
and 0.92 (0.59-1.44) for stent (n=5, 3178 pts).
Conclusion: PCI has a statistically significant decreased risk of in-hospital, stroke compared 
with CABG, but the cumulative incidence of stroke over 1-5 years of follow-up appears to be 
similar. Clustering of the type of PCI with the reporting of in-hospital or follow-up stroke limits 
this analysis and suggests a need to consistently report stroke outcomes.
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1019-133 Frequency of Provider Contact Directly Impacts 
Quality of Life for Heart Failure Patients Enrolled in a 
Telemonitoring Program
Mitchell T. Saltzberg, Divya Tiwari, Lynne J. Bouffard, Paul Kolm, Rocky DeMaio, Claire 
Gardner, Angela Disabatino, Christiana Care Health System, Newark, DE
Background: Heart failure (HF) pts quality of life (QOL) is often negatively affected. 
Frequent provider contact may reduce hospitalization rates but the impact on QOL is not 
well defined. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is an accepted 
measure of QOL in HF and a change in the Overall Score > 20 points is considered a 
large improvement or deterioration in QOL.
Hypothesis: Frequency of provider contact (defined as office/hospital/telemonitoring 
consultation or hospital intervention) would favorably impact QOL in a well monitored 
group of HF pts enrolled in a telemonitoring program.
Methods: HF pts enrolled in the Christiana Care HF Telemonitoring program were 
administered the KCCQ at baseline, 3,6,9 and 12 months. Provider contact data was 
prospectively collected by TM nurses. KCCQ overall summary (OS) and clinical summary 
(CS) scores were computed and compared from baseline to 12 months (end of TM 
program). Pts were grouped by tertiles for change in KCCQ (<10, 10-29 or >/= 30 visits) 
and the impact of provider contact on QOL was analyzed using one-way analysis of 
variance. Changes in KCCQ OS and CS were compared using the paired t-test.
Results: 186 HF pts were evaluated (age 72.7 + 11.8 yrs; 43 % Male; 67 % Caucasian). 
Overall and clinical scores of the KCCQ at baseline and 12 months were compared. HF 
pts with > 30 point increase (Group 1) in OS scores had significantly greater provider 
contacts than pts with < 10 point (Group 2) improvement in OS scores (17.6+5.9 vs. 
14.1+5.9; p=0.001). Similar findings were noted for the CS scores as well (18.2+4.6 vs. 
13.9+5.9; p< 0.001).
Absolute changes in KCCQ OS and CS scores between Group 1 and Group 2 were 
significantly different: OS Score (0.70+7.9 vs. 41.7+11.2; p< 0.0001) and CS Score 
(0.26+8.9 vs. 40.5+13.5, p<0.0001).
Conclusions: HF pts enrolled in a TM program with a higher frequency of provider contact 
demonstrate significantly greater changes in QOL as determined by the KCCQ. The study 
implies that more regular contact with health care providers may positively impact QOL 
in HF pts.
11:00 a.m.
1019-134 NT-proBNP and Cardiovascular Mortality in Community-
Dwelling Elderly: The Cardiovascular Heart Study (CHS)
Christopher R. deFilippi, Robert H. Christenson, John S. Gottdiener, Willem J. Kop, 
Stephen L. Seliger, University of Maryland, Baltimore, MD
Background: NT-proBNP predicts cardiovascular (CV) death in patients with known CV disease. 
However, the ability to predict CV death in asymptomatic subjects is uncertain, especially 
among older adults who often have comorbidities that influence NT-proBNP levels.
Methods: NT-proBNP levels were measured from baseline samples in CHS subjects. CHS is 
a study of CV risk factors and outcomes in community-dwelling older adults. CV death was 
determined by expert review. Subjects were divided into quintiles based on NT-proBNP level 
and survival curves plotted. Cox hazards regression was used to estimate the association 
of NT-proBNP and CV mortality, after adjusting for demographics, traditional CV risk factors, 
prevalent heart failure, renal function and known coronary disease.
Results: Serum for NT-proBNP measurement was available in 4,524 (76.8%) of CHS 
subjects. Median age was 73, 19.8% had coronary disease, 4.7% had prevalent heart 
failure, and 22.8% had estimated GFR<60 mL/min/1.73m2. Rate of CV death was 1.9 per 
100 person-years over a median 10.5 years follow-up. Increasing quintiles of NT-proBNP 
level were associated with greater risk of CV death (Figure). After multivariate adjustment, 
there was a 3.8-fold greater risk of CV death among those in the highest (>291.2 pg/mL) 
versus the lowest NT-proBNP quintile (<48.5 pg/mL) (p<.001).
Conclusions: NT-proBNP is a strong predictor of CV death in an ambulatory elderly 
population, independent of known CV disease, common CV risk factors and renal function.
11:00 a.m.
1019-135 Predictors of Outcome in Heart Failure With Preserved 
Ejection Fraction: One Year Findings From the 
Irbesartan in Heart Failure With Preserved Systolic 
Function Trial (I-PRESERVE)
Peter E. Carson, Washington VAMC, Washington, DC
Predictors of outcome in heart failure with preserved ejection fraction - 1 year findings from 
the Irbesartan in Heart Failure with Preserved Systolic Function Trial (I-PRESERVE)
Background: We examined clinical and laboratory data at baseline in the Irbesartan in 
Heart Failure with Preserved Systolic Function (EF≥45%) Trial (I-PRESERVE) to identify 
independent predictors of outcome of 1 year outcome.
Methods: The following outcomes were examined in multivariable models: (i) the I-
PRESERVE primary outcome of all-cause mortality or cardiovascular hospitalization and 
(ii) a secondary outcome of HF mortality or HF hospitalization.
Results: 419 patients had a primary endpoint and 263 a HF endpoint. The independent 
predictors of outcome are shown in the table (HR and 95%CI).
Conclusions: In preserved EF heart failure, commonly available clinical variables are 
powerful predictors of outcomes at one year. NT-proBNP, ischemic etiology and prior HF 
hospitalization were the strongest predictors for both the primary and HF outcome.
HR(95%CI) for primary Endpoint HR for HF Endpoint
HF Hosp within 6 months 1.93 (1.56,2.38) 2.51 (1.89, 3.32)
Log (BNP) (per unit increase) 1.43 (1.32,1.54) 1.59 (1.44,1.76)
BUN (<25, >=25) 1.38 (1.10, 1.74) 1.46 (1.13, 1.90)
Heart rate (linear) 1.11 (1.00, 1.23) 1.20 (1.05, 1.38)
History of diabetes 1.45 (1.19, 1.77) 1.53 (1.19, 1.96)
Etiology - Ischemic Heart 
Disease 1.60 (1.31, 1.96) 1.48 (1.15, 1.91)
11:00 a.m.
1019-137 Perceptions of Race/Ethnic Discrimination and 
Mortality Among Black Women
Michelle Albert, Yvette Cozier, Paul M. Ridker, Julie Palmer, Robert Glynn, Lynda Rose, 
Nitsan Halevy, Lynn Rosenberg, Brigham and Women’s Hospital/Harvard Medical 
School, Boston, MA, Slone Epidemiology Center at Boston University, Boston, MA
Background: Since racial discrimination is a form of chronic stress that might unfavorably 
affect health outcomes via physiologic/behavioral mechanisms and access to goods 
and services, we examined whether experiences of racism among black women are 
associated with mortality.
Methods: We followed 48,924 black women participating in the Black Women’s Health 
Study (BWHS) over six years to assess the risk of all-cause, cancer, and cardiovascular 
mortality associated with perceived experiences of racism. Perceived racism was 
evaluated by eight questions about institutionalized racism (unfair treatment on the job, in 
housing or by the police), and everyday experiences of racism (e.g., others acting as if the 
woman was not intelligent). We estimated the relative risk of death with Cox-proportional 
hazard models, adjusting for traditional and socio-environmental risk factors.
Results: During 316,128 person years of follow-up from 1997 to 2003, there were 616 
deaths, of which 227 were related to cancer and 115 were due to cardiovascular causes. 
Eighty six % of women reported perceived experiences of racism. All cause mortality 
was not associated with reports of institutionalized racism, relative risk=1.0 (95 percent 
confidence interval 0.8 to 1.4, for the highest category relative to the lowest), or personally 
mediated/everyday racism (relative risk 0.9, 95 percent confidence interval 0.7 to 1.2, for 
the highest quartile compared to the lowest), nor was death from cancer associated with the 
racism variables. The estimated relative risks for the association of perceived racism with 
cardiovascular death were below one, but they were generally not statistically significant.
Conclusions: In this large prospective cohort study of black women, reports of experiences 
of racism were unrelated to short term all cause and cancer mortality. The non-significant 
decreases in cardiovascular mortality associated with reports of racism warrant further 
research.
11:00 a.m.
1019-138 Concordance of Seattle Angina Questionnaire Scores 
and Canadian Cardiovascular Society Class of Angina 
in the COURAGE Trial
William S. Weintraub, Paul Kolm, John Spertus, David Maron, Marcin Dada, Claudine 
Jurkovitz, Robert O’Rourke, Koon Teo, Pamela Hartigan, William E. Boden, Christiana 
Care Health System, Newark, DE
Background: The Clinical Outcomes Utilizing Revascularization and Aggressive DruG 
Evaluation (COURAGE) trial randomized 2,287 patients to percutaneous coronary 
intervention (PCI) plus optimal medical therapy (OMT) or OMT alone. The primary endpoint 
was the composite of death or myocardial infarction. No difference was noted at 4.5 years.
Methods: Angina was assessed at baseline and followup by the physician-assessed 
Canadian Cardiovascular Society (CCS) Class and the patient-centered Seattle Angina 
Questionnaire (SAQ).
Results: The Table presents results for 2 of 5 SAQ domains, angina frequency and quality 
of life as well as percent free of angina by CCS class. At baseline almost all patients 
had angina and SAQ scores were similarly depressed in both groups. Within 3 months 
the majority of patients were angina-free in both groups, and there was considerable 
improvement in SAQ scores. These improvements were maintained for 3 years. PCI 
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offered better anginal relief than OMT, although the marginal benefits were small, and 
largely observed in the first year.
Conclusions: The CCS and SAQ are concordant measures of angina. Although PCI offers 
better angina relief, there is considerable reduction in angina in both arms by 3 months, 
and this was maintained for 36 months.
PCI+OMT OMT Only P Value
SAQ Angina Frequency Baseline 68+26 69+26 0.20
12 Months 87+19 84+21 0.0029
36 Months 89+18 88+18 0.37
SAQ Quality of Live Baseline 51+25 51+25 0.79
12 Months 76+21 73+22 0.0077
36 Months 79+20 77+20 0.32
CCS Angina-Free Baseline 12% 13% 0.37
12 Months 66% 58% 0.0006
36 Months 72% 67% 0.017
11:00 a.m.
1019-139 Which Controls Are Best for CAD Association Studies: 
A Random Population Sample or Angiographically 
Normal Subjects? A Comparison of Genetic and 
Traditional Risk Factors
Christopher R. Tuttle, Brian S. McClure, Benjamin D. Horne, Heidi T. May, Kent G. 
Meredith, John F. Carlquist, Joseph B. Muhlestein, Jeffrey L. Anderson, Intermountain 
Medical Center, Murray, UT, University of Utah, Salt Lake City, UT
Background: Association studies evaluating coronary artery disease (CAD) risk may 
utilize controls from angiographically-normal subjects (AC) or a random population 
sample (RC). AC may not be similar to RC due to referral bias but have superior 
phenotypic characterization. We evaluated allele frequency differences in 11 cholesteryl 
ester transfer protein (CETP) single nucleotide polymorphisms (SNPs) and prevalence of 
traditional risk factors between AC, RC, and CAD patients.
Methods: Participants included randomly-selected, consenting subjects≥18 years old who 
lived in Utah’s urbanized Wasatch Front (RC, n=503) and CAD-free (stenosis <10%) AC 
(n=479) and patients with angiographic CAD (CAD pt, n=916) enrolled in the Intermountain 
Heart registry. All p-values were multiple-comparison corrected for the 3 endpoints.
Results: Age and BMI differed between RC (53±16 years, 27±5 kg/m2) and both AC 
(50±8 years, 32±19 kg/m2) and CAD pt (51±7 years, 31±13 kg/m2) (all p≤0.001), but not 
between AC and CAD pt (p=0.63, p=0.32, respectively). Total cholesterol, HDL-C, and 
triglyceride levels differed for RC vs. AC, RC vs. CAD pt, and AC vs. CAD pt (all p<0.001) 
and for LDL-C (all p<0.05), with RC having the lowest levels and AC, intermediate levels. 
Only minor allele frequency difference trends were found between RC and AC (i.e., 
T+1086A for RC and CAD pt vs. AC of p=0.18 and p=0.07, respectively, and A373P for 
AC and CAD pt vs. RC of p=0.18 and p=0.039).
Conclusions: This study demonstrates general genotypic similarity between AC, a 
phenotypically more homogeneous CAD control group, and RC. Modest selection bias 
was found for traditional risk factors (age, weight, lipids) in AC, as might be expected, 
but significant genetic selection bias for CETP polymorphisms, representing a relevant 
genetic test set, did not occur. These findings suggest that both AC and RC are acceptable 
controls for CAD association studies. AC may cause some bias towards the null for 
genetic factors relating to traditional risk factors, but since the clinical coronary status of 
RC is unknown, AC may be the preferred comparison group for studies of genetic factors 
relating specifically to CAD because of superior phenotypic characterization.
11:00 a.m.
1019-140 Clinically Significant Improvement in Seattle Angina 
Questionnaire Scores in the COURAGE Trial
William S. Weintraub, Paul Kolm, John Spertus, David Maron, Marcin Dada, Robert 
O’Rourke, Claudine Jurkovitz, Koon Teo, Pamela Hartigan, William E. Boden, Christiana 
Care Health System, Newark, DE
Background: The Clinical Outcomes Utilizing Revascularization and Aggressive DruG 
Evaluation (COURAGE) trial randomized 2,287 patients to percutaneous coronary 
intervention (PCI) plus optimal medical therapy (OMT) or OMT alone. The primary 
endpoint was the composite of death or myocardial infarction. No difference was noted 
at 4.5 years.
Methods: Angina was assessed at baseline and followup by the Seattle Angina 
Questionnaire (SAQ). Clinically significant improvement was defined as >10 increase 
from baseline.
Results: At baseline almost all patients had angina, and SAQ scores were similarly 
depressed in both groups. A substantial proportion of patients in both groups experienced 
clinically significant improvement in angina scores which were maintained for 3 years (see 
Table for 2 year data). There was greater improvement with PCI for all scales to 6 months 
and for angina frequency to 2 years.
Conclusions: PCI+OMT offers clinically significant angina relief more frequently than OMT 
alone, but these advantages were not as consistent with longer follow up. Through 6 months, 
an absolute 8% advantage of PCI+OMT in achieving clinically significant gains in physical 
function, angina relief and quality of life means 12.5 patients would need to be treated with 
PCI for 1 patient to experience significantly better health status in these domains.
Percentage of Patients With 10 Point or Greater Improvement from Baseline
SAQ Domain Follow-up Time PCI+OMT OMT Only P Value
Physical Limitation 3 Months 45% 36% 0.0008
6 Months 47% 39% 0.0025
24 Months 43% 40% 0.24
Angina Frequency 3 Months 60% 51% 0.0005
6 Months 64% 56% 0.0015
24 Months 67% 59% 0.0036
Quality of Life 3 Months 60% 54% 0.021
6 Months 64% 56% 0.0012
24 Months 65% 67% 0.65
11:00 a.m.
1019-141 (S)Ticker Shock: The Cost-Effectiveness of Cardiac 
Resynchronization Therapy With and Without an 
Implantable Defibrillator in Advanced Symptomatic 
Heart Failure
Dhruv S. Kazi, Mark A. Hlatky, University of California, San Diego, CA, Stanford 
University, Stanford, CA
Background: Clinical trials have demonstrated the efficacy of cardiac resynchronization in 
heart failure patients, but the cost-effectiveness of this therapy, particularly when coupled 
with a defibrillator, is unclear.
Methods: A discrete-time Markov model with Monte Carlo simulations was used to 
evaluate the cost-effectiveness of adding cardiac resynchronization therapy, with or 
without a defibrillator (CRT-D and CRT-P respectively), to optimal pharmacological 
therapy (OPT) in a hypothetical cohort of 10,000 65 year old patients who met Medicare 
eligibility criteria for CRT. The analysis was conducted from the Medicare perspective 
with a lifetime analytic horizon. Costs were calculated from published tariffs; disease- and 
therapy-related probabilities were obtained from the literature. Future costs and benefits 
were discounted at 3%. Uncertainty and variability were evaluated through extensive 
deterministic and probabilistic sensitivity analyses.
Results: Patients in the OPT, CRT-P and CRT-D arms had a life expectancy of 4.9, 6.1 and 
7.1 (discounted) years respectively. Relative to OPT, patients receiving CRT-P and CRT-D 
cost an additional $37,419 and $79,308 respectively, with incremental cost-effectiveness 
ratios of 37,935 and 44,797 dollars per quality-adjusted life year (QALY). Compared to 
CRT-P, CRT-D produced 0.78 additional QALYs at a cost of $53,430/QALY.
At a notional willingness-to-pay threshold of $75,000/QALY, CRT-D was the most cost-
effective strategy. At $50,000/QALY, CRT-D was cost-effective only when the annual risk 
of sudden cardiac death was ≥ 5.3%. The results were sensitive to the cost and efficacy 
of the devices, procedural complications and underlying risk profile of the patient. Relative 
to OPT, the number of patients needed to be treated for one year to save one life was 32 
and 21 for CRT-P and CRT-D respectively.
Conclusion: Despite being expensive, CRT-D is cost-effective in patients with advanced 
heart failure who meet inclusion criteria of published randomized clinical trials, provided 
the procedure is carried out with low complication rates. Results from ongoing trials may 
help further clarify the clinical and economic implications of this technology.
11:00 a.m.
1019-142 Impact of Impaired Pulmonary Arterial Capacitance on 
the Incidence of Renal Insufficiency in Advanced Heart 
Failure
Wilfried Mullens, Wilson Tong, Hadi N. Skouri, Zuheir Abrahams, David O. Taylor, 
Randall C. Starling, W H Wilson Tang, Cleveland Clinic, Cleveland, OH
Background: Pulmonary arterial capacitance (PAC), defined as the quotient of stroke 
volume and pulmonary artery pulse pressure, is a measure of how much the pulmonary 
arteriolar tree will dilate with each contraction of the right ventricle. We hypothesize that 
lower PAC may predict subsequent development of cardio-renal syndrome (CRS) in 
patients with advanced heart failure (HF).
Methods: We reviewed 724 consecutive patients with advanced HF at the Cleveland 
Clinic between 2000-5 who underwent a right heart catheterization (RHC) evaluation. 
Baseline serum creatinine (sCr) at the moment of the RHC together with most recent 
value were recorded (mean difference 1.7±1.6 years). Development of CRS was defined 
increase in sCr ≥0.5 mg/dL when compared to baseline with an absolute sCr >1.5 mg/dL 
at follow-up.
Results: During a mean follow-up of 3.2±2.2 years, a total of 224 deaths (31%) and 163 
cardiac transplants (23%) had occurred. When stratified according to median PAC levels, 
patients with below median PAC levels had higher rates of development of CRS (20% 
versus 14%, p=0.0056, figure). In multivariable analysis, lower PAC was predictive for 
development of CRS independent of baseline PCWP, RV stroke work index, Fick cardiac 
index, LV ejection fraction, NYHA class, and eGFR.
Conclusion: Lower PAC is an emerging independent predictor of future cardio-
renal compromise independent of underlying baseline eGFR or any hemodynamic 
derangement. 
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1019-143 Assessment of Transmural Strain Profile Using Tissue 
Strain Imaging is An Useful Method to Evaluate The 
Time Course of Myocardial Stunning in Patients with 
Reperfused ST Elevation Acute Coronary Syndrome
Noriaki Iwahashi, Kazuo Kimura, Jun Okuda, Kengo Tsukahara, Yoshio Tahara, Kiyoshi 
Hibi, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Toshiyuki Ishikawa, Kazuaki 
Uchino, Satoshi Umemura, Yokohama City University, Medical Center, Yokohama, 
Japan, Yokohama City University Hospital, Yokohama, Japan
Background : Early reperfusion therapy has been established to improve prognosis with ST 
elevation acute coronary syndrome (STEACS). Angle corrected short-axis tissue Doppler 
echocardiography (TDI-Q, Toshiba) can assess tissue strain imaging (TSI). It is a new 
method to evaluate transmural myocardial strain profile (Am J Physiol.2007;292,921).
Methods : Consecutive 75 inferior STEACS with successful reperfusion within 12 
hours were divided into Aborted MI (GroupA, n=20: peakCK220) and Established MI 
(GroupE, n=55: peakCK2039) by the level of peakCK. We observed 12 age-matched 
healthy subjects (GroupC). Conventional Doppler parameters with tissue velocity(E/e’) 
and TSI were obtained after 2 weeks and 10 months repeatedly. Peak systolic radial 
strain of subendocardium(SRendo) and subepicardium(SRepi) and location of peak 
strain(SR%:%distance of wall thickness from endocardium) were obtained.
Results : Although there was no difference in conventional parameters, significant 
differences in TSI were observed between GroupA and GroupC. TSI parameters showed 
correlation with reperfusion time(SRendo,SRepi,SR%, r=0.58,0.37,0.50,p<0.05) and 
myocardial blush grade. TSI parameters improved in GroupA, whereas GroupE did not 
change after 10 months.
Conclusion: Although successful early reperfusion has preserved left ventricular 
contraction after 2 weeks, TSI could detect regional subtle myocardial damage. TSI might 
demonstrate the time course of myocardial stunning in reperfused STEACS.  
11:00 a.m.
1019-144 Efficacy of an Algorithm-Based, Nurse-Led Intervention 
for Reducing Cardiac Events After Major Noncardiac 
Surgery - A Randomized Comparison Against Usual 
Care
Thomas H. Marwick, Helen Branagan, Bala Venkatesh, Carly Jenkins, Joseph Brown, 
Malcolm Burgess, Simon Stewart, University of Queensland, Brisbane, Australia, 
Princess Alexandra Hospital, Brisbane, Australia
Background. Beta blockers (BB) are recommended to reduce cardiac events (CE) in pts 
undergoing major non-cardiac surgery. Trials recording lack of protection with BB have 
been attributed to suboptimal duration or dose-titration. To test whether an algorithm-
based, nurse-led intervention (NL) could address these problems, we compared two 
strategies - NL and usual care (UC).
Methods. 405 pts at intermediate risk (1 or 2 clinical risk variables) were randomized to 
2 strategies before major noncardiac surgery; NL (bisoprolol titration over 2 weeks in all 
pts pre-operatively) or UC (BB without intensive titration, dobutamine echo [DbE] and 
specific advice in those with a positive test). Ischemia at DbE was identified on the basis 
of new or inducible wall motion abnormalities. ECG and troponin were monitored daily 
post-operatively and pts were followed for 1 month for death, infarction and soft events 
(angina, heart failure).
Results. Noncardiac surgery was performed in 181/197 pts in NL group and 188/208 pts 
in UC group. NL provided significantly better heart-rate control peri-operatively, with 43 
pts (22%) having HR>80 on day 1 (vs 71 [34%] in the UC group, p=0.006). Bradycardia 
(heartrate <50) but not hypotension was more common in NL. There were 30 CE (27 MI 
and 3 cardiac deaths, 8%), with no differences between groups (Table). 
Bradycardia 
<48h
Hypotension 
<48h Death
Myocardial 
infarction Soft events
NL (n=197) 22 (11%) 36 (18%) 1 15 16
RB (n=208) 10 (5%) 36 (17%) 2 12 18
p 0.02 NS NS NS NS
Conclusions. The 8% major cardiac event-rate after major noncardiac surgery persists despite 
nurse-led dose-titration of bisoprolol, and is no different from UC incorporating DbE.
11:00 a.m.
1019-145 Acute Type A Dissection. The Surgeon as Risk Factor
Stephen Westaby, Richard Schulenburg, Polychronis Antonitsis, John Radcliffe Hospital, 
Oxford, United Kingdom
Background: Type A dissection is one of the most taxing of cardiovascular emergencies. 
In most centres an “on call rota” allocates surgeon to patient. Can this system provide an 
equitable solution or does chance govern survival?
Methods: We recorded risk factors and 30 day mortality in 201 consecutive patients 
operated by 5 surgical teams at between April 1990 and April 2007. One hundred and 
fifty were male. Age ranged from 26-87 years (63 + 8). Twelve had Marfan’s syndrome. 
Pre-operative risk factors included cardiogenic shock (58, 29%), stroke (12, 6%), limb 
ischemia (10, 5%) and acute renal failure (6, 3%). Eleven mistakenly had thrombolysis. 
Number of patients operated per surgeon ranged from 16 to 105. Multivariate logistic 
regression analysis was used to determine risk factors for mortality.
Results: Mean cardiopulmonary bypass time per surgeon ranged from 72-169 minutes 
(overall mean 93 + 48). Overall mortality was 28 patients (14%). Individual surgeon’s 
mortality ranged from 6% to 38% (p <0.05) and reflected level of experience and interest 
in thoracic aortic surgery. Prolonged cardiopulmonary bypass time >90 minutes was a 
risk factor (p <0.05). The significance of other perioperative variables is shown in Table I. 
Thrombolytic therapy also played an important role in elevating risk.
Conclusions: Random allocation of surgeon by rota is a risk factor for mortality. This 
argues strongly for a specialist team approach. The iatrogenic issue of thrombolysis 
needs further consideration.
Table I 
Variable Odds ratio (95% CI) p
Age 1.00 (0.95-1.07) 0.82
Female gender 1.39 (0.32-6) 0.66
Thrombolysis 23.63 (3.26-171.1) <0.01
Cardiogenic shock (tamponade) 6.56 (1.74-24.71) <0.01
Stroke 0.24 (0.02-2.53) 0.23
Myocardial ischemia 6.86 (1.72-27.34) <0.01
Acute renal failure 0.06 (0.005-0.79) < 0.05
Marfan syndrome 0.68 (0.06-7.7) 0.75
Surgeon 7.91 (0.86-72.97) <0.05
CPB time > 90 mins 1.61 (0.3-8.46) <0.05
11:00 a.m.
1019-146 Moderate Drinkers Show Improved Post Myocardial 
Infarction Long Term Outcomes Compared to Non-
drinkers
John H. Lee, Josh Valtos, John A. Spertus, Fengming Tang, Kimberly J. Reid, Donna M. 
Buchanan, Eric D. Peterson, James H. O’Keefe, Mid America Heart Institute, Kansas 
City, MO, University of Missouri-Kansas City, Kansas City, MO
Background: Moderate alcohol consumption has been consistently associated with a 
lower risk of myocardial infarction (MI) and mortality. Using a prospective, contemporary 
cohort of MI patients, we investigated whether drinkers (Ds) had improved 1 and 3 year 
outcomes compared to non-Ds.
Methods: After the exclusion of binge Ds, non-Ds who started or Ds who quit, Ds of <3 
per month, and incomplete data, 1,033 pts remained who were then classified by World 
Health Organization criteria into non-Ds (n=735) and Ds (n=298). The Seattle Angina 
Questionnaire (SAQ) and SF-12 physical and mental component summary scales (PCS 
and MCS) were employed to assess freedom from angina and quality of life at post-MI 
baseline and 1 year. 3-year mortality, 1-year rehospitalization, and combined adverse 
outcomes of mortality, rehospitalization, and angina were also assessed. Multivariable 
regression models adjusted for baseline health status, age, gender, Caucasian race, 
smoking, diabetes, renal failure, and congestive heart failure.
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Results: The 298 Ds had significantly lower 3-year mortality and were also less likely to 
have a combined 1-year adverse outcome than the non-Ds (figure). Non-significant trends 
towards better health status and rehospitalization rates for drinkers were also observed.
Conclusion: Post-MI patients who regularly drink alcohol have less angina, better quality of 
life, fewer readmissions and better 1- and 3-year outcomes compared with non-drinkers. 
11:00 a.m.
1019-147 Operative Mortality in Women and Men Undergoing 
Coronary Artery Bypass Graft Surgery: The California 
Coronary Artery Bypass Graft Surgery Outcomes 
Reporting Program
Radhika N. Bukkapatnam, Khung Keong Yeo, Zhongmin Li, Ezra A. Amsterdam, 
University of California, Davis Medical Center, Sacramento, CA
Background:The comparative operative mortality (OM) in women and men undergoing 
isolated coronary artery bypass graft surgery (CABG) in the current era has not been 
clarified. Therefore, we evaluated OM and related factors in a large cohort of patients 
undergoing isolated CABG.
Methods: Data reporting to the California CABG outcomes reporting program (CCORP) 
is mandated under state law in California. Results from 121 hospitals on patients 
undergoing isolated CABG in 2003 and 2004 were analyzed, including demographics, 
clinical characteristics and surgical outcome.
Results:10,708 women and 29,669 men had isolated CABG in 2003-2004. Observed OM 
in women (4.06% vs predicted 4.58%) was significantly (p<0.0001) higher than in men 
(OM 2.53%, predicted 2.52%). While men had a higher prevalence of >3 diseased vessels 
and left ventricular dysfunction, women were more likely to be older, diabetic, stage 3-
5 chronic kidney disease, smokers, and have non-elective CABG (table). Although 
multivariate analysis indicated that women were at higher risk for OM than men (OR 1.61, 
95%CI 1.40-1.84), adjusted risk was equivalent in the two groups (3.10%).
Conclusions:Risk factors for OM with isolated CABG differed in women and men. 
Although both predicted and observed operative mortality were higher in women, risk-
adjusted mortality was similar.
Baseline Characteristics of Patients Undergoing Isolated CABG in California, 2003-04
Male 
(N=29,669)
Female 
(N=10,708) p
Age (yrs)
< 65 
65-74 
>75
45.53% 
32.06% 
22.41%
33.46% 
34.40% 
32.13%
<0.0001
Race
Caucasian 
African American 
Hispanic 
Asian
71.28% 
11.49% 
2.97% 
8.78%
66.32% 
13.88% 
5.66% 
8.93%
<0.0001 
0.652
BMI
<18.5 
18.5-39.9 
>40
0.62% 
96.74% 
2.64%
1.79% 
92.59% 
5.61%
<0.0001
Acuity
Elective 
Urgent 
Emergent 
Salvage
37.29% 
57.26% 
5.27% 
0.18%
31.29% 
62.26% 
6.12% 
0.33%
<0.001 
0.0061
Diabetes Yes 35.88% 46.82% <0.001
Chronic kidney disease
Stage 1-2 
Stage 3 
Stage 4 
Stage 5
76.54% 
19.68% 
1.25% 
2.53%
57.56% 
35.15% 
3.48% 
3.81%
<0.0001
Hypertension Yes 76.51% 85.14% <0.001
Heart Failure 
Left main stenosis (>50%) 
Ejection Fraction
Yes 
Yes 
<40%
16.11% 
25.01% 
19.34%
22.25% 
25.01% 
16.47%
<0.0001 
0.8537
>3 diseased vessels 
Mitral regurgitation 
Prior CABG
Yes 
Mod/ Severe 
Yes
79.87% 
2.90% 
5.91%
73.59% 
5.20% 
4.23%
<0.0001
11:00 a.m.
1019-148 Coronary Artery Revascularization Versus Medical 
Management Before Elective High-Risk Noncardiac 
Surgery: A Meta-Analysis
Param P. Singh, Janos Molnar, Rohit Arora, Amol Bahekar, Sarabjeet Singh, Rosalind 
Franklin University of Medicine and Science / Chicago Medical School, North Chicago, IL
Background: Previous studies comparing preoperative coronary revascularization 
(percutaneous coronary intervention or coronary artery bypass grafting) and medical 
management in patients with coronary artery disease undergoing elective high-risk 
noncardiac surgery (vascular or nonvascular) have shown conflicting results. Meta-
analysis of these studies was done to evaluate the incidence of thirty-day postoperative 
all cause mortality and myocardial infarction (MI).
Methods: A systematic review of literature found one prospective randomized controlled 
and nine retrospective studies (N=5043). As the studies were homogenous for outcomes, 
combined relative risks (RR) across all the studies and the 95% confidence intervals were 
computed using the Mantel-Haenszel fixed-effect model. A two-sided alpha error < 0.05 
was considered to be statistically significant.
Results: There were no significant differences in the demographics of both groups. 
Compared with control, the risk of all cause mortality was significantly lower in 
revascularization group (RR: 0.55, CI: 0.378-0.822; p=0.003). However, both groups had 
similar risk of MI (RR: 0.59, CI: 0.328-1.095; p=0.096).
Conclusions: The meta-analysis suggests that preoperative revascularization is superior 
to medical managment in reducing incidence of postoperative thirty-day all cause mortality 
in patients undergoing elective high risk noncardiac surgery. However, the incidence of 
postoperative MI may be similar in both the groups. 
11:00 a.m.
1019-149 Racial and Gender Trends in the Use of Implantable 
Cardioverter-Defibrillators Among Medicare 
Beneficiaries Between 1997 and 2003
Paul S. Chan, John D. Birkmeyer, Harlan M. Krumholz, John A. Spertus, Brahmajee 
K. Nallamothu, Mid-America Heart Institute, Kansas City, MO, University of Michigan 
Medical Center, Ann Arbor, MI
Background: Differences in the use of medical procedures by race and gender are well 
known. However, the extent to which such differences exist for implantable cardioverter-
defibrillators (ICDs) and whether they have widened after the publication of major clinical 
trials supporting their use is unclear.
Methods: Using data on Medicare beneficiaries, we determined annual age-standardized 
population-based utilization rates of ICDs for white men, black men, white women, and 
black women from 1997 to 2003. Mean annual increases in utilization differences between 
white men and other subgroups were determined using linear regression models. Models 
were constructed for ICD use overall and separately for patients receiving ICDs for 
primary and secondary prevention.
Results: During the study period, overall use of ICDs increased most for white men (81.7 
procedures per 100,000 in 1997 to 254.7 procedures per 100,000 in 2003) and black 
men (38.0 to 151.7 procedures per 100,000), with white women (28.9 to 98.4 procedures 
per 100,000) and black women (18.2 to 77.3 procedures per 100,000) showing smaller 
increases in comparison. For all comparisons, differences in utilization rates between 
white men and the other groups widened between 1997 and 2003. For black men, 
this difference widened on average by +9.0 procedures per 100,000 per year (relative 
increase of 21% per year; p=0.002). For white and black women, this difference widened 
on average by +16.3 procedures per 100,000 per year (31%; p=0.002) and +17.8 
procedures per 100,000 per year (28%; p=0.001), respectively. These findings appeared 
to be most pronounced for ICDs performed for primary prevention.
Conclusion: Utilization rates of ICDs differ by race and gender among Medicare 
beneficiaries and these differences have widened as indications for these devices have 
expanded in recent years.
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11:00 a.m.
1019-150 The Impact of Niacin-Induced Flushing during the First 
Week of Therapy in a Real World Setting
Andrew T. Trovato, Josephine M. Norquist, Thomas Rhodes, Kelly McQuarrie, Tiffany B. 
Miller, John F. Paolini, Douglas J. Watson, Merck and Co., Upper Gwyned, PA, Quintiles 
Strategic Research and Safety, Research Triangle Park, NC
Background: Niacin has proven lipid-modifying efficacy and cardiovascular benefit. 
Previous studies have suggested that niacin-induced flushing (NIF) significantly limits 
patient adherence to therapy. A prospective observational study to characterize the 
impact and severity of NIF symptoms in subjects newly prescribed niacin is ongoing. This 
report is an interim analysis of the first week.
Methods: Data are reported for the first week of niacin use only. Subjects (n=154) were 
surveyed daily during week 1 of therapy via telephone. Surveys included the validated 
Global Flushing Severity Score (GFSS), Global Flushing Bothersome Score (GFBS), and 
Flushing Impact Questionnaire (FIQ).
Results: The sample was 64% men, mean (SD) age 56.4 (12.7), 79% white. About 
91% began niacin treatment at 500 mg. Overall 28.6% reported a maximum GFSS ≥ 
4 (moderate or greater; Moderate, 13.7%; Severe, 11.0%; Extreme, 3.9%) and 23.9% 
reported a maximum GFBS ≥ 4 (moderate or greater; Moderate, 10.3%; Severe, 9.7%; 
Extreme, 3.9%) during Week 1. About 45% (66/146) of subjects were told by their health 
care provider ways to minimize flushing. 58% (38/66) of these subjects reported using 
aspirin, ibuprofen, or other medications. Overall, 40% (58/146) used medications to 
alleviate flushing symptoms. No significant differences were observed in max GFSS and 
max GFBS in patients who reported using medications to alleviate flushing vs. those who 
did not. Mean bother increased with increased flushing severity ranging from 0 for “None” 
to 9.8 for “Extreme”. Likewise, mean (SD) FIQ domain scores increased with increasing 
flushing severity (GFSS) driven primarily by the Irritation/Frustration domain (None, 1.2 
(0.7); Mild, 1.7 (1.0); Moderate, 2.1 (1.0); Severe 2.7 (1.2); Extreme, 2.6 (0.7)).
Conclusion: Although most subjects started niacin therapy on the low recommended 
dose of 500 mg, a sizeable proportion of patients reported moderate or greater flushing 
severity and bother due to flushing. Aspirin use to alleviate flushing appears to be under-
utilized. Subjects who reported greater flushing severity reported greater bother and 
greater impact.
11:00 a.m.
1019-151 Racial Differences in Functional Capacity Among 
Patients with Heart Disease: Analysis of the National 
Health Interview Survey (NHIS)
Ian Persaud, Girardin Jean-Louis, Ferdinand Zizi, Lazar Jason, Mohammed Boutjdir, 
Brooklyn Center for Health Disparities, Brooklyn, NY, SUNY Downstate Medical Center, 
Brooklyn, NY
Background: Functional capacity is an important prognostic factor in patients with 
cardiovascular disease. While structural heart disease is contributory, other factors are 
likely responsible for reduced exercise tolerance in these patients. The objective of this 
analysis was to determine whether racial differences exist in functional capacity among 
patients with heart disease.
Method: The NHIS uses a multistage area probability sampling technique to conduct 
a cross-sectional household interview survey among respondent representative of the 
civilian U.S. population (mean age = 48 ± 18 yrs; range: 18-85). Face-to-face interviews 
were conducted by trained staff from the U.S census Bureau, obtaining information 
regarding physician-diagnosed chronic illnesses along with various sociodemographic 
data.
Results: Of the 29,815 adults enrolled in the 2005 National Health Interview Survey 
(NHIS), 8% reported heart disease. The prevalence of heart disease among white and 
black patients was 8.6% and 6.3%, respectively. Blacks had a higher body mass index 
(BMI) compared to whites (27.10 ± 5.73 vs. 28.66 ± 6.58, F= 251.71 p < 0.0001). Of the 
respondents with heart disease, white participants were more likely than blacks to report 
being able to walk one-quarter mile without assistance (81.0% vs. 77.5%, χ2 =28, p < 
0.0001) or being able to climb 10 steps without assistance (85.2% vs. 80.8%, χ2 = 54, 
p< 0.0001). Logistic regression analysis showed that patients’ ability to purchase their 
prescription medications was the most significant predictor of their ability to walk one-
quarter mile (Wald = 155, p < 0.0001). The corresponding multivariate-adjusted odds 
ratio was 3.6 (95% Confidence Interval = 2.92 - 4.36). Results were similar using ability to 
climb 10 steps as a dependent measure.
Discussion: Blacks with heart disease demonstrated less functional capacity than did their 
white counterparts. However, these racial differences appear to be mediated by the ability 
to purchase prescription medications. The disparity in BMI was a less significant predictor of 
functional capacity. This study has large implications in terms of public health policy.
11:00 a.m.
1019-152 Relationship of Quality of Life Scores with Baseline 
Characteristics and Outcomes in the African-American 
Heart Failure Trial
Peter E. Carson, Anne L. Taylor, Jay N. Cohn, Jalal K. Ghali, Inder S. Anand, S. William 
Tam, Virginia M. Braman, Manuel Worcel, Veterans Affairs Medical Center, Washington, 
DC, University of Minnesota, Minneapolis, MN
Background: The Minnesota Living with Heart Failure questionnaire (MLHF) is designed 
to measure the effects of physical and emotional limitations on a subject’s quality of life 
(QOL). We studied the relationship of MLHF QOL scores with baseline characteristics 
(BC) and outcomes in 1050 African-American (AA) patients enrolled in A-HeFT.
Methods: 2-Sample t-test or ANOVA were used to compare differences within patient 
(pt) BC. Cox proportional multivariate analyses were used to test the association of QOL 
scores with outcomes.
Results: Mean baseline QOL scores were significantly poorer in AA pts who were <65 
yrs, female, NYHA class IV, higher BMI, low systolic BP (SBP), and non ischemic etiology. 
There was no significant difference in QOL between pts stratified by diabetic status, 
creatinine (<2.0>), quartiles of LVEF or tertiles of BNP. Baseline QOL and change in 
QOL scores from baseline to 3 and 6 months were not associated with mortality but were 
independent predictors of mortality or first heart failure (HF) hospitalization (Table). 
HR (95% CI) p-value
Mortality
Baseline QOL score 1.006 (0.991-1.020) 0.441
Change in QOL at 3 mo from baseline 1.015 (0.999-1.032) 0.058
Change in QOL at 6 mo from baseline 1.005 (0.988-1.022) 0.551
Mortality or First HF Hospitalization
Baseline QOL score 1.015 (1.008-1.022) <0.0001
Change in QOL at 3 mo from baseline 1.014 (1.006-1.022) 0.0011
Change in QOL at 6 mo from baseline 1.015 (1.006-1.024) 0.0008
Conclusion: In A-HeFT, poorer baseline MLHF QOL scores were present in younger pts 
and females; and were associated with some indicators of advanced disease (low SBP 
and high NYHA class) but not with others (LVEF, BNP, or ischemic etiology). However, 
baseline QOL scores and change in QOL at 3 and 6 months were independently 
associated with combined mortality or first heart failure hospitalization suggesting that 
this instrument may be a useful measure of progression of the disease.
11:00 a.m.
1019-153 Cardiac Rehabilitation Improves Memory in Older 
Adults With Cardiovascular Disease
Kelly M. Stanek, John Gunstad, Jim Rosneck, Donna Waechter, Richard Josephson, 
Kent State University, Kent, OH
Background: Cardiovascular disease (CVD) is associated with cognitive deficits, including 
impairment in executive function, attention, and psychomotor speed. There is some 
indication that improvement in cardiovascular fitness, specifically through participation 
in cardiac rehabilitation (CR), may be associated with improvements in these areas. The 
present study measured performance in multiple cognitive domains in persons with CVD 
before and after a 12 week CR program.
Methods: Forty-two older adults with CVD and no history of significant neurological or 
psychiatric disorder underwent 12 weeks of CR, including structured aerobic exercise 
three times per week. A battery of neuropsychological tests assessed multiple cognitive 
domains and the Rapid Assessment of Physical Activity (RAPA), quantified frequency and 
intensity of physical activity at baseline and 12 week follow-up.
Results: Repeated-measures analyses showed statistically significant improvement in 
performance on Hopkins Verbal Learning [F(1,41) = 9.815, p = 0.003], and Delayed Recall 
[F(1,41) = 9.075, p = 0.004], and on Letter Number Sequencing [F(1,41) = 4.509, p = 0.040]. 
Exploratory analyses indicated that a lower RAPA baseline score, indicating lower levels 
of physical activity prior to CR, was associated with greater changes in performance on 
Hopkins Verbal Learning (r = -0.359, p = 0.018), Delayed Recall (r = -0.344, p = 0.024), and 
Letter-Number Sequencing (r = -0.399, p = 0.008) following 12 weeks of CR.
Conclusion: Participation in CR was associated with significant improvement in multiple 
cognitive domains, particularly verbal learning and recall and working memory. Cognitive 
improvement was greatest for individuals with lower levels of physical activity prior to CR. 
Future studies are needed to address the mechanisms responsible for these changes, 
particularly studies that further explore the type, intensity and duration of cardiovascular 
exercise that result in optimal neurocognitive improvement.
11:00 a.m.
1019-154 Relative Contribution of Patient Characteristics and 
Clinical Site Characteristics to Saphenous Vein Graft 
Stenosis and Adverse Cardiac Events Following 
Coronary Artery Bypass Graft Surgery: A PREVENT-IV 
Analysis
Jacqueline L. Buros, Yuri B. Pride, John H. Alexander, Nicholas T. Kouchoukos, Eric 
D. Peterson, T. Bruce Ferguson, C. Michael Gibson, Cardiovascular Division, Dept of 
Medicine, Beth Israel Deaconess Medical Center, Harvard Medical Sch, Boston, MA, 
Duke University Medical Center, Durham, NC
Background: The goal of this analysis was to evaluate the relative contribution of patient 
characteristics and surgical clinical site characteristics on saphenous vein graft (SVG) 
stenoses at routine follow-up angiography as well as major adverse clinical events 
(MACE) during clinical follow-up in the PREVENT-IV study.
Methods: PREVENT-IV randomized 3,014 patients undergoing CABG at 105 sites to 
either edifoligide or placebo. 1,293 patients underwent routine follow-up angiography 
to evaluate the patency of saphenous vein grafts from 12-18 months following surgery. 
Percent diameter stenosis was measured by quantitative coronary analysis (QCA) at an 
angiographic core laboratory. MACE were defined as the composite of all-cause mortality, 
myocardial infarction, or repeat revascularization procedure with graft failure.
Results: 20% of the variance in SVG percent diameter stenosis by QCA at follow-up 
was attributable to patient characteristics (i.e. the intra-class correlation (ICC) was 0.20, 
p<0.001). Independent of the contribution of patient characteristics, 3% of the variance in 
SVG stenoses was explained by characteristics of the clinical center enrolling the patient 
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(ICC=0.03, p=0.02). 15% of the variance in MACE was attributable to the clinical center 
(theta=0.15, p<0.001).
Conclusion: While 20% of the variance in SVG stenoses is explained by patient 
characteristics, up to 15% of the variance in MACE outcomes are attributable to the 
clinical site characteristics. Future CABG trials should consider adjusting for clustering of 
events within enrolling centers. Further research in cardiovascular trials is warranted to 
understand the processes of care, techniques or decisions that contribute to the role of 
clinical sites in adverse outcomes.
11:00 a.m.
1019-155 Relation between Rate of Change in Glycated 
Hemoglobin A1c (HbA1c) over Time and Long-Term 
Mortality in Ambulatory Diabetic Patients with Chronic 
Heart Failure
Manish Jhawar, Wilson Tong, Ashok Panneerselvam, Anil Jain, W. H. Wilson Tang, 
Cleveland Clinic, Cleveland, OH, University of Missouri, Columbia, MO
Background: Recent observations from heart failure registries have challenged the 
benefits of tight glycemic control in reducing long-term mortality in diabetic heart failure 
patients. The prognostic implication of the rate of change in serial HbA1c over time has 
not been examined.
Methods: We identified 2,571 ambulatory patients with diabetic heart failure with serially 
measured HbA1c. We define rate of change as the slope of HbA1c linearly regressed over 
time in days (“HbA1c slope”).
Results: In our study cohort (mean age 70 ±13 years, 60% male, mean baseline HbA1c 
7.8 ±2%, 49% on insulin), 799 deaths/transplants occurred over a period of 4.4 ±2 years. 
We observed a U-shaped mortality curve with better mortality rates in patients with less 
rapid rise and fall in HbA1c over time. Patients with more rapid fall in HbA1c experienced 
poorer outcomes than those with more rapid rise in HbA1c (Quartile 1 vs 4, p=0.0038). 
In multivariate Cox proportional hazard analysis, rise in slope is associated with more 
favorable prognosis (Hazard Ratio 0.465, 95% CI 0.34 - 0.64, p<0.001) after adjusting for 
age, renal function, hypertension, and use of anti-diabetic medications.
Conclusion: In our large single-center experience, rapid fall in HbA1c was associated with 
poorer long-term prognosis. Further studies are needed to clarify whether overzealous or 
intentional tight glycemic control may contribute to these observations.
11:00 a.m.
1019-156 Incidence of Contrast Induced Nephropathy in Patients 
With Chest Pain is Not Zero Despite Exclusion of HIgh 
Risk Features: Impact of Noninvasive Screening CT 
Scans
JoEllen Kohlman, Jeff Ciaramita, Stephen Kuehn, Michael Lim, Saint Louis University, 
Saint Louis, MO
Background: With greater availability of specialized computed tomography to evaluate 
patients presenting with chest pain comes increased intravenous contrast administration. 
We sought to quantify the potential impact of contrast in a series of patients presenting 
with chest pain.
Methods: All patients with the chief complaint of chest pain presenting to the Saint Louis 
University Emergency Department for 3 consecutive months were included. Those with 
serum creatinine values > 1.4 mg/dl and those on dialysis were excluded. We calculated 
a contrast induced nephropathy (CIN) risk score for each patient and then analyzed the 
incidence CIN (defined as an increase in serum creatinine of 0.5 mg/dl).
Results: 551 patients were included (mean age 44.5 years, 53% male). 12.7% of patients 
had a coronary angiogram, 20.3% had a CT scan with contrast, and 2.9% had both. The 
incidence of diagnosed acute coronary syndrome was 3.3% (n=18). All other patients 
had a non-cardiac diagnosis. We found that 5 (0.9%) patients had CIN (3 patients had CT 
scans, 1 patient had a coronary angiogram, and 1 patient had both). The average contrast 
bolus in the affected patients was 172 ml. The average CIN risk score was 1.42 for the 
cohort and 2.2 for the affected patients.
Conclusions: Even with utilization of a previously published risk stratification scheme, CIN 
does occur in patients identified as low risk. This finding warrants caution when utilizing 
CT scans in patients with chest pain, regardless of their CIN risk score. The administration 
of contrast remains a harbinger for contrast-induced nephropathy.
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3:00 p.m.
1026-127 Development of Appropriateness Criteria for 
Percutaneous Coronary Intervention and their 
Application in Japanese Teaching Hospitals
Takahiro Higashi, Shun Kohsaka, Shunichi Fukuhara, Kunihiko Matsui, Sunao Kojima, 
Hisao Ogawa, Tetsu Yamaguchi, Kyoto University, Kyoto, Japan, Toranomon Hospital, 
Tokyo, Japan
Background: A national survey in Japan reported a disproportionately large number of 
percutaneous coronary interventions (PCI) compared to the number of surgical cases, 
raising questions on the appropriateness of indications. We sought to (1) establish 
separate independent appropriateness criteria for PCI in Japan based on local clinical 
expert opinion and (2) quantify the burden of inappropriately performed PCI in the 
strongly surgical-refractory Japanese medical society.
Methods: We developed comprehensive appropriateness criteria for PCI indications using 
more than 880 mutually exclusive clinical scenarios, in which angiographic findings and 
clinical variables were combined to determine indications for percutaneous coronary 
intervention (PCI). The appropriateness of PCI in each scenario was rated by nine 
nationally recognized clinical experts on a scale of 1-9 in two rounds, between which 
a full-day face-to-face consensus meeting was held. The second rating determined 
the appropriateness of the PCI indications in the clinical scenarios. To determine the 
frequency of PCIs performed with appropriate/inappropriate indications, these clinical 
scenarios were applied to patients who underwent PCI from January 2005 to August 
2006 in two major teaching hospitals in Japan.
Results: Among the 707 PCI cases examined, 70% of indications were rated appropriate 
(median rating of 7-9) while 4% were inappropriate (median 1-3), and 26% were uncertain 
(median 4-6 or ≥3 raters rated opposed to the majority). For 9.1%, at least 3 experts rated 
appropriateness as 1-3 while the other 3 rated it as 7-9, showing strong disagreement 
over the appropriateness of the indication among experts. One hospital performed PCIs 
for uncertain or contentious indications significantly more frequently (32%) than the other 
hospital (22%, p<0.01)
Conclusion: Although inappropriate indications deemed by local expert opinion based 
on current guidelines for PCI were rare in Japan, a significant proportion of PCIs were 
performed based on uncertain rather than definite indications.
3:00 p.m.
1026-128 Impact of Stress SPECT Imaging After Revascularization: 
Evaluating the Appropriateness Criteria
Manesh Patel, Emily Honeycutt, Linda Shaw, Bimal Shah, Pamela Douglas, Salvador 
Borges-neto, Duke University, Durham, NC
Background: The appropriateness of stress SPECT imaging shortly following 
revascularization is unclear, rated as uncertain for scenarios within 2 years of PCI and 
within 5 years of CABG by the ACCF guideline.
Methods: To understand the impact of stress nuclear post revascularization, a retrospective 
analysis was performed of patients in the Duke Cardiac Databank undergoing first PCI or 
CABG between 1997 and 2006. Patients were followed for rates of stress imaging, and 
rates of subsequent angiography and revascularization. Data are presented as medians. 
A Kaplan-Meier analysis of time to first stress testing was performed.
Results: A total of 14,835 (61.5% PCI and 39.5% CABG) patients were identified. The 
CABG patients were older (60 vs.65), male (69.1 vs. 63.1%), and diabetic (35.1 vs. 
25.2%). On Kaplan-Meier analysis, 18.6% of post PCI patients and 12.4% of post CABG 
patients had nuclear imaging during follow up (Figure). Median days to imaging was 213 
following PCI and 431 days following CABG. Subsequent angiography occurred in 22.8% 
of post-PCI patients and 24.4% post-CABG patients, and repeat revascularization in 
11.1% of post-PCI and 9.2% of post-CABG patients.
Conclusion: In a large representative sample of first time revascularization patients, stress 
nuclear imaging occurs frequently, with varying temporal patterns, leading to nearly 10% 
getting subsequent revascularization. Improved understanding stress nuclear imaging 
patterns will help inform efforts to identify appropriate use.
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1026-129 Effect of Stress Myocardial Perfusion Imaging Results 
on Liver Transplant Eligibility
Steven M. Bradley, Laurie A. Soine, James H. Caldwell, Steven L. Goldberg, University 
of Washington, Seattle, WA, Veterans Affairs Puget Sound, Seattle, WA
Background: Screening for coronary artery disease (CAD) is common practice in the 
evaluation of orthotopic liver transplant candidates. We sought to assess the impact of 
stress myocardial perfusion imaging (MPI) results on liver transplant eligibility in relation 
to the cost of screening in this population.
Methods: We identified consecutive adult liver transplant candidates at the University 
of Washington Medical Center referred for a single stress MPI between April 1998 and 
February 2004. Medical records were reviewed for baseline demographics, history of and 
risk factors for CAD, and stress MPI findings. Stress MPI results were interpreted as 
positive (reversible defect, fixed defect, or both) or negative (normal or findings consistent 
with artifact). Follow-up data was assessed for transplant status and CAD as a component 
of denial criteria for transplant listing.
Results: A total of 632 patients were identified who underwent a single stress MPI study 
as part of transplant evaluation. Stress MPI studies were positive in 113 patients (18%) 
and negative in 519 patients (82%). Patients with a positive stress MPI were more likely to 
have a family history of coronary artery disease, personal history of peripheral vascular 
disease, myocardial infarction or coronary bypass surgery. Of the 632 patients evaluated 
as transplant candidates, 279 patients were denied transplantation. Coronary artery 
disease was a component of denial criteria in 14 (2%) candidates. Positive stress MPI led 
to detection of previously unsuspected severe CAD and exclusion from transplantation in 
4 (0.6%) transplant candidates. At $2250 per test, stress MPI screening was performed at 
an average cost of $335,000 per exclusion from transplantation.
Conclusions: It is important to screen liver transplant candidates for conditions that may 
lead to adverse outcomes after transplantation given the scarcity of this resource. Our 
study demonstrates stress MPI results affect liver transplant candidate status in less 
than 1% of candidates at an average cost of $335,000 per exclusion. More cost-effective 
screening methods for coronary artery disease in the liver transplant population are 
needed.
3:00 p.m.
1026-130 Prevalence of obstructive coronary artery disease in 
patients undergoing diagnostic cardiac catheterization: 
analysis of National Cardiovascular Database  
Registry data
Grace A. Lin, R. Adams Dudley, Al Woodward, Jim Beachy, Syamal Dey, Rita F. 
Redberg, University of California San Francisco, San Francisco, CA
Background: As cardiac catheterization has become safer and the available treatments 
more efficacious, there is greater interest in identifying coronary artery disease (CAD) at 
an earlier stage. Since subclinical CAD may be asymptomatic, we sought to determine 
the relationship between type of symptoms and presence of obstructive CAD.
Methods: Using the American College of Cardiology’s National Cardiovascular 
Data Registry CathPCI database, we examined all patients undergoing diagnostic 
catheterization from October 2005 to June 2006. We stratified patients by presence of 
symptoms and severity of disease.
Results: We analyzed data on 334,232 patients who underwent diagnostic cardiac 
catheterization during the specified time period. Most patients (67.9%) had symptoms; 
12.5% of patients had no symptoms and 19.6% had atypical chest pain. Using a 50% 
stenosis cutoff, we classified the severity of disease for each symptom category (Table). 
Table. Distribution of obstructive coronary artery disease at 50% stenosis in patients 
undergoing diagnostic cardiac catheterization.
All 
(N=334,232) Normal 1 vessel 2 vessel 3+ vessel p*
No symptoms 
(N=41,678) 44.2% 24.9% 15.4% 15.4%
<0.0001Atypical chest pain (N=65,570) 66.6% 16.9% 8.7% 7.8%
Symptomatic 
(N=226,984) 26.8% 30.8% 21.2% 21.2%
*P-value is for a linear test of trend across vessel categories
Conclusions: A substantial proportion of patients with no symptoms or atypical chest 
pain undergoing diagnostic cardiac catheterization have normal coronary arteries, while 
few have 3-vessel disease, compared with patients who are symptomatic. These findings 
have implications for the use of cardiac catheterization in patients without clear anginal 
symptoms, particularly in patients with atypical chest pain. Further research is needed to 
define the characteristics of patients who would most benefit from undergoing invasive 
coronary angiography.
3:00 p.m.
1026-131 Cost analysis of an intensive smoking cessation 
intervention in cardiac patients
Robyn Kondrack, Daniel E. Hilleman, Stephanie R. Maciejewski, Timothy L. Grollmes, 
David A. Cloutier, Syed M. Mohiuddin, Creighton Cardiac Center, Omaha, NE
Introduction: Overwhelming evidence indicates that smoking cessation interventions (SCI) 
are associated with substantial quit rates in hospitalized smokers with cardiac disease. 
Most hospitals do not offer formal smoking cessation interventions which may result from 
concerns that such programs are not cost-effective. We recently demonstrated that our 
SCI not only reduced rates of smoking, but also reduced morbidity and mortality. A cost 
analysis of this study was performed.
Methods: The methods and outcomes of our SCI have been previously published (Chest 
2007;131:446-452). Benefits of the SCI included a reduction in mortality (RRR 77%; 95% 
CI 27% to 93%; p = 0.014) and a reduction in hospitalizations (RRR 44%; 95% CI 16% to 
63%; p = 0.007). Costs of the SCI and costs of direct medical care in the intervention (INT) 
and usual care (UC) groups were prospectively determined over the 5 years subjects 
were enrolled and treated. Costs were discounted by 5% per year and sensitivity analyses 
were conducted. A cost-effectiveness (CE) ratio was calculated as the difference in costs 
between the treatment groups divided by the absolute risk reduction between the groups 
to produce a cost per life year gained.
Results: A total of 209 smokers hospitalized with acute cardiac disease were included 
in the analysis. Cost of the SCI in the INT group was $247,376 over the 5 years. Direct 
medical care costs in the intervention group were $625,000 compared to $1,025,000 in 
the UC group. The use of the SCI was cost saving with the INT group having $152,625 
less in total costs than the UC group. Hospital costs over the follow-up were the major 
driver of cost savings. Sensitivity analysis indicated that hospital cost would have to be 
discounted by 70% before the SCI was no longer cost saving. The CE ratio, if calculated 
only on the cost of providing the SCI ignoring subsequent hospital costs, was $1443 per 
life year gained.
Conclusion: An intensive SCI is actually cost saving in high risk cardiac smokers. The 
intervention is extremely cost-effective. This study indicates that health care insurance 
payers should cover intensive tobacco cessation interventions.
3:00 p.m.
1026-132 Determining the Cost of Bleeding in Patients 
Undergoing Percutaneous Coronary Intervention: 
Implications for Economic Analyses of Randomized 
Trials
Edward F. Ewen, Liping Zhao, Paul Kolm, Dogan Fidan, William S. Weintraub, Christiana 
Care Health System, Newark, DE, sanofi-aventis, Paris, France
Background: Randomized clinical trials (RCTs) in acute coronary syndromes and 
percutaneous coronary intervention often assess safety by comparing bleeding rates of 
the trial arms. As micro-cost data often cannot be collected within trials due to logistic 
limitations or the inclusion of multi-national sites, estimates of costs cost for major and 
minor bleeding that are required for both cost and cost-effectiveness analyses may need 
to be determined from sources other than RCTs. In this analyses, we estimated the cost 
of minor and major bleeding in PCI patients from a large hospital data registry. Methods: 
All non-emergent PCI cases not requiring a subsequent coronary artery bypass were 
identified between 1/2003 and 3/2006 in the PCI registry. These cases were then 
identified in laboratory and patient record databases to determine change in hemoglobin 
(Hgb) levels and identify occurrence of blood transfusions. ICD9 diagnosis codes, 
CPT procedure codes, and medication use associated with major and minor bleeding 
categories were identified and used in addition to the PCI registry vascular bleeding 
indicator, change in Hgb, and transfusion history in assigning a bleeding classification. 
These cases and their bleeding classification were then matched to hospital charges. 
Charges were converted to cost using departmental level, direct cost to charge ratios 
adjusted for year. The independent contributions of major and minor bleeding to cost 
were determined by multiple regression. Results: Of 6,504 PCI patients 6,339 had their 
first PCI. Of these PCIs 4.4% (n=279) were classified with minor bleeding and 3.5% 
(n=221) with major bleeding. The cost of minor and major bleeding was $4,983 and 
$6,187, respectively. Costs related to African-Americans were higher than Caucasians 
($873 vs. $155, p = 0.07), though only age and bleeding class contributed significantly to 
the model.Conclusions: Bleeding is associated with considerable cost over and above 
interventional procedures. Accurate estimates of the cost of bleeding are essential for 
analysis of the economic impact. These data may be used to improve medical decision-
making and to better inform clinical trials where bleeding is the major safety outcome.
3:00 p.m.
1026-133 The Consequences of Major Bleeding in Acute 
Coronary Syndromes
Ruslan Horblyuk, Laura E. Happe, Orsolya Lunacsek, Laura Menditto, GlaxoSmithKline, 
Philadelphia, PA, Xcenda, Palm Harbor, FL
Background: Anticoagulants reduce ischemic events in patients with ACS yet often at 
the expense of increased bleeding. Recent clinical trial data suggest that bleeding is 
associated not only with increased myocardial infarction (MI) and stroke but also increased 
mortality, which translate to higher consumption of healthcare resources. We investigated 
whether the trial findings are supported by real-world in-hospital data.
Methods: Patients with an admitting diagnosis of unstable angina (UA; ICD-9 code 411.1) 
or non-ST-segment elevation MI (NSTEMI; 410.7x) who received dalteparin, enoxaparin, 
fondaparinux, or unfractionated heparin were identified retrospectively from the Premier’s 
Perspective hospital discharge database, representing over 500 US hospitals between 
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1/1/2003 and 3/31/2006. Major bleeding included hemoperitoneal bleeds (568.81), 
intracranial hemorrhage/hemorrhagic stroke (430-432), hemorrhages complicating 
a procedure (998.11) or any other bleeding diagnoses accompanied by >2 units of 
blood. Length of stay (LOS), readmission rate, all-cause in-patient mortality and total 
hospitalization costs over 30 days were compared between patients with versus without 
major bleeding using statistical models to control for covariates.
Results: A total of 292,779 patients with UA/NSTEMI who received an injectable 
anticoagulant were identified. Major bleeding occurred in 8,566 (2.93%) patients. Patients 
with major bleeding had significantly greater LOS (15.0 vs. 5.7 days; incidence rate 
ratio=1.69; 95% confidence interval [CI] 1.67-1.72), readmission rate (30.7% vs. 14.7%; 
odds ratio [OR]=1.54; 95% CI 1.46-1.62) and all-cause in-patient mortality (15.6% vs. 
4.5%; OR=1.85; 95% CI 1.73-1.98) than patients without major bleeding. Total adjusted 
hospitalization costs were 58% (95% CI: 57%-60%) higher for patients with major bleeding 
(adjusted: $31,128 vs. $17,346).
Conclusions: ACS patients with major bleeding are associated with significantly longer 
hospital stays, higher readmission rates and costs, and increased mortality. The wider 
use of anticoagulants that reduce ischemic events without increasing major bleeds should 
be considered.
3:00 p.m.
1026-134 Heart Transplant for Status 2 Patients May Not be Cost 
Effective
Vijay Vaidya, Meghana Yajnik, Paul Heidenreich, Jignesh Patel, Michelle Kittleson, Matt 
Kawano, Ajay Vaidya, Allison Ankrom, Abbas Ardehali, Jon Kobashigawa, David Geffen 
School of Medicine at UCLA, Los Angeles, CA, Stanford University, Stanford, CA
Background: We compared the costs per life year gained with heart transplant vs medical 
treatment of end stage heart failure. The standard for cost effectiveness is seen in kidney 
dialysis ($50,000-$100,000 per life year gained).
Methods: From 1997-2004, 625 patients (pts) were listed for heart transplant as UNOS 
Status 1 (1A or 1B) or Status 2, at our institution. Listed pts were placed into four groups: 
Group A = Status 1 Transplanted (n=164), Group B = Status 1 Medical Treatment (n=52), 
Group C = Status 2 Transplanted (n=245), and Group D = Status 2 Medical Treatment 
(n=164). Costs were obtained from hospital accounting. Survival and mean cost after 
listing were obtained annually for each group over 10 years, and were discounted at a 
3% annual rate. The costs per quality-adjusted-life-year gained were calculated by utility 
scores.
Results: The average follow-up (including death) for groups A,B,C,D was 3.6, 0.5, 5.1, 
and 3.5 years, respectively. For Status 1 pts, 4.95 life years were gained in transplant 
(group A) vs medical treatment (group B). For Status 2 pts, 2.05 life years were gained 
in transplant (group C) vs medical treatment (group D). Due to greater survival benefit, 
costs per life year gained were lower for transplant of Status 1 vs Status 2 pts ($69,622 vs 
$123,417) compared to medical management (see table).
Conclusions: Heart transplant appears to be more cost effective for Status 1 vs Status 2 
pts. Compared to the standard of kidney dialysis, the transplantation of Status 2 patients 
may not be cost effective.
3:00 p.m.
1026-135 Adjusted Clopidogrel Loading Doses According to 
VASP Phosphorylation Index Decrease Rate of Major 
Adverse Cardiovascular Events in Patients With 
Clopidogrel Resistance: A Multicentre Randomized 
Prospective Study
Laurent bonello, laurence camoin, stephane arques, christian boyer, dimitri panagides, 
olivier wittenberg, paul barragan, francoise dignat george, franck paganelli, Hopital 
universitaire nord, marseille, France, laboraoire d’hématologie, INSERUMRS608, hopital 
la conception, marseille, France
Clopidogrel resistance plays a key role in ischemic recurrence after PCI. In-vitro tests 
of clopidogrel resistance have demonstrated their accuracy to predict major adverse 
cardiovascular event(MACE) after PCI.
Objectives:To evaluate the clinical impact of adjusted loading dose (LD) of clopidogrel 
according to VASP index in patients undergoing PCI.
Methods: A prospective, randomized multicenter study was undertaken. Clopidogrel 
resistance was defined as a VASP index>50% after 600mg LD. Patients with clopidogrel 
resistance undergoing coronary stenting were randomized to the control group or to the 
VASP guided group. In the VASP guided group, additional bolus of 600 mg of clopidogrel 
were administrated in order to decrease VASP index below 50%.
Results: One hundred and sixty four patients were included. Control (n=90) and VASP 
guided group (n=74) had similar demographic, clinical and biological characteristics. 
In the VASP guided group, VASP index was significantly decreased after LD 
adjustment(68.7±10.3 to 34.6±10.6, p<0.001). Nine MACEs (5.5%) were recorded during 
the one month follow-up. The VASP guided group had a significantly lower rate of MACE(0 
vs 10%, p=0.004)(figure 1). There was no difference in the rate bleedings between the 
two groups(4 vs 4%, p=0.6).
Conclusion: This is the first study demonstrating that adjusted LD of clopidogrel according 
to platelet monitoring, using VASP index, is safe and significantly improves clinical 
outcome after PCI in patients with clopidogrel resistance. 
3:00 p.m.
1026-137 Percutaneous treatment of unprotected left main 
coronary stenoses with Paclitaxel-eluting stents. Mid-
term results of a French prospective study (friend 
register)
Didier Carrié, Hélène Eltchaninoff, Thierry Lefevre, Marc Silvestri, Gérard Levy, Eric 
Maupas, Philippe Brunel, Bernard Glatt, Didier Blanchard, Laurent Schmutz, Emmanuel 
Salengro, Martine Gilard, Marc Bedossa, Jean Fajadet, Khalife Khalife, Joël Sainsous, 
Jacques Berland, Alain Dibie, Olivier Darremont, Jean-Marc Lablanche, Pierre Labrunie, 
Jean-Philippe Metzger, on behalf of FRIEND investigators, Toulouse, France
Background: We assessed early and mid-term results of patients (pts) treated for ULMCA 
disease in the FRIEND registry.
Methods: After ethical committee approval and informed consent, all consecutive pts with 
unprotected left main stenoses treated with Taxus stents were included in a multicenter 
prospective study from 23 centers. Major adverse cardiac and cerebro-vascular events 
(MACCE) : death, myocardial infarction, stroke, target lesion (TLR), target vessel 
revascularisation (TVR), acute, sub-acute and late thrombosis were adjudicated at 1,12 
and 18 months by an independent committee. Immediate and 9-month angiographic 
results were assessed by a central core lab. For the distal lesion of ULMCA, a strategy 
of main branch stenting with provisional T-stenting of the side branch followed by kissing 
balloon inflation was strongly recommanded.
Results: From December 2005 to July 2006, 155 pts were included, mean age 68 ± 11 
years, 83 % male, 31 % unstable angina, 25% diabetics, 46 % 3-vessel disease.The mean 
Euroscore was 4.2 ± 2.8. The LM reference diameter was 3.6 ± 0.5mm. LM lesion was 
ostial-proximal in 28 %,mid shaft 18 % and distal 66% of whom 72 % were located at the 
bifurcation including LAD, LCX or both ostia affected. All patients were successfully treated 
on the LM (stent length 15.7 ± 5.2 mm) and a final kissing balloon inflation was performed 
in 90%. Apart from the LM stenosis, a total of 1.2 ± 0.8 lesions were treated during the 
hospitalisation (total stent length 47 ± 16mm). In-hospital MACCE rate was 4.5 % : death in 
2.6% (3 acute stent thrombosis at day 2, 3, 5 ; 2 Pts had asymptomatic non-Q-wave MI,1 pt 
Q-wave MI and 1CABG. At 9-month follow-up (122 pts) there was one extra-cardiac death, 
no cardiac failure and 3 pts (2.5 %) had recurrence of symptoms. The global rate of event-
free survival was 93.5 % with a very low angiographic restenosis rate of 3 %.
Conclusions
LM PCI using the TAXUS stent is feasible and safe. Preliminary results showed favourable 
9-month follow-up. Stenting deserves to be considered a safe and effective alternative to 
CABG in institutions performing large numbers of PCIs. Adjudicated angiographic and 
clinical long-term (18-month) data are warranted and will be available for presentation.
3:00 p.m.
1026-138 Retrograde Approach in Percutaneous Coronary 
Intervention for Chronic Total Occlusion
Shigeru Saito, ShonanKamakura General Hospital, Kamakura, Japan
Background:Retrograde approach through the collateral channels has been recently 
proposed and has the potential to improve the success rate of PCI in chronic total 
occlusion (CTO) lesions of the coronary arteries. However, its results have not yet been 
fully reported.
Methods:Total of 55 patients, who were treated for CTO lesions by retrograde approach 
from January 2006 to July 2007, were included in this study. The details of the techniques 
were examined retrospectively.
Results:The septal branch route was used in 93 percent of the cases. We classified the 
strategies into six types after the successful crossing of a guidewire into the target artery 
distal to the CTO lesion through the collateral channels. Among them, “Just landmark”, 
“CART” and “Proximal true lumen puncture” strategies were used most frequently (32, 
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27 and 30%, respectively). The final success rate with previous failed attempts was 83 
percent. One patient achieved the final success by the 2nd attempt of retrograde approach 
after the failed 1st attempt of retrograde and another antegrade approaches. There were 
no serious complications related to the retrograde approach.
Conclusions:Retrograde approach with different strategies, mainly through septal arteries, 
can provide a high success rate with PCI, as shown in 83% of patients with previous failed 
attempts at traditional PCI for CTO lesions, with there being no serious complications.
3:00 p.m.
1026-139 Impact of Arterial Injury on Neointimal Hyperplasia 
After Implantation of Drug-Eluting Stents in Coronary 
Arteries: An Intravascular Ultrasound Study
Parham Eshtehardi, Stéphane Cook, Lorenz Räber, Peter Jüni, Peter Wenaweser, Mario 
Togni, Michael Billinger, Christian Seiler, Marco Roffi, Roberto Corti, Gabor Sütsch, 
Willibald Maier, Franz R. Eberli, Otto M. Hess, Bernhard Meier, Windecker Stephan, 
Cardiology, University Hospital Bern, Bern, Switzerland, Cardiology, University Hospital 
Zurich, Zurich, Switzerland
Background. The aim of this study was to evaluate the impact of arterial injury, defined 
as the balloon-to-artery ratio (BAR) on the amount of neoinitmal hyperplasia assessed 
by intravascular ultrasound (IVUS) after implantation of sirolimus-eluting stents (SES) or 
paclitaxel-eluting stents (PES) in patients with coronary artery disease.
Methods and Results: A total of 159 patients underwent IVUS 8 months after implantation 
of drug-eluting stents: 75 patients were treated with SES and 83 patients with PES. The 
baseline clinical and procedural characteristics were similar for both groups. The maximal 
balloon pressure amounted to 14.8±2.6 bar for SES and 13.8±2.6 bar for PES, and BAR 
was similar for both groups (SES: 1.13±0.21 vs. PES: 1.12±0.17, p=0.72). IVUS imaging 
was performed using motorized pullback and images were analyzed offline by blinded 
outcome assessors. Neointimal hyperplasia was low for both drug-eluting stents (SES: 
0.09±0.21 mm2; PES: 0.29±0.53 mm2; p=0.02) as was percent net volume obstruction 
(SES: 1.2±2.5%; PES: 3.7±5.3%; p<0.001). The pattern of restenosis was focal in 82% 
of SES and 68% of PES (p=0.12). Arterial injury assessed by BAR showed absolutely 
no correlation with the amount of neointimal hyperplasia (see figure) for either PES 
(R2=0.00001, p=0.78) or SES (R2=0.019, p=0.78).
Conclusion. The degree of arterial injury as assessed by the balloon-to-artery ratio is 
not associated with the amount of neointimal proliferation following implantation of drug-
eluting stents. 
3:00 p.m.
1026-140 Outcomes of Complex Coronary Intervention at a 
Single, High Volume Center Without On-Site Surgical 
Backup
Imran M. Bawaney, John A. Kao, Bernadette Speiser, Stephanie Murray, Mohan 
Nandalur, Adhir Ramesh Shroff, Jesse Brown VA Medical Center, Chicago, IL, University 
of Illinois at Chicago, Chicago, IL
Objective: Although percutaneous coronary intervention without on-site surgical backup 
carries a class III indication, only limited data exist that document the outcomes in a high 
volume center. We sought to report the outcomes and safety of coronary intervention in 
an unselected group of high risk patients.
Methods: From 9/2004 to 9/2006, 518 consecutive patients (661 lesions) were analyzed 
from an interventional database at the Jesse Brown VA Medical Center. Lesions were 
classified according to modified ACC/AHA grades and procedural success according to 
SCAI/ACC/AHA guidelines. Myocardial infarction post intervention was defined as CK-MB 
greater than 3x upper limit of normal or troponin-I elevation at or above the level defined 
as definite MI.
Results: Lesion types, characteristics, and outcomes are as in Table 1. Incidence of 
myocardial infarction was slightly greater than national averages as described from the 
SCAI, ACC-NCDR, and the NHLBI Registries. There were no transfers for emergent 
cardiac surgery, emergent/urgent CABG procedures. There were no procedural or in-
hospital deaths among patients undergoing PCI during this period.
Conclusions: In this high volume center, despite predominantly complex (B2/C) coronary 
lesions, percutaneous intervention was safely completed with complication rates 
comparable to national averages. No patients required emergent surgery, nonetheless a 
very clear strategy for emergent transfer to a local center is in place. 
Characteristics and Complications of Lesions
Lesion Type Number Success Myocardial Emergent
Infarction CABG/Death
A 121 (18.3%) 120 (99.2%) 3 (2.5%) 0
B1 170 (25.7%) 167 (98.2%) 5 (2.9%) 0
B2 204 (30.9%) 198 (97.1%) 11 (5.4%) 0
C 166 (25.1%) 147 (88.6%) 9 (5.4%) 0
Total Lesions 661 (100%) 632 (95.6%) 28 (4.2%) 0
Specific Lesion Subsets
CTO 47 (7.1%) 34 (72.3%) 0 (0%) 0
Bifurcation 82 (12.4%) 79 (96.3%) 5 (6.1%) 0
STEMI 19 (2.9%) 18 (94.7%) 4 (21.1%) 0
SVG/LIMA 47 (7.1%) 44 (93.6%) 2 (4.3%) 0
3:00 p.m.
1026-141 Examination of the four different stent designs 
deployed from the main vessel to side branch in the 
bifurcation using micro focus computed tomography
Yoshinobu Murasato, Naoto Miyagi, Masataka Horiuchi, New Yukuhashi Hospital, 
Yukuhashi, Japan, Chikuho Social Insurance Hospital, Nogata, Japan
Purpose: The purpose of this study is to investigate the precise condition of the stent 
deployed from the main vessel (MV) to the side branch (SB) in a true bifurcation case. 
Closed and open cell stents were also studied.
Methods: Four different stents, Bx Velocity, Multilink, Driver, and Liberte, were deployed 
from the MV to the SB using three kinds of wide-angled bifurcation vessels in a 3-
dimentional phantom model. Stent expansion and strut configuration of each stent was 
investigated using fluoroscopy and micro focus computed tomography (MFCT).
Results: In each bench test, the guide wire remained on the lateral side of the SB ostium 
and on the opposite side at both ends of the stent during the entire inflation. The stent 
was dilated to a dumbbell shape initially followed by full expansion using high pressure 
inflations. MFCT revealed the restriction of the expansion at the SB ostium (figure, arrow). 
In closed-cell stents, the strut on the outer side at the SB ostium was stretched (figure, 
dotted arrows), and the expanded stent had less conformability at the angled area of the 
vessel. In open-cell stents, the conformability was acceptable, however, the outer strut 
was so widely opened that it led to a gap at the SB ostium and the dispersed distribution 
of the struts was seen in the cross sectional view.
Conclusion: Stent deployment from the MV to the SB in the wide-angled bifurcation has 
a potential risk of gap formation and stent distortion at the SB ostium regardless of the 
stent design.
3:00 p.m.
1026-142 Prevention of Contrast-Induced Nephropahty With 
Sodium Bicarbonate and Long-Term Clinical Outcomes 
in Patients Undergoing an Emergent Coronary 
Procedure
Masaharu Masuda, Takahisa Yamada, Yuuji Okuyama, Takashi Morita, Yoshio Furukawa, 
Shouji Sanada, Yasumasa Tsukamoto, Keiji Okuda, Yuusuke Iwasaki, Taku Yasui, 
Masatake Fukunami, Osaka General Medical Center, Osaka, Japan
Background:Previous studies have shown that sodium bicarbonate (SB) reduces the 
risk of contrast-induced nephropathy. However, the effect of SB on long-term clinical 
outcomes is uncertain.
Methods:We enrolled 59 patients who had renal dysfunction (serum creatinine > 1.1mg/dl) 
and underwent an emergent coronary angiography or intervention. They were randomized 
to receive a 154mEq/L infusion of either sodium chloride (SC, n = 29) or SB (n = 30), as a 
bolus of 3ml/Kg/h for 1 hour before the administration of contrast, followed by an infusion 
of 1ml/Kg/h for 6 hours during and after the procedure. Serum creatinine levels were 
measured at baseline and 2 days and 1 year after the contrast administration.
Results:There were no significant group differences in age, sex, incidence of diabetes 
mellitus, contrast volume, left ventricular ejection fraction and baseline serum creatinine. The 
serum creatinine remained unchanged in SB group, although it significantly increased 2 days 
after the contrast administration and remained elevated for 1 year in SC group (Fig1). For a 
follow-up period of 12.7 ± 5.6 months, the incidence of death or induction of maintenance 
hemodialysis was significantly lower in SB group than that in SC group (Fig2).
Conclusions:In patients undergoing an emergent coronary procedure, hydration with SB 
preserves not only short- but also long-term renal function and reduces the risk of death 
or induction of maintenance hemodialysis. 
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3:00 p.m.
1026-143 Trends in the use of drug eluting stents
Sunil Nadar, Chetan Varma, Teri Millane, Gregory Lip, City Hospital, Birmingham, 
United Kingdom
Background: By August 2006 there was a series of highly publicised data pertaining to the 
increased risk of late stent thrombosis associated with their use. We aimed to determine 
the impact of these data on our use of DES and compare it with the guidelines issued by 
the National Institute of Clinical Excelence (NICE) in the UK.
Methods:Retrospective observational study over an 18 month period from September 2005 
to February 2007. Period 1 was defined as September 2005 to August 2006 and period 2 as 
September 2007 to February 2007 in the setting of a teaching hospital serving a population 
of 600000. We sought to find out (i) The change in DES use between the two periods, and 
(ii) the comparison of DES use with the NICE guidelines (DES use recommended if lesion 
length > 15 mm and/or diameter < 3mm), between the two periods.
Results: Data was retrieved from the British Cardiovascular interventional Society (BCIS) 
database. A total of 1446 patients with 2208 stents were studied. Baseline clinical 
measures and lesion characteristics were similar between the 2 periods. Similar numbers 
of lesions in the two periods were eligible to receive a DES as per NICE guidelines 
(49% of lesions in period 1 and 47% in period 2, p=ns). There was an overall significant 
reduction in the use of DES from period 1 compared to period 2 (66 % vs 56 %, p <0.001). 
For lesions fulfilling NICE criteria for DES there was no difference in DES use (period 1 82 
% vs period 2 80 %, p = 0.01). For lesions not fulfilling NICE criteria there was a significant 
reduction in DES use between periods (51 % vs 35 % p < 0.001). There remained a high 
level of DES use for complicated lesions (birfurcations lesions, chronic total occlusions 
(CTO), saphenous vein grafts (SVG) and instent restenois (ISR)). However on comparison 
between the two periods, there was a statistically significant reduction in the number of 
patients who received a DES for ISR (96% vs. 80%, p=0.02) and for SVG (80% vs. 57%, 
p<0.001) but not for bifurcation lesions(77% vs 72% p=ns) and CTO (66%vs. 58%, p=ns) 
between the two periods.
Conclusions:There has been a significant reduction in the overall use of DES, driven by 
reduction in non NICE criteria fulfilling use of DES. Use of DES for all complex cases 
however remains high.
3:00 p.m.
1026-144 The Effect of Drug-Eluting Stents on Intermediate 
Angiographic and Clinical Outcomes in Diabetic 
Patients: Insights From Randomized Clinical Trials 
Dharam J. Kumbhani, Anthony A. Bavry, Apur R. Kamdar, Thomas J. Helton, Deepak L. 
Bhatt, Cleveland Clinic, Cleveland, OH
Background: Implantation of drug-eluting stents has emerged as the predominant 
percutaneous revascularization strategy in diabetic patients, despite limited outcomes 
data. Accordingly, our aim was to conduct a meta-analysis to assess the benefit and 
safety profile of drug-eluting stents in diabetic patients.
Methods: We included randomized trials comparing either the paclitaxel-eluting or 
sirolimus-eluting stent with a bare-metal stent or with each other in diabetic patients 
during a follow-up of at least 6 months.
Results: A total of 16 studies were identified, which included 2,951 diabetic patients 
who were followed for 6-12 months. Target lesion revascularization was less frequently 
performed in patients who received drug-eluting stents compared with bare-metal 
stents (Risk ratio [RR]=0.35, 95% Confidence Interval [CI] 0.27-0.46; P<0.0001). 
Similar reductions were noted in the incidence of major adverse cardiovascular events 
(RR=0.42, 95% CI=0.31-0.56; P<0.0001), in-segment restenosis (RR=0.31, 95% CI 0.25-
0.40; P<0.0001), and non-Q wave myocardial infarction (RR=0.57, 95% CI 0.32-0.99; 
P=0.046). Event rates were similar for Q wave myocardial infarction (RR=0.72, 95% CI 
0.25-2.07; P=0.54), death (RR=0.64; 95% CI 0.32-1.28; P=0.20), and stent thrombosis 
(RR=0.41, 95% CI 0.13-1.27; P=0.12). Use of sirolimus-eluting stents was associated 
with less target lesion revascularization (RR=0.47, 95% CI 0.26-0.84; P=0.012) but not 
in-segment restenosis (RR=0.66, 95% CI 0.30-1.48; P=0.32), compared with paclitaxel-
eluting stents.
Conclusions: In conclusion, this is the first study to systematically demonstrate that diabetic 
patients who receive drug-eluting stents have a significantly lower incidence of target lesion 
revascularization, in-segment restenosis and myocardial infarction at 6 to 12 months, 
compared with bare-metal stents. The rates of mortality and stent thrombosis are similar.
3:00 p.m.
1026-145 Improved In-Hospital Mortality of Rheumatoid Arthritis 
Patients Undergoing Coronary Revascularization 
Procedures:Rheumatoid Arthritis Paradox
Joji J. Varghese, Sushma Koneru, Steven L. Scaife, Whitney Zahnd, Mark L. Francis, 
Southern Illinois University School of Medicine, Springfield, IL
Background: Rheumatic diseases are associated with higher rates of cardiovascular 
mortality due to accelerated atherosclerosis. We, therfore hypothesized that patients with 
rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have worse clinical 
outcomes after coronary revascularization.
Methods: Using Nationwide Inpatient Sample (2003-2004), we identified patients who 
had coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) 
and examined in-hospital mortality in RA (n=3669) and SLE (n=1099) patients compared 
to patients without RA and SLE (controls; n=457403). The odds ratios for in-hospital 
mortality after coronary revascularization in patients with RA or SLE are compared to 
controls after adjusting for confounding by age, gender, race, Charlson comorbidity index, 
hypertension, diabetes, hyperlipidemia, income, insurance, rural/urban residency, elective 
admission, and weekend admission.
Results:
Odds ratio of in-hospital mortality
Crude Odds Ratio Adjusted Odds Ratio
RA (95% CI) 0.977 (0.749, 1.273) 0.515 (0.394, 0.673)
SLE (95% CI) 1.393 (0.944, 2.053) 0.764 (0.517, 1.129)
The adjusted odds ratio for in-hospital mortality after coronary revascularization were 
significantly lower for RA but not SLE patients. There was no increased mortality for RA 
or SLE patients who underwent PCI or CABG.
Conclusions: While RA patients have higher incidence of premature atherosclerosis, they 
paradoxically have better in-hospital mortality after coronary revascularization compared 
to patients without RA and SLE. This study does not support the need to avoid coronary 
revascularization procedures in patients with RA and SLE.
3:00 p.m.
1026-146 Prevalence and Prognostic Significance of Pre-
Procedure Cardiac Troponin Elevation Among Patients 
with Stable Coronary Artery Disease Undergoing 
Percutaneous Coronary Intervention: Results from the 
EVENT Registry
Allen Jeremias, Deborah Nassif, Wen-Hua Hsieh, Michael J. Pencina, Kelly Maresh, 
Manish A. Parikh, Donald E. Cutlip, Peter B. Berger, Neal S. Kleiman, David J. Cohen, 
Stony Brook University Medical Center, Stony Brook, NY, Harvard Clinical Research 
Institute, Boston, MA
Background: While cardiac troponin elevation is associated with periprocedural 
complications during percutaneous coronary intervention (PCI) in the setting of unstable 
angina, the prevalence and significance of pre-procedure troponin elevation among pts 
with stable coronary artery disease (CAD) undergoing PCI is unknown.
Methods: Between 7/04 and 9/06, 2382 consecutive pts who underwent stent placement 
at 42 hospitals throughout the United States were enrolled in a prospective multicenter 
registry. We analyzed the frequency of an elevated baseline troponin and its relation to 
clinical outcome among the elective PCI subgroup.
Results: Among 2382 pts who underwent PCI for either stable angina or an abnormal 
stress test, 142 (6.0%) had a troponin level above the upper limit of normal prior to the 
procedure. Compared with pts who had normal baseline troponin, pts with elevated 
troponin were more likely to suffer a peri-procedural ischemic complication (13.4% vs. 
5.6%, p<0.001). Multivariate analysis adjusting for demographic, clinical and angiographic 
factors revealed baseline troponin elevation to be independently associated in-hospital 
death or MI (OR 2.069; 95% CI 1.159-3.693, p=0.01).
Conclusion: Baseline elevation of cardiac troponin is relatively common among pts with 
stable CAD undergoing PCI and is a powerful prognostic indicator of adverse in-hospital 
events. Consideration should be given to routine testing of troponin prior to performance 
of PCI in this patient population.
In-Hospital Clinical Outcomes
Normal Troponin 
(n=2240)
Troponin > ULN 
(n=142) P-Value
Death 0.0% 0.7% 0.060
Myocardial Infarction 5.6% 13.4% <0.001
Urgent Repeat Coronary Intervention 0.2% 1.4% 0.061
Stent Thrombosis 0.2% 0.0% 1.00
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1026-147 SPIRIT II Study: A Clinical Evaluation of the XIENCE 
V Everolimus Eluting Coronary Stent System in the 
Treatment of Patients With de novo Native Coronary 
Artery Lesions
Patrick W. Serruys, On behalf of the SPIRIT II Investigators, Thoraxcenter, Erasmus 
Medical Center, Rotterdam, The Netherlands
Background: SPIRIT FIRST results demonstrated continued safety of the XIENCE V 
Everolimus Eluting Coronary Stent System (CSS) in a limited number of patients. The 
purpose of the SPIRIT II study is a continuation in the assessment of the XIENCE V stent 
in the treatment of patients with a maximum of 2 de novo native coronary artery lesions 
(2.5 mm to 4.25 mm in diameter, ≤ 28 mm in length).
Methods: In the SPIRIT II study, the XIENCE V stent is compared (non-inferiority) to the 
TAXUS Paclitaxel-Eluting CSS. The primary endpoint is in-stent late loss at 180 days. 
The secondary analyses include comparisons between the two groups, for measures 
including in-segment late loss, in-stent percentage volume obstruction, and angiographic 
binary restenosis at 180 days and 2 years. Ischemia Driven Major Adverse Cardiac 
Events (MACE) are assessed through to 5 years.
Results: 300 patients were randomised in the proportion of 3:1 (XIENCE V: TAXUS) at 28 
sites in Europe, New Zealand and India.
At 180 days, the mean in-stent Late Loss (LL) was significantly lower for the XIENCE V 
group compared to the TAXUS group, 0.11±0.27mm versus 0.36±0.39mm (non-inferiority 
p<0.0001, superiority p<0.0001). In the XIENCE V group the neointimal volume was 3.8 
mm and the % volume obstruction 2.5%. In the TAXUS group the neointimal volume was 
14.4 mm and the % volume obstruction 7.4 %. Hierarchical analysis of 1-year clinical 
results showed that the total MACE rates for the procedure through the 1 year interval 
were 2.7% in the XIENCE V group and 9.2% in the TAXUS group [p=0.04 from two-
sided Fishers’s Exact]. According to ARC, one patient in the TAXUS group presented a 
sub-acute stent thrombosis and a late stent thrombosis (same patient) through 1 year 
post-procedure and no cases of stent thrombosis were reported in the patients in the 
XIENCE V group.
Conclusions: Based on the protocol design and statistics, XIENCE V showed non-
inferiority (primary endpoint) and superiority to TAXUS in terms of late loss. Additionally, 
at 1 year a low MACE rate and no stent thrombosis were observed. The two-year clinical, 
angiographic and IVUS results will be presented at ACC.
CAUTION: XIENCE V is an investigational device. Limited by Federal (U.S.) to 
investigational use only.
3:00 p.m.
1026-148 Patient Adherence to Clopidogrel Prescribing 
Instruction Predicts Stent Related Myocardial Infarction
Leonardo Tamariz, Ana Palacio, Eduardo de Marchena, Pablo Echeverria, Hermes 
Florez, Donald Parris, William O’Neill, University of Miami, Miami, FL
Background: The lack of adherence to clopidogrel prescribing instructions could explain 
the incidence of myocardial infarction (MI) after stent placement. We compared MI rates 
for clopidogrel users after a stent.
Methods: We performed a retrospective analysis in a large managed care plan between 
January 1, 2003 to June 20, 2005. We identified subjects who received coronary stents, 
using CPT codes: DES (CPT 36.07) and BMS (CPT 36.06). We identified clopidogrel 
treatment using the GPI code 85158020 and calculated medication possession ratios. 
Inappropriate clopidogrel use was defined as having a medication possession ratio lower 
than 80%. MI was defined by the ICD-9 code for acute myocardial infarction (410.xx) with 
an associated hospitalization.
Results: We identified 5,838 subjects prescribed clopidogrel after a stent implantation. 
Twenty-two percent used clopidogrel innapropriately. These subjects were younger 
(62.7±11.9 vs. 63.5±11.5, years), and more likely to be female (37 vs. 32,%). After 
20.3±7.2 months of follow-up 8% of the inappropriate clopidogel users had a MI 
compared to 6% appropriate clopidogel users (p<0.01) (figure). The RH of MI for 
inappropriate clopidogrel use was 1.4 (95% C.I.: 1.1-1.7) when compared to appropriate 
use of clopidogrel after adjustment for type of stent, demographics, MI at presentation, 
heart failure, cardiovascular risk factors.
Conclusions: Improper adherence to clopidogrel prescribing instructions increases the 
risk of MI in patients with stents. 
3:00 p.m.
1026-149 Percutaneous Coronary Interventions for Chronic Total 
Occlusion: Novel Three-Dimensional Imaging and 
Quantitative Analysis
Danny Dvir, Ran Kornowski, Abid Assali, Rabin Medical Center, Petah-Tikva, Israel
Background: Chronic total occlusion (CTO) in the coronary arteries is one of the most 
technically challenging lesion subsets. Our objectives were to analyze for the first time in 
real-time CTO lesions in three-dimensions (3D) before and after stenting and to examine 
the yield of this method in planning interventional procedures.
Methods: The novel CardiOp-B validated system for 3D reconstruction was used to 
evaluate 302 angiographic images from 58 consecutive patients (86% men, age 62±11 
years) undergoing interventional treatment for CTO (total 61 lesions).
Results: The success rate of 3D reconstruction was 83%, and when successful, the 3D 
reconstructions significantly improved lesion analysis, especially at the stump area (figure). 
Importantly, in 92% of the 3D reconstructions, the artery path in the lesion area could be 
delineated. The 3D mean stenosis area was significantly smaller than the 2D stenosis area 
(94±5.1% versus 99±0.3%, p<0.001), and the 3D mean lesion length was significantly 
shorter (15.3±7.4mm versus 20.9±8mm, p<0.001). Using Bland-Altman method, the 
variability of 3D measurements was significantly lower (12.3% versus. 17.6%, p=0.007).
Conclusions: In most cases, 3D reconstruction of CTO can clearly image the stump 
area, delineate the lesion path, and provide enough information to precisely calculate the 
severity of stenosis and lesion length. 3D reconstructions may serve as a useful tool for 
planning interventional procedures for CTO and improving their success rate. 
3:00 p.m.
1026-150 Preprocedural Levels of C-Reactive Protein and Stent 
Thrombosis After Drug-Eluting Implantation
Duk Woo Park, Seong-Wook Park, Jong-Pil Park, Jae Hyoung Park, Jeong-Woo Lee, 
Won-Jang Kim, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Myeong-Ki Hong, 
Jae-Joong Kim, Seung-Jung Park, asan medical center, seoul, South Korea
Background:The safety concerns regarding stent thrombosis have been raised with the 
use of drug-eluting stents (DES). However, the accurate risk prediction and stratification 
for these events still remain challenging.
Methods:We examined the predictive value of preprocedural levels of C-reactive protein 
(CRP) on the long-term clinical outcomes in 2,632 patients with DES implantation. The 
end point of the study was stent thrombosis and the composite of death or MI
Results:During the 3 year follow-up, patients (n=923) with high serum levels of CRP 
(≥3 mg/L) had a significantly higher incidence of stent thrombosis, as compared to 
those (n=1,709) with normal CRP levels (3.1% vs. 1.7%, HR 1.90; 95% CI, 1.08-3.35; 
P=0.027). Also, the rate of death or MI was significantly higher in patients with elevated 
levels of CRP (7.0% vs. 3.3%, HR 2.32; 95% CI, 1.57-3.43; P<0.001). In multivariate 
Cox-regression analysis, elevated CRP levels (HR 1.85; 95% CI, 1.06-3.42; P=0.032), 
LVEF(HR 0.96; 95% CI, 0.93-0.99; P=0.018), and the number of stents per patients (HR 
1.01; 95% CI, 1.004-1.02; P=0.003) were the independent predictors of stent thrombosis. 
Elevated CRP levels (HR 1.78; 95% CI, 1.14-2.77; P=0.011), LVEF(HR 0.97; 95% CI, 
0.95-0.99; P=0.004), and older age (HR 1.05; 95% CI, 1.02-1.07; P<0.001) were the 
independent predictors of the composite of death or MI.
Conclusions: Elevated preprocedural levels of CRP were significantly associated with the 
development of stent thrombosis and death/MI after DES implantation. 
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1026-151 The Treatment of Bare-Metal In-Stent Restenosis With 
Drug-Eluting Stents in an Unselected Population, A 
Single-Center Study
Fazil M. Alidjan, Karel T. Koch, José P. Henriques, René J. Van der Schaaf, Jan Baan, 
Marije Vis, Jan G.P. Tijssen, Jan J. Piek, Robbert J. De Winter, Academic Medical 
Center-University of Amsterdam, Amsterdam, The Netherlands
Background: Randomised trials have shown that in patients with bare-metal stent in-stent 
restenosis (BMS ISR), implantation of drug-eluting stents (DES) results in better event-
free survival compared to balloon angioplasty or intravascular brachytherapy. The clinical 
outcome following DES implantation for the treatment of BMS ISR in an unselected 
population remains largely unknown. We report the clinical outcome of a consecutive 
single-center cohort undergoing DES implantation for the treatment of BMS ISR.
Methods: Between May 2002 and December 2005, a total of 203 patients received a 
DES for the treatment of BMS ISR lesions (n= 220) at our institution. Fourteen patients 
received sirolimus-eluting stents (SES) and one hundred and eighty-nine patients 
received paclitaxel-eluting stents (PES) for at least one BMS ISR lesion. Clinical follow-up 
was prospectively collected and completed for all patients at 12-months.
Results: Of all patients, 172 (85%) had stable angina and 39 (20%) were diabetic. The left 
anterior descending coronary (52%) was the most common target vessel and the mean lesion 
length was 21.09 ± 16 mm. The majority of BMS ISR treated lesions had a diffuse pattern of 
ISR (87%). At one year follow-up, 4 patients(2.0%) died from cardiovascular causes, 8 patients 
(3.9%) suffered a myocardial infarction. Target lesion revascularization was performed in 4.4% 
(3.4% PCI and 1.0% CABG) of patients. The 12-month combined MACE rate (cardiac death, 
myocardial infarction or target lesion revascularisation) was 9.4%.
Conclusions: Our study shows that the incidence of MACE after DES implantation for 
BMS ISR at 12-months is low. PCI with BMS that includes the option to treat BMS ISR 
with DES may be an attractive strategy in many patients.
3:00 p.m.
1026-152 Effect, Safety and Feasibility of Intracoronary 
Administration of Anisodamine on Slow Reflow 
Phenomenon Following PCI in Patients With AMI
Xianghua Fu, Xinshun Gu, Weize Fan, Yunfa Jiang, Yongyun Wei, Ling Xue, Guozhen 
Hao, Guozhen Hao, 2nd Hospital of Hebei Medical University, Shijiazhuang, People’s 
Republic of China
Background: Anisodamine is an inhibitor of M-cholinergic receptor with strong antispastic 
effectiveness, which was refined from a traditional Chinese herb Anisodus Tonguticus 
produced in ST. Tangula Mountain, Tibet. Since 1970s, many basic and clinic studies 
have proved that Anisodamine has the effects of releasing microvessel spasm, improving 
and dredging the microcirculation. It maybe beneficial for the improvement of slow-reflow 
phenomenon (SRP) during PCI for AMI. So we firstly investigated the effect, safety and 
feasibility with intracoronary administration of Anisodamine on SRP following PCI in 
patients with AMI.
Methods:Twenty one patients with SRP from 148 ST segment elevation AMI patients 
accepted primary PCI were enrolled into this study. As soon as SRP was identified 
following PCI, 200μg of nitroglysin was “bolus” injected into the repatent IRA as control 
agent. Ten minutes later, 1000μg of Anisodamine was injected into IRA at the rate of 
200μg/s, then 1, 3 and 10 min after the injection the corrected TIMI frame count (cTFC) 
and TIMI myocardial perfusion grade (TMPG) as well invasive hemodynamic parameters 
were measured and analyzed, quantitatively. The changes of heart rate and rhythm were 
recorded. Results: cTFC was decreased by 58.3%, 56.2% and 54.6% at 1st, 3rd, 10thmin 
and TMPG increased from (1.13±0.21) grade to (2.03±0.32, 2.65±0.45, 2.51±0.57) 
grades (P< 0.001), with slight dilation of IRA (from 3.2±0.4 to 3.4±o.5, P>0.05), at 1st, 3rd 
or 10thmin after intracoronary administration of Anisodamine but no significant change 
was found at 1st,3rd or 10th min after intracoronary administration of nitroglysin. The 
systolic, diastolic and mean pressure of intracoronary were increased by 3.47%, 3.73%, 
4.55% (115 to 119mmHg, 75 to 77.8mmHg, 88 to 92mmHg), respectively, with the rising 
of heart rate (from 68 to 84, P<0.05). PR interval, QT interval and QRS duration were not 
found significant change (P >0.05), and no any severe arrhythmia happened.
Conclusions: Intracoronary administration of 1000μg Anisodamine proved to be a safety 
and effectiveness for attenuating SRP following primary PCI in AMI patients, especially, it 
is suitable for SRP patients with bradycardia and hypotension.
3:00 p.m.
1026-153 The Place of Surgical Standby for Coronary Angioplasty
Erwin Schroeder, University Hospital of Mont-Godinne, Yvoir, Belgium
Background : Surgical standby is recommended for emergency bypass surgery and 
surgical pericardial drainage.
Aim : To assess the prevalence of procedural failure and cardiac tamponnade, both 
potentially life-treatening, and the need for cardiac surgery in a consecutive series.
Methods : All consecutive procedures performed between 1.1.1996 and 31.12.2006 
in our institution were prospectively entered in a well controlled database. Inhospital 
outcome was available in all cases including subsequent referrals. 8590 procedures were 
performed in 6682 pts with the following clinical data : mean age was 64 ± 11 yrs; female 
gender : 26 %; diabetes : 17 %; peripheral vascular disease : 12 %; cerebrovascular 
disease : 9 %; previous PTCA : 32 %; previous CABG : 10 %; myocardial infarction < 24 
H : 7 %; cardiogenic shock : 1.4 %; NHYA III : 6 %; NHYA IV : 2 %; multivessel disease 
: 58 %.
Multivessel PTCA was performed in 12 %; anti GP2B3A were used in 15 %.
Results : Angiographic failure occurred in 350 cases (4.07 %). Emergency bypass surgery 
was needed in 38 cases (0.44 %). Cardiac tamponnade occurred in 13 cases (0.14 %), 
needing surgical pericardial drainage in 8. Emergency cardiac surgery was needed in 49 
cases (0.57 %) as 2 patients needed both interventions. The overall inhospital mortality 
was 1.57 %.
In case of angiographic failure, the overall mortality was 8 %.
The inhospital mortality in case of bail-out CABG was 13.2 %. By multivariate analysis, 
the inhospital mortality after failed angioplasty was related to the hemodynamic conditions 
before the procedure (presence of cardiogenic shock, NHYA III/IV) and peripheral 
vascular disease.
Conclusion : In this large single center registry.
Emergency cardiac surgery was needed in 0.57 %, predominantly for bail-out bypass 
surgery (0.44 %).
These contemporary data schould be kept in mind for the ongoing discussion on 
restructruring the offer of PTCA facilities, possibly without inside surgical standby.
3:00 p.m.
1026-154 Chronic Renal Failure Is Associated With Angiographic 
Evidence of Peripheral Vascular Disease and 
Independently Associated With Retroperitoneal 
Hemorrhage
Klaus A. Tiroch, Suwada A. Hinds, Christopher Liu, Michael E. Matheny, Frederic S. 
Resnic, Brigham and Women’s Hospital, Boston, MA
Background: Previous studies have identified female gender, body surface area and high 
puncture as independent risk factors for retroperitoneal hemorrhage (RPH). Chronic renal 
failure (CRF), defined as creatinine >2.0, and diabetes mellitus (DM) have been associated 
with both, peripheral vascular disease (PVD) and vascular access complications. We 
sought to investigate a putative association of CRF and DM with RPH and PVD based on 
review of the femoral angiography for a large cohort of PCI patients.
Methods: 3537 consecutive patients underwent PCI at Brigham and Women’s Hospital 
between 01/2005-04/2007. All 3311 patients with available femoral angiography had 
a hand caliper based quantitative vascular analysis (QVA) with assessment of vessel 
diameters and presence of PVD in major iliac and femoral branches. Logistic regression 
was performed to assess the relationship of DM and PVD with RPH during hospitalization. 
A multivariable model analysis was performed using a backwards selection algorithm.
Results: The incidence of RPH was 0.48% (12/3537). DM was not associated with 
angiographic presence of PVD (P=0.19) or with RPH (P=0.64). CRF was associated with 
PVD (P<0.001). After multivariate analysis, covariates that significantly influence RPH 
were CRF, GP IIbIIIa inhibitors, and high stick location (see Table).
Conclusions: Chronic renal failure, in contrast to DM, is associated with angiographic 
evidence of PVD, and is an independent predictor for the development of retroperitoneal 
hemorrhage.
Multivariate analysis for RPH risk factors
Covariate RPH odds ratio 95% CI
Chronic renal failure 7.57 2.51-22.89
GP IIbIIIa inhibitors 6.11 1.94-19.18
High stick location 3.67 1.30-10.38
3:00 p.m.
1026-155 Point-of-Care Measurement of Clopidogrel 
Responsiveness Predicts Clinical Outcome in Patients 
Undergoing Percutaneous Coronary Intervention: 
Results of the ARMYDA-REACT Study
Giuseppe Patti, Vincenzo Pasceri, Fabio Mangiacapra, Laura Gatto, Vincenzo Vizzi, 
Germano Di Sciascio, Department of Cardiovascular Sciences, Campus Bio-Medico 
University, Rome, Italy
Background. Individual variability of clopidogrel response may influence results of 
percutaneous coronary intervention (PCI). Aim of this study was to prospectively evaluate 
the correlation of point-of-care measurement of platelet inhibition with clinical outcome in 
patients undergoing PCI.
Methods. A total of 160 patients on therapy with clopidogel and receiving coronary 
stenting were enrolled. Degree of platelet reactivity was measured by a rapid, bedside 
test (VerifyNow P2Y12 assay, Accumetrics Inc.). Primary endpoint was 30-day occurrence 
of major adverse cardiac events (MACE) according to quartiles distribution of P2Y12 
reaction units (PRU).
Results. Incidence of the primary end point was significantly higher in patients with pre-
procedural PRU levels in the 4th quartile vs those in the lowest quartile (20% vs 3%; 
P=0.034), and it was entirely due to occurrence of peri-procedural myocardial infarction 
(MI). Mean PRU absolute values were more elevated in patients developing peri-
procedural MI (258±53 vs 219±69 in patients without infarction; P=0.030). Multivariable 
analysis revealed that PRU levels in the 4th quartile before intervention were associated 
with a 6-fold increased risk of MACE (OR 6.1, 95% CI 1.1-18.3; P=0.033).
Conclusions. The ARMYDA-REACT study indicates that point-of-care detection of 
elevated pre-PCI platelet reactivity in patients receiving clopidogrel is associated with an 
increased risk of peri-procedural MI. Use of a rapid, bedside assay for monitoring residual 
platelet reactivity after clopidogrel administration may help identifying patients at higher 
risk of events, in whom more aggressive therapeutic strategies may be addressed.
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1026-156 Drug Eluting Stent Reduction in Target Vessel 
Revascularization Extends Beyond On-Label Usage
David J. Malenka, Mirle Kellet, Michael Hearne, John Robb, Thomas Ryan, Theodore 
Silver, Harold Dauerman, Craig Thompson, John O’Meara, Craig Langner, Northern 
New England Cardiovascular Disease Study Group, Lebanon, NH
Background: Pooled trial data indicate that compared to BMS, the on-label use of DES reduces 
the 1 year rate of target lesion revascularization from 16.6% to 6.2%. The extent to which this 
benefit is realized in general practice, with substantial off-label use of DES, is unknown.
Methods: From our Northern New England Registry of all PCI and CABG procedures, with 
vital status, we identified 1VD patients undergoing a first PCI in 2001-2002 (n=6,093) when 
only BMS were available (BMS-era) and a similar cohort from 2004-2005 (n=5651) when DES 
were available (DES-era). We compared 1-year survival and target vessel revascularization 
(TVR) using Kaplan-Meier analysis and Cox regression to adjust for casemix.
Results: More patients were stented in the DES-era (81.6% DES; 14.0% BMS) than in 
the BMS-era (92.4% BMS). The DES-era patients were more likely to undergo emergent 
procedures (29.1% v 23.7%), to be <7 days of an MI (42.4% v 38.8%), to have LAD 
disease (44.4 % v 41.8%), and to have complex lesions (ACC B2/C 51.5% v 40.8%). 
Survival was comparable (Figure). TVR decreased from 9.8% BMS-era to 4.3% DES-era, 
a significant reduction (adjusted HR 0.42, 95%CI 0.36-0.49). This was true for diabetics 
(HR 0.32) and those being treated for an MI (HR 0.54).
Conclusions: The frequent unrestricted use of DES was associated with a significantly 
decreased risk of TVR in 1VD patients undergoing their first revascularization. The magnitude 
of the benefit was smaller than reported in the randomized trials but clinically relevant.
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1033-127 Contrast-Induced Nephropathy (CIN) in Patients 
at the Highest Risk: Data From the CARE (Cardiac 
Angiography in REnally Impaired Patients) Study
Jonathan S. Reiner, Cezar S. Staniloae, Samin K. Sharma, Richard E. Katholi, Abel E. 
Moreyra, Richard J. Solomon, George Washington University, Washington, DC
Background: Contrast-induced nephropathy (CIN) is characterized by a sudden, rapid 
deterioration in renal function following contrast administration. Prior studies have 
identified several risk factors for CIN. We compared the incidence of CIN after iodixanol 
320 or iopamidol-370 in high-risk patients undergoing angiography or percutaneous 
coronary intervention (PCI) in the CARE trial.
Methods: 414 patients with chronic kidney disease (eGFR 20-59 mL/min) undergoing 
angiography or PCI were randomized to iodixanol (n=210) or iopamidol (n=204). Serum 
creatinine (SCr) was measured at baseline and 2-5 days post angiography. We report 
data in 4 cohorts at highest risk for development of CIN; diabetics (n=170), patients 
undergoing PCI (n=163), those with baseline eGFR ≤40 mL/min/1.73 m2 (n=114), and 
those receiving >140 mL of contrast media (n=154). Differences in CIN incidence (SCr 
increases ≥0.5 mg/dL) and mean postdose SCr changes were evaluated.
Results: Mean baseline SCr (mg/dL) levels were similar in the iopamidol and iodixanol 
groups (diabetics=1.65 and 1.68; PCI=1.57 and 1.57; low eGFR=1.96 and 1.97; high 
contrast dose=1.55 and 1.50; p>0.05 for all). Postdose SCr increases ≥0.5 mg/dL were 
not significantly different in the iopamidol vs iodixanol groups although the trend favored 
iopamidol in all high risk subsets (diabetics: iodixanol 13.0% [12/92] vs iopamidol 5.1% 
[4/78], p≤0.11; PCI patients: iodixanol 7.3% [6/57] vs iopamidol 2.5% [2/57], p≤0.28; low 
eGFR: iodixanol 12.3% [7/57] vs iopamidol 8.8% [5/57], p≤0.76; and high CM dose: iodixanol 
10.6% [9/92] vs iopamidol 4.3% [3/78], p≤0.23). Mean postdose SCr increases were 
significantly higher after iodixanol in diabetics (iodixanol=0.16±0.3 vs iopamidol=0.07±0.3 
mg/dL, p≤0.03) and patients undergoing PCI (iodixanol=0.13±0.2 vs iopamidol=0.06±0.2 
mg/dL, p≤0.05) and trended towards higher values in the other high risk groups.
Conclusions: CIN occurred with similar frequency after iodixanol 320 or iopamidol-370 
in high-risk patients undergoing angiography. In diabetics and patients undergoing PCI, 
postdose SCr increases were significantly higher after iodixanol.
11:00 a.m.
1033-128 Predictive Value of Preinterventional C-reactive Protein 
Levels on Angiographic Restenosis and Cardiac 
Events After Sirolimus-Eluting Stent Implantation
KEIJI INOUE, Makoto Kitamura, Hiroshi Fujita, Tetsuya Tanaka, Akiko Matsuo, Yoshiharu 
Nishibori, Shinichiro Yamaguchi, Naohiko Nakanishi, Yasutsugu Shiono, Kiyonari 
Matsuo, Kyoto Second Red Cross Hospital, Kyoto, Japan
Background:After percutaneous coronary intervention (PCI), inflammatory mechanisms 
play a crucial role in the restenosis. However, possible role of inflammation in restenosis 
after drug-eluting stents has not been established. We assessed the association of 
preprocedural C-reactive protein (CRP) levels with angiographic restenosis and adverse 
clinical events after Sirolimus-eluting stent (SES) implantation.
Methods:We studied 318 consecutive patients (mean age 68.9±9.4yrs) who underwent 
successful SES implantation. Blood samples were taken before PCI to evaluate CRP and 
patients were grouped into quartile according to baseline CRP values for data analysis. 
The end point was a major event defined as cardiac death or Q-wave myocardial infarction 
and angiographic restenosis requiring repeat revascularization at 8-month follow-up.
Results:Baseline clinical and angiographic characteristics were similar between the 
quartile groups. At 1-year follow-up, primary end point occurred in 1 (1.3%) patient of the 
third quartile and in 5 (6.5%) patients of the highest quartile whereas no major cardiac 
event occurred in the lowest quartile and second quartile. Restenosis were observed in 
38 patients (12.3%) of total subjects at 8-month follow-up. Binary restenosis rates were 
remarkably lower in the first quartile group compared with the second, third and fourth 
quartile groups (3.8% in quartile I vs 12.2% in quartile II vs 16.7% in quartile III vs 16.9% 
in quartile IV, respectively, p = 0.03). In-stent late loss were lower in the first quartile 
among 4 groups (-0.07±0.78 vs 0.25±0.94 vs 0.27±1.10 vs 0.29±1.09, respectively, p 
= 0.04). In multivariate analysis, the higher quartile of CRP levels was an independent 
predictor of a subsequent restenosis (p=0.013).
Conclusions:Preprocedural CRP levels are clearly associated with cardiac events and 
angiographic restenosis after SES implantation. Baseline CRP levels may be useful to 
predict clinical risk in patients treated with SES.
11:00 a.m.
1033-129 The Impact of Diabetes Mellitus on Early and Late 
Mortality and Major Adverse Cardiac Events After 
Percutaneous Coronary Intervention With Drug-Eluting 
Stents
Michelle J. Butler, David J. Clark, Andrew Ajani, Greg Szto, Nick Andrianopoulos, Angela 
Brennan, Gishel New, Alexander Black, Anthony Dart, Stephen J. Duffy, Alfred Hospital, 
Melbourne, Australia, Monash University, Department of Epidemiology and Preventive 
Medicine, Melbourne, Australia
Background: Diabetics generally have worse outcomes following percutaneous coronary 
intervention (PCI). The introduction of drug-eluting stents (DES) has reduced the rate of 
restenosis, but the effect on major adverse cardiac events (MACE) is unclear.
Methods: We analysed 5,068 patients who underwent PCI from the Melbourne 
Interventional Group (MIG) registry. Diabetics comprised 23% of the patient group.
Results: Diabetics were more likely to be older and have hypertension, dyslipidaemia, 
previous MI, and be treated with a small (<2.5mm) stent (all p<0.0001). Non-diabetics 
were more likely to be current smokers and present with a ST-elevation MI (both 
p<0.0001). Diabetics had greater DES use (68.1% vs. 47.1%, p<0.0001). Thirty-day 
follow-up demonstrated that mortality and MACE were significantly higher in diabetics 
(3.2% vs. 1.6%, p<0.001; and 7.4% vs. 5.9%, p<0.05, respectively). Twelve-month follow-
up demonstrated that DES use reduced target-lesion revascularization in diabetics 
(4.3% vs. 10.8% for bare-metal stenting, p=0.01), and that target-lesion revascularization 
was similar in diabetics and non-diabetics (6.5% vs. 5.3%, p=0.29). Despite this, there 
was excess mortality (6.6% vs. 3.6%, p=0.002) and MACE (18.1% vs. 13.8%, p=0.01) 
amongst diabetics at 12 months. Logistic regression revealed that the strongest predictors 
of MACE at 12 month were the presence of diabetes (OR 1.5; 95% CI 1.2-2.0) and the 
absence of a DES (OR 1.6; 1.2-2.1).
Conclusions: Despite the frequent utilization of DES in diabetic patients undergoing PCI, 
and the attendant reduction in the need for repeat revascularization, diabetics continue to 
have excess mortality and MACE at 12 months.
11:00 a.m.
1033-130 The Influence of Gender on Acute and Three Year 
Clinical Outcome after Sirolimus-eluting Stent in the 
Arterial Revascularization Therapy Study (ARTS) II: 
Comparison with ARTS I Patients
Vassilis Voudris, Joost Daemen, Marie-Claude Morice, Sophia Vaina, Georg Szurawitzki, 
Alessandro Fontanelli, Knut Endresen, Kristel Wittebols, Hans-Peter Stoll, Dennis V. 
Cokkinos, Patrick W Serruys, Cordis Clinical Research Europe, Waterloo, Belgium
Background: A higher rate of in-hospital complications has been reported in women (W) 
undergoing coronary revascularization. To determine whether W have an unfavorable 
long-term outcome after percutaneous (PCI) or surgical (CABG) coronary interventions 
compared to men (M), we assessed patients (pts) in the Arterial Revascularization 
Therapies Studies (ARTS) I and II.
Methods: ARTSI was a randomized multicenter trial of 1205 patients with multivessel 
disease (MVD), comparing surgery (ARTSI-CABG, n=605, W=24%) with bare metal 
stenting (ARTSI-PCI, n=600, W=23%) . ARTSII is a multicenter (n=45), non-randomized, 
open-label trial of 607 patients (W=23%) with MVD treated with sirolimus-eluting stent 
(SES). Primary aim was to compare the effectiveness of SES with ARTSI-CABG 
measured as freedom from major adverse cardiac and cerebrovascular events (MACCE) 
at 1 year. The clinical presentation, in-hospital complications, and freedom from MACCE 
at 1 and 3 year were assessed.
Results: Compared to both arms of ARTS I, W in ARTS II had a higher prevalence of 
diabetes (p<0.005), hypertension (p<0.0001) and 3-vessel disease (p<0.0001); the mean 
number of treated lesions was 3.4 in ARTS II vs. 2.7 in ARTS I-PCI and 2.7 in ARTS I-
CABG (p<0.0001). M enrolled in ARTS II were older (p<0.0001), with a higher incidence 
of diabetes (p<0.005), hypertension (p<0.0001), hypercholesterolemia (p<0.0001), and 
3-vessel disease (p<0.0001) compared to ARTS I; the mean number of treated lesions 
was 3.6 in ARTS II vs. 2.8 in ARTS I-PCI and 2.8 in ARTS I-CABG (p<0.0001). At 30 days 
a higher rate of MACCE was observed in ARTS I-PCI, compared to ARTS II (p<0.005 
for W and p<0.001 for M). One year MACCE-free survival was 91% in ARTS II vs. 71% 
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in ARTS I-PCI (p<0.001) and 86% in ARTS I-CABG (p:ns) in W and 89% in ARTS II vs. 
74% in ARTS I-PCI (p<0.001) and 89% in ARTS I-CABG (p:ns). Three-year results will 
be presented at ACC 2008.
Conclusions: The clinical outcome in W and M with MVD undergoing PCI was better in 
ARTS II, compared to ARTS I pts, despite a higher risk profile and more lesions treated in 
ARTS II. This favorable outcome may be attributed to the use of SES in ARTS II. However 
there were no differences between ARTS II and ARTS I-CABG regardless the gender.
11:00 a.m.
1033-131 Could We Predict Successful Percutaneous Coronary 
Intervention (PCI) in Chronic Total Occlusion (CTO) by 
64-Multi-detector Computed Tomography (MDCT) with 
Regional Calcium Geomorphology
Chul Min Ahn, Young Jin Kim, Jung Sun Kim, Donghoon Choi, Yangsoo Jang, Namsik 
Chung, Byoung Wook Choi, Won Heum Shim, Seung Yun Cho, Yonsei University 
College of Medicine, Seoul, South Korea
Background: Prediction of successful PCI in CTO depends on mainly guidewire 
penetration which is closely related to geometry of occluded segment. Recently, MDCT 
of coronary artery could evaluate location and amount of regional calcium (CA), as well 
as percentage area of calcium to external elastic membrane. We intended to evaluate 
regional CA related parameters which could determine procedural outcome of PCI in CTO 
lesions. Methods: A total of 64 patients (aged 55.4±11.2 years, 55 males, 72 lesions) who 
have CTO at least one major coronary artery in conventional angiography were studied. 
All the patients underwent 64 MDCT (Somatom Sensation 64, Siemens, Germany) prior 
to PCI. The lesions were divided into two groups: Group I (PCI-success, 55 lesions) was 
defined as successful PCI without any complication, whereas group II (PCI-failure, 17 
lesions) was defined as guidewire passage failure or presence of complication during 
PCI. Three regional CA derived parameters in 64-MDCT - regional CA volume, regional 
CA equivalent mass, regional CA score - and off-line measurement of percentage CA 
area compared to EEM area were calculated by using dedicated software.
Results: See the following table 
Group I Group II P-value
Lesion length (mm) 22.0±18.0 37.4±27.4 0.021*
Total CA score (Agatston score) 198.8±355.9 299.±375.1 0.333
Regional CA volume 7.2±15.2 52.8±58.3 <0.001*
Regional CA score 9.6±20.2 72.7±78.4 <0.001*
Regional CA equivalent mass 1.8±3.7 12.5±12.9 <0.001*
% of CA. area/EEM area 30.4±17.1 53.9±20.3 0.009*
Conclusion: Regional CA geomorphology by MDCT can be useful to predict procedural 
outcome in PCI of CTO. By accurate identification of the length of the CTO segment 
and pertinent evaluation of CA distribution, MDCT could be adopted as pivotal tool for 
prediction of successful outcome in PCI of CTO.
11:00 a.m.
1033-132 Coronary Flow Velocity Pattern Immediately After 
Percutaneous Coronary Intervention Predicts Cardiac 
Rupture in Patients With Acute Myocardial Infarction
Takeshi Kitai, Koichi Tamita, Yoshimori An, Kite Kim, Takafumi Yamane, Tomoyuki 
Oda, Natsuhiko Ehara, Minako Katayama, Makoto Kinoshita, Syuichiro Kaji, Atsushi 
Yamamuro, Tomoko Tani, Kazuaki Tanabe, Shigefumi Morioka, Yasuki Kihara, Kobe 
General Hospital, Kobe, Japan
Background: The no reflow phenomenon after coronary reflow aggravates myocardial 
damage. According to the Doppler guidewire studies, even in the presence of TIMI III 
reperfusion, the coronary flow velocity (CFV) pattern with early systolic retrograde flow and 
short deceleration time of diastolic flow (DDT) indicates severe damage in microvascular 
beds. However, the relationship between the CFV pattern and cardiac rupture has not 
been discussed. The aim of this study was to examine whether this CFV pattern may 
predict the risk of cardiac rupture following acute myocardial infarction (AMI).
Methods: The study population consisted of 215 consecutive patients with the first 
anterior AMI successfully treated with emergent percutaneous coronary intervention. 
We examined the CFV pattern immediately after coronary intervention using the Doppler 
guidewire. In accordance to our previous findings, we defined the severe microvascular 
injury as a diastolic deceleration time <600ms and the presence of systolic flow reversal. 
Patients were divided into two groups: those subsequently complicated by cardiac rupture 
(n=12; goup 1) and those without cardiac rupture (n=203; group 2).
Results: Coronary flow velocity variables showed significantly lower systolic peak velocity 
(-31±23 vs 8±20 cm/s; p=0.0001) and longer DDT (312±157 vs 722±196 ms; p=0.0001) 
in group 1 compared to those in group 2. The severe microvascular injury had a sensitivity 
of 100% and a specificity of 16.2% for the cardiac rupture following AMI.
Conclusion: These data suggests that the CFV pattern immediately after PCI is an 
accurate predictor of the risk of cardiac rupture in patients with anterior AMI. Hence, 
the Doppler flow measurement of reperfused coronary enables us the risk stratification 
among the patients with AMI.
11:00 a.m.
1033-133 Predictors and Outcomes of Optimal Medically-Treated 
COURAGE Patients Who Crossed Over to Coronary 
Revascularization
John A. Spertus, Mihaela Aslan, Paul Kolm, David Maron, William S. Weintraub, Daniel 
Berman, Robert O’Rourke, Koon Teo, Leslee Shaw, Steven Sedlis, Merril Knudtson, 
William J. Kostuk, Andrew Frutkin, William E. Boden, G.B. John Mancini, Mid America 
Heart Institute/UMKC, Kansas City, MO
Background: While the COURAGE trial showed no incremental benefit of percutaneous 
coronary intervention (PCI) plus optimal medical therapy (OMT) with OMT alone, one-third 
of OMT patients (pts) required revascularization. Identifying pts more likely to fail OMT 
may facilitate better clinical management. We examined clinical characteristics, known at 
the time of randomization, associated with crossing over (XO) to revascularization in OMT 
pts. We then compared clinical events and 1-year health status outcomes of XO pts with 
those treated by OMT alone using the Seattle Angina Questionnaire (SAQ).
Methods: Over 45 baseline demographic, clinical and angiographic characteristics 
were used to compare OMT pts who did and did not require XO. Statistically significant 
candidates were eligible for inclusion in a multivariable logistic regression model. Fully 
adjusted clinical and 1-year health status outcomes were compared between XO and 
OMT-alone pts.
Results: As compared with the 789 pts treated with OMT alone, the 349 XO pts were 
more likely to have hypercholesterolemia, multi-vessel CAD, to be taking >2 anti-
anginal meds and to have worse scores on all 5 domains of the SAQ (p<0.05 for all). 
In multivariable models adjusting for health system, independent predictors of XO were 
hypercholesterolemia (1.4; 1.0-2.0), 3-vessel CAD (1.6; 1.1-2.3) and baseline SAQ angina 
frequency score (OR=0.86/10-point increase (better) score; 95% CI=0.81-0.91). Fully 
adjusted outcomes models suggested no difference in mortality, but higher rates of non-
fatal MI (6.7; 4.4-10.3 with 80% occurring after XO) and worse 1-year SAQ Angina (81.3 
vs. 85.2), Physical Limitation (71.3 vs. 73.8) and Quality of Life (71.7 vs. 73.8) scores 
(p<0.0001 for all) in XO pts vs. those treated with OMT alone.
Conclusions: Hypercholesterolemia, 3-vessel disease and a greater burden of angina 
were all associated with a need for XO in COURAGE OMT pts. Since these pts had worse 
clinical outcomes than those managed with OMT alone, identifying pts likely to need 
upfront revascularization may minimize the period during which such pts have worse 
health status, but the impact on recurrent events is unknown.
11:00 a.m.
1033-134 Inhibition of Plaque Neovascularization and Intimal 
Hyperplasia by Specific Targeting Vascular Endothelial 
Growth Factor with Bevacizumab-eluting Stent: An 
Experimental Study
Konstantinos Toutouzas, IX, Andreas Synetos, Elli Stefanadi, Jonh Karabelas, Andreas 
Lazaris, Eleftherios Tsiamis, Efstratios Patsouris, Nicholas Kipshidze, Christodoulos 
Stefanadis, Hippocration Hospital, Athens, Greece
Background: Plaque neovascularization is associated with destabilization of the 
atheromatic plaques. Increased expression of vascular endothelial growth factor 
(VEGF) is important in the process of neovascularization. The aim of the current study 
was to assess the effect of bevacizumab, a monoclonal antibody specific for VEGF, on 
neovascularization and intimal hyperplasia.
Methods: We used 12 New Zealand rabbits under atherogenic diet for 3 weeks. We 
immersed a phosphorycholine coated stent into a solution of 4 ml bevacizumab. Twelve 
eluting stents and 12 non-eluting stents were implanted in the middle segment of the 
rabbit’s iliac arteries. Follow-up angiography was performed at 4 weeks and tissues were 
obtained for histomorphometric measurements and immunohistochemistry analysis. The 
following variables were measured: the lumen area, adventitial area, and areas within the 
Internal Elastic Lamina (IEL), external elastic lamina (EEL), and stent. The neointimal area 
was calculated (stent area minus lumen area) as was the medial area (EEL area minus 
IEL area) the neointimal thickness at and between each stent wire site was measured, 
and the mean neointimal thickness for each arterial segment was calculated.
Results: There was no difference in angiographic measurements before, after implantation 
and at follow-up between the 2 groups. Lumen area, mean lumen stenosis, mean IEL area, 
and mean adventitia area were not different between the 2 groups (p>0.05). Neointimal 
area (1.08±0.09mm2 vs 1.22±0.10mm2), mean neointimal thickness between stent struts 
(0.09±0.02 mm2 vs. 0.12±0.02 mm2) and mean neointimal area (1.08±0.04 mm2 vs 
1.20±0.12 mm2) were less in the bevacizumab treated segments (p<0.01). Bevacizumab-
treated arterial segments demonstrated significantly decreased microvessel density 
compared with the control group (2.1±0.8 vessels per mm2 versus14.8±1.7 vessels per 
mm2; p<0.001) and VEGF expression was decreased in the media and adventitia of 
bevacizumab group.
Conclusion: These results suggest that bevacizumab-eluting stent implantation in 
rabbit iliac arteries is safe, and effectively inhibits both neovascularization and intimal 
hyperplasia.
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1033-135 Optimal Antithrombotic Therapy in Patients on 
Hemodialysis Requiring Percutaneous Coronary 
Intervention: Bivalirudin Monotherapy or Heparin Plus 
a Glycoprotein IIb/IIIa Inhibitor?
Pramod Krishnamurthy, Daniel Donohue, Sharad Kothari, Prakash Krishnan, 
Annapoorna S. Kini, Pedro R. Moreno, Samin K. Sharma, Michael C. Kim, Mount Sinai 
Medical Center, New York, NY
Background: End stage renal disease (ESRD) is associated with an increase in bleeding 
and ischemic events in patients undergoing percutaneous coronary intervention (PCI). 
Bivalirudin has shown to be effective in stable and unstable patients undergoing PCI 
with normal to mildly impaired renal function. However no data exists on the safety and 
effectiveness of bivalirudin during PCI for ESRD patients requiring dialysis.
Methods: The records of all patients undergoing PCI with ESRD over a four-year period 
at one academic medical center were reviewed for death, bleeding, and ischemic 
complications at 30 days based on receiving bivalirudin alone or heparin plus a GP IIb/IIIa 
inhibitor (GPI). All patients received aspirin (81-325 mg) and clopidogrel (600 mg loading 
and 75 mg daily). Bleeding included TIMI major and minor bleeding. Ischemic endpoints 
included MI (CK-MB>3X), stent thrombosis or urgent target revascularization.
Results: Baseline patient characteristics and angiographic characteristics were similar 
except for the heparin plus GPI group had more bifurcation lesions (14.5% vs 4.4% 
p=0.008). Patients receiving bivalirudin had less ischemic events, bleeding events, 30-
day mortality, and composite end points (table).
Conclusions: Bivalirudin is safer and has less ischemic/bleeding events after PCI in 
patients with ESRD requiring HD compared to heparin plus a GPI. Therefore, bivalirudin 
should be the standard antithrombotic monotherapy in ESRD patients requiring PCI. 
Outcome Heparin plus GPI (N=55) Bivalirudin  (N=361) P value
Composite end point *(%) 21.8 8.9 0.004
30-day Mortality (%) 5.5 1.4 0.07
Ischemic events (%) 7.3 1.7 0.01
Bleeding (%) 14.5 6.1 0.02
*Composite end points are 30-day mortality, ischemic events or bleeding.
11:00 a.m.
1033-137 Coronary Revascularization in Diabetic Patients with 
Multivessel Coronary Artery Disease - Three Year 
Follow-up of the ARTS-II Trial
Joost Daemen, Karl Heinz Kuck, Carlos Macaya, Victor Legrand, Mathias Vrolix, Didier 
Carrié, Imad Sheiban, Maarten Jan Suttorp, Pascal Vranckx, Tessa Rademaker, Marco 
Bressers, Monique Schuijer, Kristel Wittebols, Magdaleen Pieters, Hans-Peter Stoll, 
Patrick W. Serruys, Cordis Clinical Research Europe, Waterloo, Belgium
Background: ARTS-II was designed to assess safety and efficacy of the sirolimus-eluting 
stent (SES) for the treatment of multivessel coronary artery disease (MVD) as compared 
to the surgical and percutaneous (bare metal stent implantation) arms of the randomized 
ARTS-I trial. The use of SES made percutaneous coronary intervention (PCI) for MVD an 
appealing option, given the significantly reduced reintervention rates as compared to bare 
metal stenting. However, diabetes proved to be a strong and consistent predictor of (late) 
stent thrombosis in patients treated with SES and recent concerns were raised about an 
erosion of the initial treatment benefit due to occurrence of late stent thrombosis (ST). 
Methods: The ARTS studies included 367 diabetics (ARTS-II: 159; ARTS-I CABG: 96; 
ARTS-I PCI: 112). Baseline characteristics showed a more diseased patients in ARTS-II: 
50% with 3VD vs. 35% and 31% in ARTS-I CABG and ARTS-I PCI respectively. Results: 
At 3 year, the rate of major adverse cardiac and cerebrovascular events (MACCE), 
primary combined endpoint of death, cerebrovascular accident (CVA), myocardial 
infarction (MI) and repeat revascularization in ARTS-II was 27.7%, which was significantly 
lower than in ARTS-I PCI (47.3%; p=0.001) and similar in ARTS-I CABG (17.7%; p=0.1). 
Remarkable was that the combined endpoint of death/CVA/MI occurred significantly less 
frequent in ARTS-II than in ARTS-I PCI (9.4% vs. 18.8% respectively; p=0.03) but was 
observed in a similar rate in ARTS-I CABG (13.5%; p=0.31).The use of SES in ARTS-II 
was associated with a significant reduction of repeat revascularizations as compared 
to ARTS-I PCI (21.4% vs. 38.4% respective; p=0.003) but remained significantly higher 
as compared to ARTS-I CABG (7.3%; p=0.003). The incidence of ST (definite, probable 
or possible) was similar in ARTS-II diabetics as compared to non-diabetics (6.9% vs. 
6.3% respectively; p=0.85). Conclusions: At 3 year, there was no significant difference in 
MACCE rate between the diabetic patients from ARTS-II and ARTS-I CABG. While there 
was a trend towards a lower rate of death/CVA/MI in the ARTS-II arm, the need for repeat 
revascularization remained significantly higher as compared to the ARTS-I CABG arm.
11:00 a.m.
1033-138 Treatment of Paclitaxel-Eluting Stent Restenosis with 
Sirolimus-Eluting Stent Implantation - Angiographic 
and Clinical Outcomes
Robert A. Byrne, Raisuke Iijima, Julinda Mehilli, Melchior Seyfarth, Albert Schömig, 
Adnan Kastrati, Deutsches Herzzentrum Muenchen, Munich, Germany
Background: The optimal treatment for drug-eluting stent treatment failure remains unclear. 
We investigated the clinical and angiographic outcomes of patients presenting with paclitaxel-
eluting stent (PES) restenosis treated with sirolimus-eluting stent (SES) implantation.
Methods: All patients who underwent SES implantation for PES treatment failure were 
eligible for the study. All data were collected prospectively. Routine angiographic follow 
up was scheduled at 6 months post intervention. Angiographic restenosis was defined 
as diameter restenosis ≥50%, in the in-segment area. Clinical follow up was performed 
up to 2 years. A major adverse cardiac event (MACE) was defined as death, myocardial 
infarction or target lesion revascularization (TLR).
Results: Forty-three consecutive patients were eligible for inclusion. At baseline, a focal 
pattern of restenosis was found in 33 patients (76.7%), whereas diffuse restenosis was 
observed in the remaining 10 cases (23.3%). Angiographic follow up data was available 
for 36 patients (83%). Binary restenosis occurred in 6 patients (16.7%) and late luminal 
loss was 0.36 ± 0.54mm. At 2 years, TLR and MACE had occurred in 7 (16.3%) and 11 
(25.8%) of patients respectively.
Conclusion:
Implantation of SES for PES treatment failure is safe and associated with durable net 
luminal gain at follow up angiography. Two year TLR and MACE rates are acceptable in 
this particularly high risk cohort of patients.
Results of Quantative Coronary Angiographic Analysis at 6-month Follow-Up
Minimum lumen diameter, in-stent (mm) 2.14 ± 0.70
Diameter stenosis, in-stent (%) 21.66 ± 21.65
Minimum lumen diameter, in-segment (mm) 1.74 ± 0.60
Diameter stenosis, in-segment (%) 36.50 ± 18.03
Late lumen loss, in-stent (mm) 0.32 ± 0.54
Late lumen loss, in-segment (mm) 0.36 ± 0.54
11:00 a.m.
1033-139 The Impact of Age on Outcomes After Percutaneous 
Coronary Intervention With or Without Drug Eluting 
Stents Versus Coronary Artery Bypass Surgery: Three-
year Results From the Arterial Revascularization 
Therapies Study (ARTS) Part I and Part II
Victor M. Legrand, Joost Daemen, Marie-Claude Morice, Bernard De Bruyne, Antonio 
Colombo, Carlos Macaya, Gert Richardt, Jean Fajadet, Christian Hamm, Keith Dawkins, 
Kristel Wittebols, Hans-Peter Stoll, Patrick W. Serruys, Cordis Clinical Research Europe, 
Waterloo, Belgium
Background: In patients with multivessel disease (MVD), 1-year outcomes of coronary 
artery bypass grafting (CABG), percutaneous coronary intervention with bare metal stent 
(PCI BMS) and with sirolimus-eluting stent (PCI SES) differ between younger and older 
patients. However, to date there are no data relating to the long-term 3-year outcomes.
Methods: The ARTS I randomized trial compared 600 patients treated by PCI BMS and 
605 patients treated by CABG. The ARTS II trial assessed results of 607 patients treated 
with SES in a matched population with similar clinical and angiographic characteristics. 
A total of 1812 patients were reviewed according to four age quartiles. Endpoints are 
measured in terms of major adverse cardiac and cerebrovascular events (MACCE) during 
hospital stay, at 1, 3 and up to 5 year.
Results: Mean age of each quartile was 48.8, 58.8, 65.6 and 73.3 years. The frequency of 
female, diabetes, hypertension, peripheral vascular disease as well as lesion complexity 
increased with age. At 1 year, the MACCE-rate was highest in all four age groups of 
patients treated with PCI BMS. Multivariate analysis revealed that increasing age 
emerged as a predictor of MACCE for CABG, but not for SES. (figure)
Conclusions: Increasing age has an adverse prognosis in MVD patients treated by CABG 
which is not observed after PCI. The use of SES has improved the results of PCI, which 
are as good as those of CABG in any age quartile. Long-term data reporting the 3 year 
outcomes will be available at the time of the presentation. 
11:00 a.m.
1033-141 In Acute Coronary Syndromes Thin Fibrous Cap and 
Ruptured Plaques are Associated with Increased 
Local Inflammatory Activation: A Combination of 
Intravascular Optical Coherence Tomography and 
Intracoronary Thermography Study
Konstantinos Toutouzas, Maria I. Riga, Sophia Vaina, Chrysoula Patsa, Andreas 
Synetos, Manolis Vavuranakis, Eleftherios Tsiamis, Elli Stefanadi, Christodoulos 
Stefanadis, Hippokration Hospital, Athens, Greece
Background: The majority of the culprit atheromatic plaques (CP) which lead to acute 
coronary syndromes have increased local heat production due to excessive inflammatory 
activation of these plaques. Intracoronary thermography (ICT) at such culprit atheromatic 
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lesions in patients with acute coronary syndrome can detect temperature differences (DT) 
between the CP and the proximal healthy vessel wall. Optical coherence tomography 
(OCT) is a high resolution intracoronary imaging method which can discriminate between 
the several parts of the plaque. We examined the relation between functional proceedings 
at the CP and its morphological features.
Methods: 32 CP of 32 patients (21 men, 11 women, mean ages 61±6 years) with acute 
coronary syndrome were studied. ICT and OCT were performed in patients undergoing 
catheterization before pre-dilatation of the CP. By ICT, DT between the CL and the 
proximal vessel wall was measured. Fibrous cap thickness of the CP was measured by 
OCT and the minimal thickness of the fibrous cap (mTFC) was evaluated. The incidence 
of ruptured fibrous plaque and intraluminal thrombus was also analyzed by OCT.
Results: 32 CL were analysed. Nineteen CP (59%) had increased plaque temperature 
(DT≥0.05°C) and 13 CP (40%) had low DT (<0.05°C). The mTFC was thinner in CP with 
increased DT compared to CP with low DT (48±17 vs 188±82μm, p<0.01). Fourteen 
ruptured fibrous caps were found in CP with high DT (79%, 14 out of 19), and 4 ruptured 
caps in the group of low DT (31%, 4 out of 13, p=0.06). The incidence of intraluminal 
thrombus was similar between CP with increased and low DT (82% vs 76%, p=0.99).
Conclusions: Between the CP of patients with acute coronary syndrome, in those which 
have increased local inflammatory activation, as detected by ICT, fibrous caps are 
thinner with associated rupture, compared to plaques without temperature increase. The 
incidence of intraluminal thrombI in our study was not related to plaque temperature. 
These results may explain the discrepancy of inflammatory indexes in patients with acute 
coronary syndrome and provide more insights in the recognition of “high-risk” plaques.
11:00 a.m.
1033-142 Health Related Quality of Life After a Negative 
Angiogram: Not So Good
JoAnn Eastwood, Lynn V. Doering, Kathleen Dracup, University of California Los 
Angeles, Los Angeles, CA
Clinicians believe that a CAD-diagnosis would have a beneficial impact on a HRQOL in 
comparison to a CAD+ diagnosis.There is a lack of support for this belief and increasing 
anecdotal evidence that a CAD- finding has a deleterious impact. Methods: To assess the 
impact of a CAD+ diagnosis on HRQOL, we used a prospective, longitudinal comparative 
design to examine 93 index angiography patients. Subjects completed HRQOL instruments 
(Cardiac-Quality of Life Index [CQLI], physical[PCS]and mental component[MCS] scales 
of the SF-36 pre-angiogram, 6 wks. and 1 year post-angiogram. Criteria for CAD+ were: 
occlusive disease </= 40%; critical L main disease; diffuse microvascular disease; 
or definitive interventional treatment. Group differences over time were identified by 
repeated measures ANOVA. Results: Fifty-five patients were CAD+ (age 65.3 +/- 10.7, 
49% female) and 38 were CAD-(age 59.5+/- 12,53% female). CAD+ patients were older 
(p = .02). Compared to CAD+ patients,CAD- subjects reported lower HRQOL (on both 
CQLI and MCS) from baseline to one year (p<0.008). Conclusions: Contrary to common 
belief, HRQOL is worse in persons who are diagnosed CAD- in comparison to those 
who are CAD+, and this decrease in HRQOL continues for at least one year. These 
findings indicate that healthy individuals experience significant psychosocial distress 
when diagnostic procedures are not definitive. Thus, early post-procedure psychosocial 
assessment is warranted regardless of angiographic outcome. 
11:00 a.m.
1033-143 Long-Term Clinical Outcomes of Insulin-requiring 
Diabetics treated with Drug-eluting Stents in the 
DESIRE (Drug Eluting Stents In the REal World) 
Registry
Adriana Moreira, Amanda Sousa, J.Ribamar Costa Jr, Ricardo Costa, Manuel Cano, 
Galo Maldonado, Fausto Feres, Luiz Alberto Mattos, Edson Romano, Ricardo Pavanello, 
Enilton Egito, Marcos Barbosa, J.Eduardo Sousa, Hospital do Coração - Associação do 
Sanatório Sírio, São Paulo, Brazil
Background: Insulin-requiring diabetics are traditionally related to higher rates of major 
adverse cardiac events (MACE) after percutaneous coronary intervention even in the 
drug-eluting stent (DES) era. We sought to evaluate the very long-term clinical outcome 
after DES implantation in this high-risk subset of patients.
Methods and Results: Between May/2002 and May/2007, 2,081elective patients treated 
exclusively with DES were consecutively enrolled in the non-randomized, single-center 
DESIRE Registry. Among them, 1,583P (76%) completed 6 month-follow-up and were 
divided into 3 groups according to their Diabetes mellitus status. Primary endpoint was 
long-term combined MACE and stent thrombosis rate. Stent thrombosis was classified 
according to ARC definitions. Clinical follow-up was obtained at 1, 3 and 6 months and 
then annually up to 5 years. Mean follow-up time was 2.6±1.2 years and was achieved in 
97% of the eligible cohort. Baseline clinical and procedure characteristics as well as late 
outcomes are displayed in the table.
Conclusions: In the DESIRE registry both insulin and non-insulin requiring diabetics 
carried poorer long-term outcomes (MACE) when compared to non-diabetic patients. 
Importantly, there was a strong tendency for higher stent thrombosis among diabetics. 
However, the type of diabetes (insulin vs. non-insulin) did not seem to impact the 
prognosis of PCI with DES. 
Group 
Variables
Non 
Diabetics 
(n =1,119)
Non-insulin- requiring 
DM  
(n =361)
Insulin-requiring 
DM  
(n = 103)
p-value
Mean age ,y 63.6 64.4 65.6 0.562
Female,% 21.8 23.8 42.7 <0.001
B2/C lesion Type,% 71.3 76.3 75.7 0.244
DES/patient ratio 1.4 1.5 1.6 0.466
Cumulative MACE(%) 7.7 11.4 12.0 0.027
Cardiac death 2.4 3.2 3.4 0.586
Non-fatal MI 2.6 4.0 4.3 0.243
TLR (PCI/CABG) 2.7 4.2 4.3 0.210
Stent thrombosis 
rate,% 1.16 1.9 1.8 0.245
11:00 a.m.
1033-144 One -Year Clinical Follow-Up of Endothelial Progenitor 
Cell Capture Stent versus Uncoated Stent in Patients 
Undergoing Primary Percutaneous Coronary 
Intervention for Acute Myocardial Infarction
Yian-Ping Lee, Edgar Tay, Melissa Co, Wee Tiong Yeo, Chi-Hang Lee, Adrian F. Low, 
Swee Guan Teo, Jimmy Lim, Ing Han Lim, Yean Teng Lim, Huay Cheem Tan, National 
University Hospital, Singapore, Singapore
Background: The endothelial progenitor cell (EPC) capture stent is a bioengineered R 
stent with immobilized antibodies on its stent struts which allows for capture of circulating 
EPCs to promote rapid endothelization. We compare the mid-term efficacy and safety of 
this novel stent with bare metal stent in patients with ST-elevation myocardial infarction 
(STEMI) undergoing primary percutaneous coronary intervention (PCI).
Methods: Between January 2005 to September 2006, 234 consecutive patients 
presenting to our centre with STEMI and who underwent primary PCI with either EPC 
or bare metal stents were enrolled. The primary study end point was target vessel failure 
(death, recurrent myocardial infarction or target vessel revascularization) at 1 year.
Results: The 2 groups were comparable in baseline demographic characteristics with 
males of 88.5% and diabetics 31.2%. The mean stent length deployed of EPC vs bare 
metal stents were 20.5±5.1mm and 23.2±6.8 mm respectively (p<0.001). At 1 year, the 
primary end point was similar between the 2 groups (12.0% vs 11.3%, p=0.88). There was 
no significant difference in the rate of death (2.6% vs 5.7%, p=0.24), reinfarction (2.6% vs 
2.8%, p=1.00) or target vessel revascularization (6.8% vs 2.8%, p=0.17). The rate of late 
stent thrombosis (0.9% vs 1.9%, p=0.50) was also similar.
Conclusions: The use of EPC capture stent in patients with STEMI undergoing primary 
PCI have comparable 1-year clinical outcomes with bare metal stents.
11:00 a.m.
1033-145 Impact of Bleeding Complications on Clinical Outcome 
of Patients Undergoing Percutaneous Coronary 
Intervention
Arshad Ali, Mustafa Hashim, Arshad Rehan, St John Hospital and Medical Center, 
Detroit, MI
Background: Introduction of potent anti-platelet agents glycoprotein IIb/IIIa (GP IIb/IIIa) 
inhibitors has greatly enhanced the procedural success of percutaneous coronary 
intervention (PCI). Despite this success, these agents may cause increase in bleeding 
complications. Purpose of our study was to evaluate the impact of major bleeding 
complications on the clinical outcome in patients undergoing PCI.
Methods: Clinical records of 1020 patients who received GP IIb/IIIa inhibitors during PCI 
were reviewed. Data was collected for the incidence of major bleeding complications 
(as defined by Thrombolysis in Myocardial Infarction group), in-hospital mortality, MACE 
(defined as death, urgent revascularization, myocardial infarction, unstable angina or 
stroke), and predictors of MACE.
Results: All patients received weight heparin during the PCI. Over-all incidence of bleeding 
complications was 8.7%. MACE rate was 5.3 % and in-hospital mortality was3.2 %.
Incidence of MACE was significantly higher in patients experiencing bleeding complications 
(38.2% in bleeding group versus 2.1 % in non-bleeders, p <0.0001).
Predictors of MACE were, major bleeding (p<0.0001), renal insufficiency (p<0.01) and 
age greater than 70 (p< 0.001).
Conclusions: Bleeding complications following PCI are associated with significant 
increase in short term MACE. Refinement of antithrombotic agents and recognition of 
predictors of bleeding are important to improve the safety of PCI.
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1033-146 Efficient Referring Hospitals can Routinely Transfer 
Patients for STEMI PCI with Door-to-Balloon TImes < 90 
Minutes
James C. Blankenship, Marie Sledgen, Kimberly A. Skelding, Thomas Scott, Peter 
Berger, Jennifer A. Sartorius, Michael Donegan, Francis J. Menapace, Geisinger 
Medical Center, Danville, PA
Background: For US patients presenting with STEMI to non-PCI hospitals, PCI can rarely 
be performed within 90 minutes. We hypothesized that efficient systems of care can 
provide PCI for transferred as well as on-site patients within 90 minutes of presentation
Methods: In 2005 we implemented a Level 1 STEMI program employing 4 helicopters 
to transport patients to our PCI center. Further refinements were implemented 1/1/06 
and 1/1/07. Door-to-balloon (D2B) times were tracked before and after 2005. Logistic 
regression identified predictors of time delays for D2B and each component of total D2B. 
All times are reported as medians.
Results: Overall D2B decreased for transferred patients from 188 minutes (2004) to 
105 minutes (2005) to 101 minutes (2006) to 95 minutes (2007). D2B for onsite patients 
decreased from 120 to 86 to 78 to 47 minutes over the same period. Multivariate predictors 
(p < 0.05) of shorter overall D2B included referring hospital (independent of flight time) 
(fastest 82 minutes, slowest 116 minutes), current smoker, and diabetic. Weekday vs 
afterhours/weekend D2B times were 97 vs 94 minutes (p = NS). Three hospitals achieved 
median D2B of 83, 83, and 85 minutes. Multivariate predictors (p<0.05) of EKG-to-
decision to transfer included referring hospital (15 minutes fastest, 25 minutes slowest), 
culprit artery (RCA 16 minutes fastest, LAD 21 minutes slowest), and shock (13 minutes 
with versus 18 minutes without). Multivariate predictors of cath lab arrival to balloon time 
included culprit artery (RCA 17 minutes, LCx 20 min) and interventionist (15 minutes 
fastest versus 24 minutes slowest).
Conclusions: Some referring hospitals can routinely achieve D2B < 90 minutes for 
transferred STEMI patients. Afterhours/weekend presentation need not result in slower 
D2B times. In our system, QI efforts that focus on improving performance of slower 
referring hospitals and slower interventionists might result in substantially more STEMI 
patients receiving PCI in < 90 minutes.
11:00 a.m.
1033-147 Rapid right ventricular pacing facilitates transcatheter 
coronary stent implantation to the ostial left anterior 
descending artery when stent stability is not achieved 
during stent positioning
Hidetaka Nishina, Yuichi Noguchi, Miyako Kanemoto, Tomoya Hoshi, Junji Shiotsuka, 
Yuko Fumikura, Yuri Hiranuma, Shigeyuki Watanabe, Kazutaka Aonuma, Tsukuba 
Medical Center Hospital, Tsukuba, Japan, Tsukuba University Hospital, Tsukuba, Japan
Background: Stenting to the ostial left anterior descending artery (LAD) lesions requires 
precise placement to avoid unnecessary protrusion of the stent to the left main coronary 
artery. The precision of stent deployment is, however, sometimes hampered by cardiac 
motion resulting in stent instability during stent positioning. Rapid RV pacing has been 
described to facilitate transcatheter valvoplasty or prosthetic valve implantation by 
reducing stroke volume and cardiac motion. We assessed the efficacy and safety of rapid 
RV pacing during ostial LAD stenting when the stent stability was not achieved during 
conventional stent deployment.
Methods: Seven patients referred for proximal LAD angioplasty consisted study population 
(age 55 years old, one female). During stent deployment, the stent moved substantially 
with cardiac motion which made precise positioning impossible in these seven patients.
Results: During a short-time, rapid RV pacing (120-160 bpm), there was a significant drop 
in pulse pressure (59 mmHg to 17 mmHg, p=0.0001) as well as in systolic blood pressure 
(130 mmHg to 79 mmHg, p<0.002) while diastolic blood pressure remained unchanged 
(71 mmHg to 63 mmHg, p=ns). The stent motion was minimized during rapid RV pacing 
and the stents were placed successfully without dislocation. RV pacing was terminated 
immediately after the stent expansion was confirmed visually, and the patients tolerated 
the procedure without any complications. Satisfactory stent deployments were confirmed 
by intravascular ultrasound (IVUS) in all seven cases.
Conclusions: Rapid RV pacing is safe and effective to provide stent stability during ostial 
LAD stenting. It may be applied in other types of coronary artery lesions where it is difficult 
to maintain stable stent positions due to cardiac motion during stent deployment.
11:00 a.m.
1033-148 Old Dogs and New Tricks: Using an iPod® to Teach 
Cardiac Auscultation
Michael J. Barrett, Archana Saxena, Alfred Bove, Temple University, Philadelphia, PA
Background: The proficiency of physicians in cardiac auscultation is alarmingly low. 
Previous work demonstrated significant improvement following intensive repetition of 
abnormal heart sounds. The common availability of mp3 players allowed us to test the 
hypothesis that these electronic devices can be used to provide the repetition necessary 
to improve proficiency in cardiac auscultation.
Methods: A total of 203 attendees at a national cardiology meeting took a pretest on 
a computer consisting of human heart sounds and murmurs played in random order. 
They then listened to 7 mp3 files of simulated cardiac murmurs (AS,AR,MR,MS, Innocent 
Systolic Murmur and 2 extra heart sounds, S3,S4) on an iPod®. All subjects listened 
to at least 200 repetitions of each cardiac sound while viewing posters with didactic 
material including phonocardiograms of that sound. The intervention required 40 minutes 
to complete. All subjects then took a computerized posttest consisting of human heart 
murmurs and sounds played in random order.
Results: Subjects’ correct answers improved from 40.1 +/- 21.3% on the pretest to 73.0 
+/- 20.6% on the posttest, p<.001 by paired t-test. Informal survey of participants revealed 
a high degree of acceptance for this type of training.
Conclusions: An iPod® can function effectively to provide the repetition necessary to 
dramatically improve attendees’ proficiency in cardiac auscultation in a short timeframe. 
These results show that cardiac auscultation is, in part, a technical skill that can be 
mastered through repetition. This study suggests a novel approach to improve this 
important clinical skill using a commonly available mp3 player.
11:00 a.m.
1033-149 The Power of Web-Based Training in Cardiac 
Auscultation: A Quality Improvement Study
Michael J. Barrett, Ellie Kelepouris, Christian Lopez, Lawrence Kaplan, Temple 
University, Philadelphia, PA
Background: Medical students’ proficiency in cardiac auscultation is poor. Previous work 
has demonstrated dramatic improvement with intensive repetition in a classroom. We 
assessed the effect of a similar web-based curriculum on cardiac auscultation skills in 453 
first, second and third year medical students.
Methods: Students were divided according to class: 165 - first-year students, 163 - 
second-year students and 125 - third-year students. Each class logged on to their web 
site and took a pretest of human heart sounds. All students then downloaded 5 to 7 mp3 
files containing 200 repetitions of each heart sound. First-year students listened to five 
normal sounds, second-year students listened to five basic murmurs (AS, AR, MS, MR 
and innocent murmur), and third-year students listened to the five basic murmurs and 
S3, S4. One month later all students took a posttest on the respective web sites. At both 
tests, students listened to human heart sounds in a randomized sequence and selected 
the correct answer from a menu.
Results: 
Class N Pretest +/-SD Posttest +/- SD P value
1st yr 165 37.0 +/- 32.7 93.0 +/- 9.2 <.001
2nd Yr 163 43.0 +/- 32.9 95.0 +/- 10.3 <.001
3rd Yr 125 37.9 +/- 21.1 87.0 +/- 15.5 <.001
* by paired t-test
Conclusions: A web-based curriculum that uses intensive repetition is highly effective in 
improving cardiac auscultation skills in first, second and third-year students. This study 
supports the hypothesis that cardiac auscultation can be effectively taught over the 
Internet. Since the USMLE now tests auscultation skills at the step 2 level, this type of 
training will become increasingly important.
11:00 a.m.
1033-150 The porcine restenosis model using Thermal Balloon 
Injury;Comparison with the model by coronary stenting
Yoriyasu Suzuki, Alan C. Yeug, Fumiaki Ikeno, Stanford University, Stanford, CA
Background: Percutaneous coronary intervention (PCI) continues to revolutionize the 
treatment of coronary atherosclerosis and technologic advances should require pre-
clinical animal coronary stenosis model. The purpose of this study is to evaluate the 
porcine restenosis model by using heat injury compared with the restenosis model by 
stenting.
Methods: To evaluate this model, 22 swine were used. For the induction of coronary 
stenoses, thermal balloon was placed at desire location in coronary arteries and heated 
to 80 degree for 80 seconds. Quantitative coronary angiography (QCA), Quantitative 
coronary ultrasound (QCU) analysis and Histopathologic evaluation of coronary arteries 
was performed.
Results: A total of 54 coronary arteries (thermal balloon injury (thermo); n=43, coronary 
stenting (stent); n=11) in survived animals (n=18) were analyzed. At 4 weeks after the 
procedure, the significantly higher coronary stenoses were observed in thermo group than in 
stent group (minimum lumen diameter; 1.00±0.63mm vs. 1.58±0.44mm, p=0.009, %diameter 
stenosis (DS); 66.2±21.6% vs. 48.1±11.4%, p=0.02). There were significant linear correlations 
between balloon-artery ratio at 4 weeks (balloon-artery ratio; r=0.538, p=0.0012).
Conclusions: This methodology could provide reproducible and consistent coronary 
stenoses. This model can be useful for not only the evaluation of medical devices but also 
technical training of PCI and development of coronary imaging technologies. 
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11:00 a.m.
1033-151 Non-Invasive Computerized Acoustic Cardiographic 
Prediction of Left Ventricular Systolic Dysfunction
Douglas L. Kosmicki, Sean P. Collins, Christopher J. Lindsell, Michel Zuber, Michael C. 
Kontos, Peter Kipfer, Christine Attenhofer Jost, Andrew D. Michaels, University of Utah, 
Salt Lake City, UT, University of Cincinnati, Cincinnati, OH
Background: The signs and symptoms of systolic heart failure (HF) are frequently 
nonspecific and highly variable, making an accurate bedside diagnosis of left ventricular 
(LV) systolic dysfunction challenging. B-type natriuretic peptide (BNP) is commonly used 
but many times is in an indeterminate range. A rapid, bedside tool that accurately detects 
LV systolic dysfunction would be helpful. We investigated the diagnostic test characteristics 
of simultaneous recorded digital ECG and acoustic cardiographic parameters to identify 
patients with LV systolic dysfunction.
Methods: We studied 435 patients: 175 outpatients in a cardiology clinic, 82 referred for 
left heart catheterization, and 178 who presented to an emergency department with acute 
dyspnea. BNP was measured. Computerized acoustic cardiography (Inovise Medical Inc., 
Portland, OR) was obtained to assess the third heart sound (S3 Score), S2:S1 intensity 
ratio, LV systolic time (interval from S1 to S2), and the electromechanical activation time 
(EMAT; Q onset to the peak of the first heart sound). Echocardiography was obtained 
within 24 hours to assess LV ejection fraction (EF). LV systolic dysfunction prospectively 
was defined as an EF <50%. The c-statistic was computed with bootstrapping methods.
Results: The mean age was 61±14 years (range 19-90), 66% were male, 35% had 
diabetes, 88% had a history of coronary artery disease, and 82% had a clinical history of 
heart failure. Independent predictors of LV systolic dysfunction included gender, EMAT, 
QRS duration, QR interval, S3 score, ratio of S2:S1 intensity, and LV systolic time. The 
c-statistic was 0.88. Using the optimal cutpoint, the model had 80% sensitivity, 81% 
specificity, and a positive likelihood ratio of 4.1. The BNP alone model had a c-statistic of 
0.74. When BNP was added to the model, the c-statistic was not improved compared to 
the acoustic cardiographic model.
Conclusions: Non-invasive computerized acoustic cardiographic variables accurately 
predicted LV systolic dysfunction in a diverse population. Adding BNP did not improve the 
accuracy of the predictive model, and this model outperformed BNP alone for predicting 
LV systolic dysfunction.
11:00 a.m.
1033-152 Multidisciplinary lipid clinic model results in improved 
cardiovascular outcomes
M. Zubair Jafar, Dannyaal Moin, Steve Lichtenberg, David Weinrich, Sanjaya Jha, 
Stephanie Mulcahey, Noemi Mercado, Eileen Mcdowell, Glenn Gerber, Hudson Valley 
Heart Center, poughkeepsie, NY
Background: Though statin monotherapy has been effective in reducing the frequency 
of cardiovascular events, there is still considerable room for improvement. This study 
assessed the effects of aggressive statin monotherapy versus a multidisciplinary 
multidrug lipid clinic model on cardiovascular events.
Methods: We did a retrospective analysis of 700 consecutive patients who had a diagnosis 
of coronary artery disease on cardiac catheterization and who were sent for a lipid analysis. 
200 patients were treated with statin monotherapy(AT) to an aggressive ldl target of <70. 
500 patients (LC)underwent an advanced lipid panel including hdl and ldl subfractionation. 
They were then seen by an allied health professional who followed a predefined treatment 
protocol that included multidrug therapy and diet and lifestyle modification. Mean folloup 
was 25 months and the primary combined endpoint was death, mi, revascularization.
Results: Baseline characteristics were similar in the two groups. The statin monotherapy 
group(AT) had higher incidence of hypertension(59% vs. 40%;p=.001), prior ptca(75% vs. 
62%;p=.02) and a lower incidence of smoking(46% vs. 65%;p=001),family history(53% 
vs. 67%; p=.04) and prior cabg(33%vs.45%;p=.03). The initial ldl(89 vs. 91;p=ns),hdl(41 
vs. 42; p=ns),total cholesterol(161vs.162; p=ns) were similar for the two groups. The final 
ldl(75(LC) vs. 81(AT);p=ns),hdl (45(AT) vs. 48(LC);p=ns)were similar in both groups but 
total cholesterol was lower in the LC group(145 vs. 157; p=.031). Statin therapy was 
similar in both groups(88% vs.90%). Niaspan therapy was significantly higher in the LC 
group(42% vs. 9%; p<.001).
The combined endpoint of mi death and revascularization was significantly lower (7%) in 
the LC group vs. the AT group(15%); p<.01
Conclusions: A multidrug, multidisciplinary lipid clinic model resulted in a lower incidence 
of cardiovascular events when compared to aggressive statin monotherapy. This effect 
appeared to be independent of ldl and hdl levels.
11:00 a.m.
1033-153 Unexpectedly High Prevalence of Coronary Heart 
Disease in Diabetic Patients Referred From a 
Retinopathy Clinic
Hideo Fujita, Takayuki Ohno, Jiro Ando, Osamu Kinoshita, Satoshi Kato, Akira Hirose, 
Takeshi Shigeeda, Ryozo Nagai, Shinichi Takamoto, University of Tokyo Hospital, Tokyo, 
Japan
Background: Coronary heart disease (CHD) is the leading cause of death in diabetic 
population. Epidemiologic studies demonstrate that patients with diabetic retinopathy have 
an increased risk of myocardial infarction and death from CHD. Furthermore, diabetic 
patients tend to have fewer grades of symptoms, resulting in later manifestation of far 
more critical cardiovascular events compared to non-diabetics. Therefore, we hypothesized 
that many outpatients with diabetic retinopathy cared only by ophthalmologists remained 
underdiagnosed in terms of CHD and were to be appropriately treated with CABG or PCI.
Methods: We opened the “diabetic retino-coronary clinic” at the University of Tokyo 
Hospital in April 2007. The purposes of this clinic are (1) targeted diagnosis and treatment 
of CHD in patients with diabetic retinopathy, and (2) to improve life expectancy of overall 
diabetic population. CHD was diagnosed according to our protocol using treadmill stress 
test, coronary CT, and coronary angiography. Primary endpoint is significant stenosis 
(>50%) of coronary artery.
Results: Between April 2007 and September 2007, 149 patients with diabetic retinopathy 
were referred from retinopathy clinic. Of them, 99 (66%) patients reached the final 
diagnosis. Thirty-two (32%) patients had a significant stenotic coronary disease, and 
28 (88% of patients with CHD) patients presented LAD disease. As many as 26 (26%) 
patients underwent revascularization with CABG (n=9) or PCI (n=17).
Conclusions: Our preliminary result revealed that prevalence of significant CHD was 
higher among diabetic retinopathy subjects than among overall diabetic population 
as previously reported. Not only does it suggest that microangiopathy represented by 
retinopathy might provide a clinically strong predictor for CHD, but also this screening 
method designated for CHD in conjunction with retinopathy facilitate a novel scheme for 
how to manage diabetic patients in terms of long-term prognosis.
11:00 a.m.
1033-154 Long Distance Titration of Heart Failure Medications by 
Telephone Calls
Anne E. Steckler, Heba Wassif, Judy Wagner, Connie Jaenicke, Thomas Rector, Inderjit 
S. Anand, VAMC Minneapolis, Minneapolis, MN
Background: Heart failure (HF) guidelines recommend timely titration of beta blockers 
and other heart failure medications to doses shown to be effective in clinical trials. Doses 
are often not optimized in clinical practice because of difficulty in organizing frequent 
clinic visits and perceived medication side effects. We utilized an experienced HF nurse 
(RN), supervised by cardiologist or nurse practitioner to optimize medications without 
frequent clinic visits. Methods: Experience with the first 79 patients referred is described. 
A complete history and exam, SMA10, BNP, EKG, and 2-D ECHO were obtained for 
the initial visit along with dose adjustments. Patients were given home BP monitors and 
scales, educated about daily weights, recording of vital signs, low sodium diet, signs and 
symptoms of worsening HF, and medication side effects. Telephone calls were made to 
patients at 1 to 3 week intervals to titrate doses depending on HR, BP, symptoms and 
weight. Doses of beta blockers were titrated to a goal HR of 60 bpm or intolerance. Clinic 
visits and lab tests were used only as needed. Repeat 2-D ECHO was obtained 3-6 
months post optimization. Results: 11 of the 79 were withdrawn due to noncompliance 
(8), moving (2) or entering nursing home (1). Among the 68 optimized patients the average 
beta blocker dose was increased from 37% to 64% of proven doses. 22 were switched to 
approve beta blockers (carvedilol; metoprolol SR). 31 patients not receiving beta blocker 
at baseline achieved 49% of target doses while 27 who were on beta blocker achieved 
75% of target doses. Overall target dose was achieved in 29%. The post-optimization 
vitals were BP 116±12 / 66±8 mmHg, and HR 62±7 bpm. Median time to optimization 
was 52 (IQR 20-97) days. On average the EF increased by 7%. 16 out of 45 patients 
increased EF from below to above 35%, possibly precluding ICD/CRT intervention. None 
of the patients required hospitalization for symptomatic hypotension, bradycardia, hypo 
or hyperkalemia or renal failure. Conclusions: It is feasible and safe for a supervised RN 
to titrate HF therapy to the standard of care by phone without frequent clinic visits. This 
approach to optimizing HF therapy could also reduce costly ICD/CRT interventions.
11:00 a.m.
1033-155 Bioelectrical Impedance Analysis (BIA) in differentiating 
acute dyspnoea due to Decompensated Heart Failure in 
Emergency Department
GASPARE PARRINELLO, Salvatore Paterna, Pietro Di Pasquale, Daniele Torres, 
Antonio Fatta, Manuela Mezzero, Rosario Scaglione, Giuseppe Licata, Internal and 
Specialist Medicine Department University of Palermo, Palermo, Italy, Department of 
Emergency Care, University of Palermo, Palermo, Italy
Background: The current methods to diagnose acute dyspnoea due to heart failure 
(HF) had to date many limitations. Recently, BNP rapid test is validated in these setting, 
nevertheless the early accumulation of fluid in the interstitial space of the lungs, that 
characterized patients (pts) with ADHF,is well estimate by BIA and represents a 
diagnostic challenge for physicians. We investigate whether Bioelectrical Impedance 
Analysis (BIA) can serve as a non invasive diagnostic tool in differential diagnosis of 
acute decompensated heart failue (ADHF) in Emergency Department (ED).
Methods: 292 pts, presenting with acute dyspnoea to ED, were evaluated using a conventional 
diagnostic strategy and rapid BNP measures. In addition, at entry, segmental (Seg) and 
whole-body (WB) BIA resistance (Rz) and reactance (Xc), were immediately detected. After 
hospital discharge, an expert team classified enrolled pts in ADHF and non-ADHF.
Results: ADHF pts were 58.9% while non-ADHF were 41.1%. ADHF pts showed a 
significant (p<0.001) higher BNP values (591,8±501 vs 69,5±42 pg/ml), a significant 
(p<0.001) reduction of Seg ( 35.5 + 8.2 vs 66.4 + 10.5) and WB ( 402.3 + 55.5 vs 513.2 + 
41.8) Rz (Ohm) and a significant correlation (p< 0.0001) between BNP and Seg (r= -0,62) 
and WB (r=-0.63) bioelectrical Rz. Multiple regression analysis showed that Whole Body 
and segmental BIA remained strong predictors of ADHF alone or in combination with BNP.
Conclusions: our data suggest that Seg and WB BIA are a useful, simple, rapid and non-
invasive diagnostic adjunct in the early diagnosis of dyspnoea due to ADHF.
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1033-156 Correlates of Posttraumatic Growth among Cardiac 
Patients: Are There Any Sex Differences?
Yvonne W. Leung, Shannon Gravely-Witte, Janette Brual, Alison Macpherson, Jane 
Irvine, Donna E. Stewart, Louise Pilote, Sherry L. Grace, York University, Toronto, ON, 
Canada
Backgrounds: Although women suffer a greater burden of anxiety and depression after 
critical illnesses, growing evidence shows that they are also more likely than men to 
report posttraumatic growth (PTG) or resilience. As PTG is associated with positive 
psychosocial outcomes, this study aimed to assess sex differences and other correlates 
of PTG among cardiovascular disease (CVD) patients.
Methods: 1490 recent CVD outpatients consented to participate (n=430, 28.7% female; 
72% response rate) in this prospective study. Patients responded to a mailed baseline 
and 1 year follow-up surveys. Clinical data were extracted from medical charts. Surveys 
assessed correlates including sociodemographic characteristics, the Hospital Anxiety and 
Depression scale, ENRICHD Social Support Inventory, Illness Perception Questionnaire, 
Perceived Stress Scale, Beck Depression Inventory-II, and Duke Activity Status Index. 
The PTG Inventory which includes 5 subscales, namely New Possibilities (NP), Relating 
to Others (RtO), Personal Strength (PS), Appreciation of Life (AoL), and Spiritual Change 
(SC) and was administered at 1 year.
Results: Female sex was correlated with SC at the bivariate level (p<.01). MANCOVA 
revealed the following significant correlates of PTG: Non-white background was 
associated with all subscales (ps<.04). Lower activity status was associated with all 
subscales (p<.001). Depressive symptoms were negatively associated with all subscales 
except SC (p<.001-.023). Illness perceptions such as Acute/Chronic (p<.008) and CV 
Consequence (p<.001) were significantly related to greater PTG.
Conclusions: Greater PTG was related to positive psychosocial well-being, such as 
less depressive symptoms, and CVD was perceived as controllable and short-term, 
despite serious consequences and lower functional status. Contrary to expectation, no 
sex differences were found in adjusted analyses, but non-white ethnicity was related 
to greater PTG. Given the paucity of investigation of PTG in cardiac patients and the 
evidence of potential benefit for patient outcomes, research attention should be directed 
toward understanding and promoting PTG.
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818-3 Relationships Among the Kansas City Cardiomyopathy 
Questionnaire and Clinical Measures in Patients With 
Heart Failure
Kathryn E. Flynn, Li Lin, Stephen Ellis, Lawrence Fine, Ileana Pina, Susan Kay Roll, 
Stuart Russell, Kevin Schulman, John Spertus, David Whellan, Kevin Weinfurt, Duke 
Clinical Research Institute, Durham, NC
Background: Little consensus exists on the best outcome measures for clinical trials 
in heart failure. To understand the impact of interventions on heart failure, one must 
understand the relationships between physiologic outcomes and patient-reported 
outcomes. In this study we characterized the cross-sectional relationship between key 
clinical outcome measures and patient-reported outcomes and determined whether 
these relationships were consistent across different groups of patients.
Methods: As part of HF-ACTION (Heart Failure and A Controlled Trial Investigating 
Outcomes of Exercise TraiNing), the Kansas City Cardiomyopathy Questionnaire 
(KCCQ), 6-minute walk test (6MW), exercise capacity (peak VO2), and New York Heart 
Association (NYHA) class were assessed in 2,303 patients with heart failure. Using 
baseline data, general linear models were estimated in which the KCCQ total score was 
regressed on each clinical measure of severity (6MW, peak VO2, or NYHA), in addition 
to patient sociodemographic characteristics (sex, age, ethnicity, race, education level, 
marital status, insurance, employment status, annual household income). An omnibus 
test was used to evaluate all 2-way interactions between the clinical measure and patient 
characteristics, and when significant, we tested each interaction separately. To facilitate 
interpretation, relationships are reported for a 1 standard deviation (SD) change in 6MW 
(=104 meters) and peak VO2 (=4.7 mL/kg/min).
Results: Adjusting for patient characteristics, a 1 SD difference in 6MW was associated 
with a 5.99 point difference in KCCQ score (95% confidence interval: 5.04-6.92), and a 
1 SD difference in peak VO2 was associated with a 4.93 difference (3.93-5.93). A move 
from NYHA class 2 to 3 was associated with a 12.80 difference in KCCQ score (10.99-
14.61). None of these relationships were moderated by patient characteristics.
Conclusions: Differences among patients in KCCQ scores are associated with differences 
in 6MW, peak V02, and NYHA. These relationships do not vary by sociodemographic 
characteristics. These findings support current practices of considering a 5-point 
difference on the KCCQ to be clinically meaningful.
1:15 p.m.
818-4 Discordance between patient-predicted and model-
predicted life expectancy among outpatient heart 
failure patients
Larry A. Allen, Jonathan E. Yager, James A. Tulsky, Margaret T. Bowers, Gwen C. 
Dodson, Wayne C. Levy, Michele Jonsson Funk, Christopher M. O’Connor, G. Michael 
Felker, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background: Patients with chronic heart failure (HF) have impaired long term survival, but 
their own expectations regarding prognosis have not been well studied. The relationships 
between patient characteristics and perceptions of life-expectancy in HF are unknown.
Methods: We carried out a prospective interview-based survey regarding end of life issues 
in patients presenting to the Duke HF disease management program. Patients were 
asked to self-assess their predicted lifespan (SAL) using a visual analog scale. Model-
assessed lifespan (MAL) was calculated for each patient using a validated predictive 
model (Seattle HF Score). The “optimism index” (OI) was defined as the ratio of SAL 
to MAL. Associations between patient characteristics and OI were characterized using 
Wilcoxon tests and multiple linear regression.
Results: The cohort consisted of 122 patients with mean age 62 years, 47% African-
American, 42% NYHA class III or IV, 38% with ischemic etiology, ejection fraction 0.30, 
86% use of beta-blockers, and 25% with defibrillator implantation. Overall, patients 
consistently overestimated their life-expectancy relative to model-predicted life expectancy 
(mean SAL=16.6 yrs, mean MAL=10.5 yrs, mean OI 1.76 [SD 1.72]). Adjusted analysis 
showed independent predictors of optimistic prognostic outlook to be younger age, 
African-American race, lower Beck depression score, and absence of a defibrillator.
Conclusions: Ambulatory patients with HF tended to substantially overestimate their life 
expectancy compared with validated model-based predictions for survival. The reasons 
for this incongruity are unknown, but appear to be related in part to age, race, and 
depression. An optimistic outlook was also associated with lower implantation rates of 
potentially life-saving defibrillators. Because differences in perceived survival could affect 
decision-making regarding advanced therapies and end of life planning, the causes of 
these prognostic misperceptions warrant further study.
1:30 p.m.
818-5 Prospective Evaluation of the Clinical Application of the 
ACCF/ASE Appropriateness Criteria for Transthoracic 
Echocardiography
R. Parker Ward, Nicole Lemieux, Nitin Gera, Ibrahim N. Mansour, Rupa Mehta, Roberto 
M. Lang, University of Chicago, Chicago, IL
Background: The ACCF/ASE appropriateness criteria (AC) for echocardiography have 
recently been published, though the application of these criteria on current clinical 
practice remains unknown. Our goal was to prospectively evaluate the clinical application 
of published criteria for transthoracic echocardiography (TTE) in a university hospital.
Methods: Indications for TTE were prospectively determined in consecutive patients 
referred for inpatient or outpatient TTE in a single center university hospital. Each study 
indication was categorized according to the AC for TTE, as appropriate (A) or inappropriate 
(I). Patient and referring physician characteristics were recorded. All TTE findings were 
noted, including composite endpoint of any clincially important TTE abnormality (defined 
as LV or RV dysfunction, any mild or > valve disease, regional wall motion abnormality, 
pulmonary hypertension, or other clincially significant abnormality).
Results: Of the 1026 patients prospectively enrolled, a primary indication for the study 
could be determined in 1006 (98%). Of these 1006 studies, 903 (90%) were ordered 
for indications outlined in the AC document, while 104 (10%) were not. Of the 903 pts 
for whom the AC document could be applied, 806 (89%) studies were Appropriate (A) 
and 97 (11%) were Inappropriate (I). Overall, a clinically important TTE abnormality was 
present on 67% of studies, though 23% were unchanged from a prior TTE, leaving 44% 
of studies with a new clinically important TTE abnormality. There were significantly more 
new clinically important echo abnormalities among A compared to I studies (49% vs 
23%,p<0.001). I studies were more common among outpatients than inpatients (17% vs 
5%, p<0.001), and were more frequently ordered by non-cardiovascular specialists (13% 
vs 9%, p=0.07). Among indications not addressed by AC document, a number of potential 
additions/gaps were identified.
Conclusions: Overall, the AC for echocardiography appears to reasonably stratify TTE 
ordering and encompasses the majority of clinical indications for TTE. However, revisions 
to the AC for echocardiography will be needed to fully capture and stratify appropriate 
clinical practice.
1:45 p.m.
818-6 Trends in Care Disparities for Patients With Acute 
Myocardial Infarction in the National Registry of 
Myocardial Infarction From 1994 to 2006
Bimal R. Shah, Eric D. Peterson, Lori Parsons, Charles V. Pollack, William J. French, 
John G. Canto, C. M. Gibson, William J. Rogers, NRMI Investigators, Duke University, 
Durham, NC, Genentech, South San Francisco, CA
Background: It is unknown whether national efforts to improve use of guideline-based 
treatments for acute myocardial infarction (AMI) have also reduced known age-, gender-, 
and race-based care disparities.
Methods: Using the National Registry of Myocardial Infarction (NRMI) database, we 
analyzed 2,227,855 patients admitted to 2,051 enrolling U.S. hospitals between January 
1994 and December 2006. Temporal trends in use of 12 ACC/AHA acute, revascularization, 
and discharge treatments were examined. Age, gender, and race treatment odds ratios 
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(OR) were assessed for various time intervals using multivariable logistic regression 
adjusting for other demographic and clinical features.
Results: From 1994 to 2006, use of all 12 ACC/AHA recommended therapies rose 
significantly in all AMI subgroups. Table 1 shows representative adjusted OR for 
select therapies in patients at least 75 years old, women, and Blacks relative to their 
counterparts.
Conclusion: While overall adherence to AHA/ACC AMI treatment guidelines has improved 
significantly over the past decade, care disparities persist suggesting the need for ongoing 
quality improvement efforts.
Table 1. Trends in Adjusted OR for Treatment by Age, Gender, and Race 
1994 - 1996 1997 - 1999 2000 - 2002 2003 - 2006
OR for 
≤ 75 vs < 75 yrs
Beta Blocker < 24hrs 0.79 (0.77, 0.80)
0.82 
(0.81, 0.83)
0.82 
(0.81, 0.83)
0.82 
(0.80, 0.83)
CABG/PCI 0.40 (0.39, 0.41)
0.40 
(0.40, 0.41)
0.37 
(0.36, 0.37)
0.36 
(0.36, 0.37)
Discharge lipid- 
lowering agent
1.09 
(1.07, 1.11)
1.05 
(1.04, 1.07)
0.95 
(0.93, 0.96)
0.82 
(0.81, 0.84)
OR for Women vs Men
Beta Blocker < 24 hrs 0.92 (0.91, 0.93)
0.94 
(0.93, 0.95)
0.96 
(0.94, 0.97)
0.95 
(0.94, 0.97)
CABG/PCI 0.75 (0.74, 0.76)
0.72 
(0.71, 0.73)
0.69 
(0.68, 0.70)
0.64 
(0.63, 0.65)
Discharge lipid- 
lowering agent
1.02 
(1.00, 1.04)
1.03 
(1.02, 1.04)
1.02 
(1.00, 1.03)
0.99 
(0.97, 1.01)
OR for Black vs White
Beta Blocker < 24 hrs 0.92 (0.90, 0.95)
0.98 
(0.96, 1.00)
1.02 
(0.99, 1.04)
1.05 
(1.01, 1.09)
CABG/PCI 0.53 (0.51, 0.54)
0.52 
(0.50, 0.53)
0.55 
(0.53, 0.56)
0.54 
(0.52, 0.56)
Discharge lipid- 
lowering agent
1.15 
(1.12, 1.19)
1.14 
(1.12, 1.19)
1.11 
(1.08, 1.14)
1.04 
(1.01, 1.08)
2:00 p.m.
818-7 Failure of Standard Definitions to Account for Quality of 
Care in STEMI: Is Pay for Performance Ready for Prime 
Time?
Alex R. Campbell, Daniel Satran, Ivan J. Chavez, Joseph J. Decker, David M. Larson, 
Timothy D. Henry, Minneapolis Heart Institute Foundation at Abbott Northwestern 
Hospital, Minneapolis, MN
Background: The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) 
and ACC-NCDR (American College of Cardiology National Cardiovascular Data Registry) 
have developed standardized definitions and clinical performance measures for STEMI. 
Pay for performance programs link financial reimbursement to these measures. The ability 
of current definitions to accurately reflect quality of care in STEMI is unknown.
Methods: The Level 1 MI program is a standardized protocol for STEMI patients presenting 
to a PCI center or one of 31 referring hospitals (Zone 1 up to 60 miles away, Zone 2 up to 
210 miles away). We examined consecutive patients with STEMI in a one year period in 
the Level 1 database and compared them to patients meeting JCAHO and ACC-NCDR 
definitions for STEMI.
Results: From 10/2005 to 10/2006, 485 patients presented via the Level 1 protocol. 385 
underwent primary PCI for STEMI (80 no culprit, 13 CABG, 7 medical management). In the 
same period, ACC-NCDR defined STEMI in 285 patients and JCAHO defined STEMI in 62 
(Table). Median door to balloon times (D2B; minutes) by hospital presentation were similar.
Conclusions: Current JCAHO and ACC-NCDR definitions fail to recognize a significant 
number of patients presenting to a large regional center. Only 12.8% of STEMI patients 
admitted to the PCI center met reporting criteria for JCAHO. Before pay for performance 
can be adopted, definitions should be reexamined and consideration given to inclusion of 
patients transferred for PCI. 
STEMI Stratified by Standardized Definition and Hospital Presentation
Abbott 
Northwestern Zone 1 Zone 2
N D2B N D2B N D2B
Level 1 N=485 114 66 201 95 170 123
ACC - NCDR N=285 89 59 196 106 0 NA
JACAHO N=62 62 65 0 NA 0 NA
2:15 p.m.
818-8 Contemporary Predictors of Procedural Mortality 
Among Patients Undergoing Percutaneous Coronary 
Intervention (PCI): Results From the ACC-NCDR
Eric D. Peterson, David Dai, Elizabeth R. DeLong, Sunil V. Rao, Matthew T. Roe, Kalon 
L. Ho, Mandeep Singh, John S. Rumsfeld, Richard E. Shaw, William S. Weintraub, Ralph 
G. Brindis, John A. Spertus, Duke Clinical Research Institute, Durham, NC
Background: The NCDR provides risk-adjusted PCI mortality outcomes as a measure 
of comparative hospital performance. However, the evolution of PCI mandates that such 
models be updated to reflect improving contemporary results.
Methods: We developed the NCDR PCI mortality risk model using detailed clinical and 
angiographic data from 302,958 procedures performed at 470 US participating centers 
from 1/04 to 3/06. The model was validated among 285,440 procedures done from 4/06 
to 3/07. Model discrimination and calibration were assessed in the overall population and 
among varied subgroups.
Results: The overall PCI mortality rates were 1.25% and 1.17%, respectively, in the 
development and validation samples. The final model included 21 variables; with the 
5 strongest associations being: cardiogenic shock, procedural status (elective, urgent, 
emergent, salvage), renal function, age, and LVEF. The overall model C-index was 
0.926 and 0.920 in the development and validation samples, respectively. The model 
discriminated equally well in STEMI only and non-STEMI only cases (c-index 0.89-0.91). 
The model was also well calibrated across the PCI risk spectrum (Figure).
Conclusion: The new NCDR model can provide a highly accurate assessment of PCI 
mortality risk in the modern era. This model should have application for informed clinical 
decision making as well as for appropriate risk adjusted hospital outcome comparisons. 
